As Amended by House Committee

Session of 2021

House Substitute for SENATE BILL No. 158

By Committee on Federal and State Affairs

3-31

AN ACT concerning health and healthcare; enacting the Kansas medical 1 2 marijuana regulation act; relating to medical cannabis; licensure and 3 regulation of the manufacture, transportation and sale of medical 4 cannabis; crimes, punishment and criminal procedure; creating the 5 erime crimes of unlawful transport and unlawful storage of medical marijuana; exceptions from the unlawful manufacture and possession 6 7 of a controlled substance; prescribing powers, duties and functions of 8 the secretary of health and environment, secretary of revenue, board of 9 healing arts and board of pharmacy; rules and regulations; providing 10 certain fines and penalties for violations; establishing the medical marijuana registration fund, medical marijuana cultivation regulation 11 fund and the medical marijuana business entity regulation fund; 12 13 allowing counties to prohibit retail dispensaries {licensed facilities}; amending K.S.A. 44-1009, 44-1015, 65-28b08, 65-4107, 79-5201 and 14 79-5210 and K.S.A. 2020 Supp. 19-101a, 21-5703, 21-5705, 21-5706, 15 21-5706, as amended by section-67 {66} of this act, 21-5707, 21-16 5709, 21-5710, 23-3201, 38-2269, 44-501, 44-706-and, 65-1120 and 17 65-4105 and sections 2, 3, 4, 17, 18, 30 {29} and 39 {38} of this act, 18 19 and repealing the existing sections.

20

21 Be it enacted by the Legislature of the State of Kansas:

New Section 1. The provisions of sections 1 through <u>52 47</u> {46}, and
amendments thereto, shall be known and may be cited as the Kansas
medical marijuana regulation act.

New Sec. 2. As used in the Kansas medical marijuana regulation act,
 section 1 et seq., and amendments thereto:

(a) "Academic medical center" means a medical school and itsaffiliated teaching hospitals and clinics.

(b) "Associated employee" means an owner or prospective owner,
officer or board member or prospective board member of an entity seeking
a retail dispensary license.

32

(c) "Board of healing arts" means the state board of healing arts.

33 (d) "Cannabinoid" means any of the diverse chemical compounds 34 that can act on cannabinoid receptors in cells and alter

neurotransmitter release in the brain, including phytocannabinoids that are produced naturally by marijuana and some other plants.

3 (e) "Caregiver" means an individual registered pursuant to section 8, 4 and amendments thereto, who may purchase and possess medical 5 marijuana in accordance with section 11, and amendments thereto.

6 (e)(f) "Cultivate" means the same as defined in K.S.A. 65-4101,
 7 and amendments thereto.

8 (g) "Cultivator" means a person issued a license pursuant to section
 9 <u>21</u> 26, and amendments thereto, who may grow and sell medical marijuana
 10 in accordance with section<u>-22</u> 21, and amendments thereto.

11 (f)(h) "Distributor" means a person issued a license pursuant to 12 section $\underline{-31}$ 26, and amendments thereto, who may purchase and sell 13 medical marijuana in accordance with section $\underline{-33}$ 28, and amendments 14 thereto.

(g)(i) "Electronic cigarette" means the same as defined in K.S.A. 79 3301, and amendments thereto.

17 (h)(j) "Key employee" means a manager or other person responsible
 18 for the daily operation of a licensed retail dispensary.

19 $(\underline{i})(\mathbf{k})$ "Marijuana" means the same as defined in K.S.A. 65-4101, and 20 amendments thereto.

21 (j)(1) "Medical marijuana" means marijuana that is cultivated,
 22 processed, tested, dispensed, possessed or used for a medical purpose.

23 (k)(m) "Medical marijuana product" means a product that
 24 contains cannabinoids that have been extracted from plant material or
 25 the resin therefrom by physical or chemical means and is intended for
 26 administration to a registered patient.

27

(n) "Medical marijuana waste" means:
(1) Unused, surplus, returned or out-of-date marijuana;

28 29

(2) recalled marijuana;

30 (3) plant debris of the plant of the genus cannabis, including dead
 31 plants and all unused plant parts and roots; and

32

(4) any wastewater generated during growing and processing.

(o) "Owned and controlled" means ownership of at least 51% of the
business, including corporate stock if a corporation, control over the
management and day-to-day operations of the business and an interest in
the capital, assets and profits and losses of the business proportionate to
such owner's percentage of ownership.

38 (D(p) "Patient" means an individual registered pursuant to section 8,
39 and amendments thereto, who may purchase and possess medical
40 marijuana in accordance with section 10, and amendments thereto.

41 (m)(q) "Person" means any natural person, corporation,
 42 partnership, trust or association.

43 (r) "Plant material" means the leaves, stems, buds and flowers of

the marijuana plant and does not include seedlings, seeds, clones, stalks or roots of the plant or the weight of any non-marijuana ingredients combined with marijuana.

4 **(s)** "Postsecondary educational institution" means the same as defined 5 in K.S.A. 74-3201b, and amendments thereto.

(n)(t) "Processor" means a person issued a license pursuant to section
31 {30}, and amendments thereto, who may purchase, process and sell
medical marijuana in accordance with section 32 27, and amendments
thereto.

10 $(\underline{\Theta})(\mathbf{u})$ "Physician" means an individual licensed to practice medicine 11 and surgery in this state and who is certified by the board of healing arts to 12 recommend treatment with medical marijuana pursuant to section 17, and 13 amendments thereto.

14

26

27

(p)(v) "Physician's designee" means:

(1) A registered nurse, licensed practical nurse, respiratory therapist,
emergency medical responder, paramedic, dental hygienist, pharmacy
technician or pharmacy intern who has registered for access to the program
database as an agent of a practitioner or pharmacist to request program
data on behalf of the practitioner or pharmacist;

(2) a death investigator who has registered for limited access to the
 program database as an agent of a medical examiner, coroner or another
 person authorized under law to investigate or determine causes of death; or

(3) an individual authorized by rules and regulations adopted by the
board of healing arts to access the prescription monitoring program
database by the board of healing arts in rules and regulations.

(g)(w) "Qualifying medical condition" means any of the following:

(1) Acquired immune deficiency syndrome;

- 28 (2) Alzheimer's disease;
- 29 (3) amyotrophic lateral sclerosis;
- 30 (4) cancer;
- 31 (5) chronic traumatic encephalopathy;
- 32 (6) Crohn's disease;
- 33 (7) epilepsy or another seizure disorder;
- 34 (8) fibromyalgia;
- 35 (9) glaucoma;
- $36 \qquad (10) \quad \text{hepatitis C};$
- 37 (11) inflammatory bowel disease;
- 38 (12) {lupus;}
- 39 {(13)} multiple sclerosis;
- 40 (13){(14)} Parkinson's disease;
- 41 (14){(15)} positive status for human immunodeficiency virus;
- 42 (15){(16)} post-traumatic stress disorder;
- 43 (16){(17)} sickle cell anemia;

- 1 (17){(18)} spinal cord disease or injury;
- 2 (18){(19)} Tourette's syndrome;
- 3 $(19){(20)}$ traumatic brain injury;
- 4 (20){(21)} ulcerative colitis;
- 5 (21){(22)} <u>a chronic medical condition that:</u>
- 6 (A) Causes severe, persistent pain or persistent muscle spasms; or
- (B) is normally treated with a prescription medication that could lead
 to physical or psychological dependence if a licensed physician determines
- 9 <u>that treatment for such condition with medical marijuana would be</u>
 10 <u>effective and would serve as a safer alternative;</u>
- (22) a debilitating psychiatric disorder that is diagnosed by a
 physician licensed in this state who is board-certified in the practice of
 psychiatry, as determined by the board of healing arts; or
- (<u>23) any other chronic, debilitating or terminal condition that, in the</u> professional judgment of a physician licensed by in this state, would be a detriment to the patient's mental or physical health if left untreated pain that is either chronic and severe or intractable; or
- 18 (22){(23)} any other disease or condition adopted by the secretary
 of health and environment upon petition recommended for approval
 by the medical marijuana advisory-committee {committee} pursuant to
 section 5, and amendments thereto.
- 22 (f)(x) "Retail dispensary" means a person issued a license pursuant to 23 section<u>-34</u> 26, and amendments thereto, who may purchase and sell 24 medical marijuana in accordance with section<u>-35 30</u> {29}, and amendments 25 thereto.
- 29 (t)(z) "Support employee" means an individual employed by a
 30 licensed retail dispensary who does not have authority to make operational
 31 decisions.
- 32 (<u>u)</u>(aa) "Tetrahydrocannabinol" means the primary psychoactive
 33 cannabinoid in marijuana formed by decarboxylation of naturally
 34 occurring tetrahydrocannabinolic acid that generally takes place by
 35 heating.
- (bb) "Tetrahydrocannabinolic acid" means the dominant
 cannabinoid that occurs naturally in most varieties of marijuana.

(cc) "Tetrahydrocannabinol content" means the sum of the
 amount of tetrahydrocannabinol and 87.7% of the amount of
 tetrahydrocannabinolic acid present in the product or plant material.

(dd) "Vaporization" means the use of an electronic cigarette for the
purpose of consuming medical marijuana in which such medical marijuana
comes into direct contact with a heating element.

1

(v)(ee) "Veteran" means a person who:

2 (1) Has served in the army, navy, marine corps, air force, coast guard,
3 space force, any state air or army national guard or any branch of the
4 military reserves of the United States; and

5 (2) has been separated from the branch of service in which the person 6 was honorably discharged or received a general discharge under honorable 7 conditions.

8 New Sec. 3. (a) No person shall grow, harvest, process, sell, barter, 9 transport, deliver, furnish or otherwise possess any form of marijuana, 10 except as specifically provided in the Kansas medical marijuana regulation 11 act or the commercial industrial hemp act, K.S.A. 2020 Supp. 2-3901 et 12 seq., and amendments thereto.

(b) Nothing in the Kansas medical marijuana regulation act shall beconstrued to:

(1) Require a physician to recommend that a patient use medicalmarijuana to treat a qualifying medical condition;

(2) permit the use, possession or administration of medical marijuanaother than as authorized by this act;

(3) permit the use, possession or administration of medical marijuanaon federal land located in this state;

(4) require any public place to accommodate a registered patient's use
 of medical marijuana;

(5) prohibit any public place from accommodating a registeredpatient's use of medical marijuana;

(6) authorize any limitation on the number of any licenses awarded
under this act to otherwise qualified applicants or authorize any state
agency through rules and regulations to effectively limit the number of
licenses available to otherwise qualified applicants for any type of license
awarded under this act; or

(7) restrict research related to marijuana conducted at a postsecondary
 educational institution, academic medical center or private research and
 development organization as part of a research protocol approved by an
 institutional review board or equivalent entity.

New Sec. 4. (a) There is hereby established a Kansas medical marijuana regulation program.

(b) The secretary of health and environment shall administer the
 program in accordance with the provisions of this act and provide for the
 registration of patients and caregivers, including the issuance of
 identification cards to registered patients and caregivers.

40 (c) The board of healing arts shall administer the program in
41 accordance with the provisions of this act and provide for the certification
42 authorizing physicians to recommend medical marijuana.

43 (d) The board of pharmacy shall administer the program in

accordance with the provisions of this act and provide for the registration
 of pharmacist consultants and the reporting to the prescription monitoring
 program database.

- 4 (e) The director of alcoholic beverage control shall administer the 5 program in accordance with the provisions of this act and provide for the 6 licensure of cultivators, laboratories that test medical marijuana, 7 processors, distributors and retail dispensaries.
- 8 New Sec. 5. (a) The medical marijuana advisory committee is hereby 9 created in the department of health and environment. The committee shall 10 consist of the following:
- 11

(1) Eight members appointed by the governor as follows:

(A) Two members who are practicing pharmacists, at least one of
whom supports the use of medical marijuana and at least one of whom is a
member of the state board of pharmacy;

(B) two members who are practicing physicians, at least one of whom
supports the use of medical marijuana and at least one of whom is a
member of the board of healing arts;

18 19

24

25

26

(C) one member who represents employers;

(D) one member who represents agriculture;

20 (E) one member who represents persons involved in the treatment of 21 alcohol and drug addiction; and

(F) one member who engages in academic research on the use orregulation of medical marijuana;

(2) two members appointed by the president of the senate as follows:

(A) One member who represents law enforcement; and

(B) one member who represents caregivers;

(3) one member, who is a nurse, appointed by the minority leader ofthe senate;

(4) two members appointed by the speaker of the house ofrepresentatives as follows:

31 (A) One member who represents persons involved in mental health 32 treatment; and

33

(B) one member who represents patients;

(5) one member, who represents employees, appointed by theminority leader of the house of representatives; and

36 (6) the secretary of health and environment, who shall serve as 37 chairperson.

(b) The initial appointments to the committee shall be made on orbefore July 31, 2021.

40 (c) Except for the secretary of health and environment, each member
41 of the committee shall serve for a period of two years from the date of
42 appointment<u>until the committee ceases to exist</u>, except that members shall
43 serve at the pleasure of the appointing authority. A vacancy shall be filled

1 within 21 days of such vacancy in the same manner as the original 2 appointment.

3 (d) Each member of the committee shall be paid compensation,
4 subsistence allowances, mileage and other expenses as provided in K.S.A.
5 75-3223(e), and amendments thereto.

6 (e) The committee shall hold its initial meeting not later than 30 days 7 after the last member of the committee is appointed. The committee may 8 develop and submit to the secretary of health and environment and the 9 director of alcoholic beverage control any recommendations related to the 10 Kansas medical marijuana regulation program and the implementation and 11 enforcement of this act.

12 (f) The medical marijuana advisory committee shall make 13 recommendations to the secretary of health and environment and the 14 director of alcoholic beverage control regarding those offenses that would 15 disqualify an applicant from registration or licensure by the respective 16 state agency. The committee shall annually review such offenses and make 17 any subsequent recommendations the committee deems necessary.

18 (g) (1) {(A)} Any person may submit a petition to the medical 19 marijuana advisory committee requesting that a disease or 20 condition{:}

{(i)} Be added as a qualifying medical condition for the purposes of
 this act{;or}

{(ii) that was previously recommended for approval by the
committee and adopted by the secretary of health and environment
through rules and regulations be removed as a qualifying medical
condition for the purposes of this act}.

{(B)} The petition shall be submitted in such form and manner as
prescribed by the secretary of health and environment. A petition shall
not seek to add {or remove} a broad category of diseases or conditions
but shall be limited to one disease or condition and include a
description of such disease or condition.

(2) Upon receipt of a petition, the committee shall review such petition to determine whether to recommend the approval or denial of the disease or condition described in the petition as an addition to {or removal from} the list of qualifying medical conditions. The committee may consolidate the review of petitions for the same or similar diseases or conditions. In making its determination, the committee shall:

(A) Consult with one or more experts who specialize in the study
 of the disease or condition;

40 **(B)** review any relevant medical or scientific evidence pertaining 41 to the disease or condition;

42 (C) consider whether conventional medical therapies are 43 insufficient to treat or alleviate the disease or condition;

- (D) review evidence supporting the use of medical marijuana to 1 2 treat or alleviate the disease or condition: and
- 3

(E) review any letters of support provided by physicians with knowledge of the disease or condition, including any letter provided by 4 5 a physician treating the petitioner.

6 (3) Upon completion of its review, the committee shall make a 7 recommendation to the secretary of health and environment whether 8 to approve or deny the addition {or removal} of the disease or condition to the list of qualifying medical conditions. The secretary 9 10 shall adopt rules and regulations in accordance with the recommendation of the committee. 11

{(4) Prior to July 1, 2024, and every three years thereafter, the 12 committee shall review all diseases or conditions that have been 13 recommended for approval by the committee and adopted by the 14 secretary of health and environment through rules and regulations to 15 16 determine if the inclusion of any such diseases or conditions are no longer supported by scientific evidence. The inclusion of any such 17 18 disease or condition that the committee determines is no longer 19 supported by scientific evidence shall be recommended by the 20 committee to the secretary of health and environment for removal 21 from the list of qualifying medical conditions.}

22 (h) Prior to January 31 of each year, the medical marijuana advisory 23 committee shall provide a report to the legislature detailing any concerns or recommended changes that the committee has for the medical marijuana 24 25 regulation act.

26

40

(h)(i) The provisions of this section shall expire on July 1, 2026.

New Sec. 6. (a) Except as permitted under subsection (c), the 27 28 following individuals shall not solicit or accept, directly or indirectly, any 29 gift, gratuity, emolument or employment from any person who is an applicant for any license or is a licensee under the provisions of the Kansas 30 31 medical marijuana regulation act or any officer, agent or employee thereof, 32 or solicit requests from or recommend, directly or indirectly, to any such 33 person, the appointment of any individual to any place or position:

34 (1) The secretary of health and environment or any officer, employee 35 or agent of the department of health and environment;

36 (2) the secretary of revenue, the director of alcoholic beverage control 37 or any officer, employee or agent of the division of alcoholic beverage 38 control: 39

(3) any member of the board of pharmacy; or

(4) any member of the board of healing arts.

(b) Except as permitted under subsection (c), an applicant for a 41 license or a licensee under the provisions of the Kansas medical marijuana 42 43 regulation act shall not offer any gift, gratuity, emolument or employment

1 to any of the following:

2 (1) The secretary of health and environment or any officer, employee 3 or agent of the department of health and environment;

4 (2) the secretary of revenue, the director of alcoholic beverage control or any officer, employee or agent of the division of alcoholic beverage 5 6 control: 7

(3) any member of the board of pharmacy; or

8

(4) any member of the board of healing arts.

9 (c) The board of healing arts, the board of pharmacy, the secretary of health and environment and the secretary of revenue may adopt rules and 10 regulations for their respective agencies allowing the acceptance of official 11 hospitality by members of the board of healing arts, the board of pharmacy 12 or the respective secretary and employees of each such respective agency, 13 14 subject to any limits as prescribed by such rules and regulations.

(d) If any member of the board of healing arts, the board of 15 pharmacy, the secretary of health and environment, the secretary of 16 17 revenue or any employee of each such respective agency violates any 18 provision of this section, such person shall be removed from such person's 19 office or employment.

20 (e) Violation of any provision of this section is a misdemeanor 21 punishable by a fine of not to exceed \$500 or imprisonment of not less 22 than 60 days nor more than six months, or both such fine and 23 imprisonment.

24 (f) Nothing in this section shall be construed to prohibit the 25 prosecution and punishment of any person for bribery as defined in the 26 Kansas criminal code.

27 New Sec. 7. All actions taken by the board of healing arts, the board 28 of pharmacy, the secretary of health and environment or the director of 29 alcoholic beverage control under the Kansas medical marijuana regulation 30 act shall be in accordance with the Kansas administrative procedure act 31 and reviewable in accordance with the Kansas judicial review act.

32 New Sec. 8. (a) A patient seeking to use medical marijuana or a caregiver seeking to assist a patient in the use or administration of medical 33 34 marijuana shall apply to the department of health and environment for 35 registration. The physician who is treating the patient, or such physician's 36 designee, shall submit the application on the patient's or caregiver's behalf 37 in such form and manner as prescribed by the secretary of health and 38 environment

39

(b) The application for registration shall include the following:

40

(1) A statement from the physician certifying that:

41 (A) A bona fide physician-patient relationship exists between the 42 physician and patient;

43 (B) the patient has been diagnosed with a qualifying medical 1 condition;

2 (C) the physician, or such physician's designee, has requested from 3 the prescription monitoring program database a report of information 4 related to the patient that covers at least the 12 months immediately 5 preceding the date of the report;

6 (D) the physician has informed the patient of the risks and benefits of 7 medical marijuana as it pertains to the patient's qualifying medical 8 condition and medical history; and

9 (E) the physician has informed the patient that it is the physician's 10 opinion that the benefits of medical marijuana outweigh its risks;

(2) in the case of an application submitted on behalf of a patient, the
 name or names of one or more caregivers, if any, who will assist the
 patient in the use or administration of medical marijuana;

(3) in the case of an application submitted on behalf of a caregiver,
the name of the patient or patients whom the caregiver seeks to assist in
the use or administration of medical marijuana; and

(4) in the case of a patient who is a minor, the name of the patient's
parent or legal guardian who has consented to treatment with medical
marijuana and who shall be designated as the patient's caregiver.

(c) If the application is complete and meets the requirements of this
act and rules and regulations adopted thereunder and the patient or
caregiver has paid the required fee, the secretary of health and
environment shall register the patient or caregiver and issue to the patient
or caregiver an identification card.

(d) (1) A registered caregiver must be at least 21 years of age, except
that, if the caregiver is the parent or legal guardian of a patient who is a
minor, then the registered caregiver must be at least 18 years of age.

(2) A registered patient may designate up to two registered
 caregivers. If the patient is a minor, a parent or legal guardian of such
 patient shall be designated as a registered caregiver for such patient.

(3) A registered caregiver may provide assistance to not more than
 two registered patients, unless the secretary approves a greater number of
 registered patients.

34 (4) A physician who submits an application on behalf of a patient35 may not also serve as such patient's registered caregiver.

36 (e) Any information collected by the department of health and 37 environment pursuant to this section is confidential and not a public 38 record. The department may share information identifying a specific 39 patient with a licensed retail dispensary or any law enforcement agency for 40 the purpose of confirming that such patient has a valid registration. Information that does not identify a person may be released in summary, 41 42 statistical or aggregate form. The provisions of this subsection shall expire 43 on July 1, 2026, unless the legislature reviews and reenacts such

provisions in accordance with K.S.A. 45-229, and amendments thereto, 1 2 prior to July 1, 2026.

3 (f) The fees for a patient or caregiver registration, or the renewal 4 thereof, shall be set by rules and regulations adopted by the secretary of 5 health and environment in an amount not to exceed:

6

(1) Except as specified in paragraph (2), \$50 for a patient registration;

7 (2) \$25 for a patient registration if the patient is indigent or is a 8 veteran: and

9

(3) \$25 for a caregiver registration.

10 (g) A registration shall be valid for a period of one year from the date the identification card is issued and may be renewed by submitting a 11 registration renewal application and paying the required fee. 12

New Sec. 9. The department of health and environment shall assign a 13 unique 24-character identification number to each registered patient and 14 caregiver when issuing an electronically scannable identification card. 15 16 Upon scanning such identification card or entering such identification 17 number, licensed retail dispensaries may request shall obtain verification 18 by the department that a patient or caregiver has a valid registration.

19 New Sec. 10. (a) A patient registered pursuant to section 8, and 20 amendments thereto, who obtains medical marijuana from a licensed retail 21 dispensary may:

22 23 (1) Use medical marijuana;

(2) subject to subsection (b), possess medical marijuana; and

24 (3) possess any paraphernalia or accessories used to administer 25 medical marijuana.

26 (b) A registered patient may possess medical marijuana in an amount 27 not to exceed a 30-day supply.

28 (c) Nothing in this section shall be construed to authorize a registered 29 patient to operate a motor vehicle, watercraft or aircraft while under the 30 influence of medical marijuana.

31 New Sec. 11. (a) A caregiver registered pursuant to section 8, and 32 amendments thereto, who obtains medical marijuana from a licensed retail 33 dispensary may:

34 (1) Subject to subsection (b), possess medical marijuana on behalf of 35 a registered patient under the caregiver's care;

36 (2) assist a registered patient under the caregiver's care in the use or 37 administration of medical marijuana; and

38 (3) possess any paraphernalia or accessories used to administer 39 medical marijuana.

40 (b) A registered caregiver may possess medical marijuana on behalf of a registered patient in an amount not to exceed a 30-day supply. If a 41 caregiver provides care to more than one registered patient, the caregiver 42 43 shall maintain separate inventories of medical marijuana for each patient.

1 (c) Nothing in this section shall be construed to permit a registered 2 caregiver to personally use medical marijuana unless the caregiver is also a 3 registered patient.

4 New Sec. 12. (a) In addition to or in lieu of any other civil or criminal 5 penalty as provided by law, the secretary of health and environment may 6 impose a civil penalty or suspend or revoke a registration upon a finding 7 that the patient or caregiver committed a violation<u>as provided in this</u> 8 <u>section</u> {of this act}.

9 (b) Nothing in this act shall be construed to require the secretary to 10 enforce minor violations if the secretary determines that the public interest 11 is adequately served by a notice or warning to the alleged offender.

12 (c) Upon a finding that a registrant has submitted fraudulent 13 information or otherwise falsified or misrepresented information required 14 to be submitted by such registrant, the secretary may impose a civil fine of 15 not to exceed \$500 for a first offense and may suspend or revoke the 16 individual's registration for a second or subsequent offense.

(d) If the secretary suspends, revokes or refuses to renew any 17 18 registration issued pursuant to this act and determines that there is clear 19 and convincing evidence of a danger of immediate and serious harm to any 20 person, the secretary may place under seal all medical marijuana owned by 21 or in the possession, custody or control of the affected registrant. Except as 22 provided in this section, the secretary shall not dispose of the sealed 23 medical marijuana until a final order is issued authorizing such disposition. 24 During the pendency of an appeal from any order issued by the secretary, a 25 court may order the secretary to sell medical marijuana that is perishable, and the proceeds of any such sale shall be deposited with the court. 26

27 New Sec. 13. (a) There is hereby established the medical marijuana 28 registration fund in the state treasury. The secretary of health and environment shall administer the medical marijuana registration fund and 29 shall remit all moneys collected from the payment of all fees and fines 30 31 imposed by the secretary pursuant to the Kansas medical marijuana 32 regulation act and any other moneys received by or on behalf of the 33 secretary pursuant to such act to the state treasurer in accordance with the 34 provisions of K.S.A. 75-4215, and amendments thereto. Upon receipt of 35 each such remittance, the state treasurer shall deposit the entire amount in 36 the state treasury to the credit of the medical marijuana registration fund. 37 Moneys credited to the medical marijuana registration fund shall only be 38 expended or transferred as provided in this section. Expenditures from 39 such fund shall be made in accordance with appropriation acts upon 40 warrants of the director of accounts and reports issued pursuant to 41 vouchers approved by the secretary or the secretary's designee.

42 (b) Moneys in the medical marijuana registration fund shall be used 43 for the payment or reimbursement of costs related to the regulation and

1 enforcement of the possession and use of medical marijuana by the 2 secretary.

New Sec. 14. (a) On or before July 1,<u>2022</u> 2023, the secretary of health and environment shall, after consulting with the medical marijuana advisory committee, adopt rules and regulations to administer the Kansas medical marijuana regulation program and implement and enforce the provisions of the Kansas medical marijuana regulation act. Such rules and regulations shall:

9 (1) Establish procedures for registration of patients and caregivers 10 and eligibility requirements for registration;

(2) establish procedures for the issuance of patient or caregiveridentification cards;

(3) establish a renewal schedule, renewal procedures and renewalfees for registrations;

(4) subject to the provisions of subsection (b), specify, by form and
tetrahydrocannabinol content, a maximum 30-day supply of medical
marijuana that may be possessed;

(5) specify the forms or methods of using medical marijuana that areattractive to children; and

20 (6)<u>establish procedures for reviewing, approving and denying</u>
 21 <u>petitions for approval of new forms or methods of using medical</u>
 22 <u>marijuana; and</u>

establish a program to assist patients who are indigent or who are
 veterans in obtaining medical marijuana.

(b) Any maximum supply of medical marijuana that may be purchased or possessed by a patient or caregiver shall allow at least three ounces of dried, unprocessed medical marijuana or its equivalent as a 30day supply and allow for exceptions from any such limitation upon submission of a written certification from two independent physicians that there are compelling reasons for the patient or caregiver to purchase and possess greater quantities of medical marijuana.

(c) When adopting rules and regulations under this section, the
 secretary shall consider standards and procedures that have been found to
 be best practices relative to the use and regulation of medical marijuana.

New Sec. 15. On or before July 1,<u>2022</u> 2023, the department of health and environment shall make a website available for the public to access information regarding patient and caregiver registration under the Kansas medical marijuana regulation act.

New Sec. 16. A medical marijuana registry identification card, or its equivalent, that is issued under the laws of another state, district, territory, commonwealth or insular possession of the United States that is verifiable by the jurisdiction of issuance and allows a nonresident patient to possess medical marijuana for medical purposes shall have the same force and

1 effect as an identification card issued by the secretary pursuant to this act

2 if the nonresident patient has not been residing in this state for more than 3 180 days.

4 New Sec. 17. (a) Except as provided in subsection (i), a physician 5 seeking to recommend treatment with medical marijuana shall apply to the 6 board of healing arts for a certificate authorizing such physician to 7 recommend treatment with medical marijuana. The application shall be 8 submitted in such form and manner as prescribed by the board. The board shall grant a certificate to recommend if the following conditions are 9 10 satisfied:

11 (1) The application is complete and meets the requirements established in rules and regulations adopted by the board of healing arts; 12 13 and

14 (2) the applicant demonstrates that the applicant does not have an ownership or investment interest in or compensation arrangement with an 15 16 entity licensed by the department of health and environment or the director 17 of alcoholic beverage control under this act or an applicant for such 18 licensure.

19 (b) Pursuant to rules and regulations adopted by the board of healing 20 arts, a certificate to recommend shall:

21 (A) Expire annually unless renewed in the manner prescribed by the 22 board; and

23 (B) be accompanied by an annual fee in an amount not to exceed 24 \$175

25 (2) Renewal of a certificate to recommend shall be conditioned upon the holder's certification of having met the requirements in subsection (a) 26 and having completed at least two hours of continuing medical education 27 in medical marijuana annually in accordance with subsection (g). 28

29 (c) A physician licensed in this state who holds a certificate to recommend treatment with medical marijuana may recommend that a 30 31 patient be treated with medical marijuana if:

32 (1) The patient has been diagnosed with a qualifying medical 33 condition:

34 (2) an ongoing physician-patient relationship has been established by an initial office visit existed for a minimum of six months, or as 35 36 specified by rules and regulations adopted by the board, unless the 37 patient: 38

(A) Has recently moved from out-of-state and:

39 (i) Previously had medical marijuana recommended by a 40 physician in another state; and

41 (ii) the patient's previous physician contacts the new physician to share the patient's medical history and verify that the patient has a 42 43 qualifying medical condition;

1 **(B)** currently has a recommendation for medical marijuana 2 pursuant to this act and the:

3 (i) Patient no longer has a relationship with the recommending 4 physician, and the patient's previous physician contacts the new 5 physician to share the patient's medical history and verify that the 6 patient has a qualifying medical condition; or

7

(ii) recommending physician is deceased; or

8 (C) is a veteran and has not previously received a 9 recommendation for medical marijuana;

(3) a review of all old medical records, particularly relating to the
 medical indication for the tetrahydrocannabinol recommendation, and a
 physical exam have been performed;

(4) the recommending physician has a certification to recommendpursuant to section 18, and amendments thereto;

(5) the recommending physician, or physician's designee, reports all
medical marijuana recommendations for all patients to the prescription
monitoring program in accordance with K.S.A. 65-1683, and amendments
thereto; and

(6) for a patient who has previously had medical marijuanarecommended for use by another physician, the patient:

(A) Has maintained a physician-patient relationship with the new
 recommending physician for at least six months with either inpatient visits
 or via telephonic or electronic means; or

(B) no longer has the previous physician-patient relationship onaccount of death or discontinuance of care by the physician.

(d) In the case of a patient who is a minor, the physician may
 recommend treatment with medical marijuana only after obtaining the
 consent of the patient's parent or other person responsible for providing
 consent to treatment.

30 (e) When issuing a written recommendation to a patient, the 31 physician shall specify any information required by rules and regulations 32 adopted by the board of healing arts. A written recommendation issued to a 33 patient under this section is valid for a period of not more than 90 days. 34 The physician may renew the recommendation for not more than three 35 additional periods of not more than 90 days each. Thereafter, the physician 36 may issue another recommendation to the patient only upon a physical 37 examination of the patient.

(f) Each year a physician holding a certificate to recommend treatment with medical marijuana shall submit to the board of healing arts a report that describes the physician's observations regarding the effectiveness of medical marijuana in treating the physician's patients during the year covered by the report. When submitting reports, a physician shall not include any information that identifies or would tend to

1 identify any specific patient.

2 (g) Annually, each physician who holds a certificate to recommend 3 treatment with medical marijuana shall complete at least two hours of 4 continuing medical education in the treatment with and use of medical 5 marijuana as approved by the board of healing arts.

6 (h) A physician shall not issue a recommendation for treatment with 7 medical marijuana for a family member or the physician's self, or 8 personally furnish or otherwise dispense medical marijuana.

9 (i) A physician who holds a certificate to recommend treatment with 10 medical marijuana shall be immune from civil liability, shall not be subject 11 to professional disciplinary action by the board of healing arts and shall 12 not be subject to criminal prosecution for any of the following actions:

(1) Advising a patient, patient representative or caregiver about the
 benefits and risks of medical marijuana to treat a qualifying medical
 condition;

16 (2) recommending that a patient use medical marijuana to treat or 17 alleviate a qualifying medical condition; and

18

(3) monitoring a patient's treatment with medical marijuana.

(j) This section shall not apply to a physician who recommends treatment with marijuana or a drug derived from marijuana under any of the following that is approved by an institutional review board or equivalent entity, the United States food and drug administration or the national institutes of health or one of its cooperative groups or centers under the United States department of health and human services:

25

(1) A research protocol;

26 (2) a clinical trial;

27 (3) an investigational new drug application; or

28 (4) an expanded access submission.

New Sec. 18. (a) On or before July 1, 2022, the board of healing arts
shall adopt rules and regulations to implement and enforce the provisions
of section 17, and amendments thereto. Such rules and regulations shall
include:

(1) The procedures and fees for applying for a certificate torecommend treatment with medical marijuana;

35 (2) the conditions for eligibility for a certificate to recommend36 treatment with medical marijuana;

- 37 38
- (3) the schedule, fees and procedures for renewing such a certificate;
- (4) the reasons for which a certificate may be suspended or revoked;

39 (5) the standards under which a certificate suspension may be lifted;
 40 and

41 (6) the minimum standards of care when recommending treatment42 with medical marijuana {; and}

43 {(7) signage requirements for retail dispensaries to properly warn

pregnant women and anyone with psychiatric or emotional disorders of the adverse effects of marijuana}.

3 (b) The board of healing arts shall approve one or more continuing 4 medical education courses of study that assist physicians holding 5 certificates to recommend treatment with medical marijuana in diagnosing 6 and treating qualifying medical conditions with medical marijuana.

7 New Sec. 19. (a) There shall be no direct or indirect cooperative 8 advertising between or among two or more cultivators, dispensaries or 9 physicians, or any combination thereof, where such advertising has the 10 purpose or effect of steering or influencing patient or caregiver choice with 11 regard to their selection of a physician, retail dispensary or medical 12 marijuana.

(b) No advertisement may be disseminated if the submitter of the
advertisement has received information that has not been widely
publicized in medical literature that the use of the medical marijuana
product may cause fatalities or serious harm.

17 (c) All advertisements for medical marijuana or medical marijuana products that make a statement relating to side effects, contraindications 18 19 and effectiveness shall present a true statement of such information. When 20 applicable, advertisements broadcast through media such as radio, 21 television or other electronic media, or displayed in print or on any sign 22 or billboard, shall include such information in the audio or audio and 23 visual parts of the presentation. False or misleading information in any 24 part of the advertisement shall not be corrected by the inclusion of a true 25 statement in another, distinct part of the advertisement.

26 (d) An advertisement is false or otherwise misleading if such27 advertisement:

(1) Contains a representation or suggestion that a medical marijuana
 brand or product is better, more effective, useful in a broader range of
 conditions or patients or safer than other drugs or treatments, including
 other medical marijuana products, unless such a claim has been
 demonstrated by substantial evidence or substantial clinical experience;

(2) contains favorable information or opinions about a medical
 marijuana brand or product previously regarded as valid but that have been
 rendered invalid by contrary and more recent credible information;

(3) uses a quote or paraphrase out of context or without citing
 conflicting information from the same source to convey a false or
 misleading idea;

(4) cites or refers to a study on individuals without a qualifying
medical condition without disclosing that the subjects were not suffering
from a qualifying medical condition;

42 (5) uses data favorable to a medical marijuana product derived from 43 patients treated with a product or dosages different from those approved in 1 this state;

2 (6) contains favorable information or conclusions from a study that is
 3 inadequate in design, scope or conduct to furnish significant support for
 4 such information or conclusions; or

5 (7) fails to provide adequate emphasis for the fact that two or more 6 facing pages are part of the same advertisement when only one page 7 contains information relating to side effects, consequences and 8 contraindications.

9 (e) An advertisement for medical marijuana or medical marijuana 10 products shall not contain any:

11 (1) Statement that is false or misleading in any material particular or 12 is otherwise in violation of the Kansas consumer protection act;

(2) statement that falsely disparages a competitor's products;

13 14 15

(3) statement, design or representation, picture or illustration that:

(A) Is obscene or indecent;

(B) encourages or represents the recreational use of marijuana or the
use of medical marijuana for a condition other than a qualifying medical
condition;

(C) relates to the safety or efficacy of medical marijuana unlesssupported by substantial evidence or substantial clinical data; or

(D) portrays anyone under 18 years of age or contains the use of a
 figure, symbol or language that is customarily associated with anyone
 under 18 years of age;

(4) offer of a prize or award to a registered patient, caregiver orphysician related to the purchase of medical marijuana; or

(5) statement that indicates or implies that the product or entity in the
advertisement has been approved or endorsed by the secretary of health
and environment, director of alcoholic beverage control, the state of
Kansas or any person or entity associated with the state.

30 (f) (1) Any advertisement for medical marijuana shall be submitted to 31 the secretary of health and environment at the same time as, or prior to, the 32 dissemination of the advertisement and shall include the following 33 additional information:

34

(A) A cover letter that provides:

(i) A subject line stating: "Medical marijuana advertisement review
 package for a proposed advertisement for [brand name].";

(ii) a brief description of the format and expected distribution of theproposed advertisement; and

(iii) the submitter's name, title, address, telephone number, faxnumber and email address;

(B) an annotated summary of the proposed advertisement showing
every claim being made in the advertisement and the references that
support each claim that includes disease or epidemiology information;

1 (C) verification that a person identified in an advertisement as a 2 registered patient or healthcare practitioner is an actual registered patient 3 or healthcare practitioner and not a model or actor;

4

(D) verification that an official translation of a foreign language advertisement is accurate; and

6 (E) a final copy of the advertisement, including a video where 7 applicable, in an acceptable format.

8 (2) Any incomplete advertising packages, or packages that fail to 9 follow the specific details for submissions, shall be considered incomplete. 10 If the secretary receives an incomplete package, the secretary shall notify 11 the submitter.

(3) Within 21 days of receiving a complete advertising package,
 the secretary shall either approve such advertisement or notify the
 submitter of any necessary disclosures or changes. If the secretary
 does not take any action on the advertising package within 21 days,
 the advertisement shall be deemed to be approved.

- 17
- (g) The secretary may:

18 (1) Require a specific disclosure be made in the advertisement in a 19 clear and conspicuous manner, if the secretary determines that the 20 advertisement would be false or misleading without such a disclosure; or

21

(2) make recommendations with respect to changes that are:

(A) Necessary to protect the public health, safety and welfare; or
 (B) consistent with dispensing information for the product under
 review

25 (h) A re

(h) A retail dispensary shall:

26 (1) Restrict external signage to a single sign not larger than 16 inches
 27 by 18 inches;

28 (2) not illuminate a dispensary sign advertising a medical marijuana
 29 product at any time;

30 (3) not advertise medical marijuana brand names or utilize graphics 31 related to marijuana or paraphernalia on the exterior of the dispensary or 32 the building in which the dispensary is located; and

33 (4) not or display any medical marijuana or paraphernalia so as to be
 34 clearly visible from the exterior of the dispensary.

35

(i) The price of medical marijuana shall not be advertised:

36 (1) <u>For sale-</u>By a cultivator, processor or distributor, except that such
 37 entities may make a price list available to a dispensary; and

38 (2) on any billboard that is located along<u>-a</u> any interstate highway,
39 federal highway or state highway.

(j) Medical marijuana shall not be advertised on a billboard or
similar advertising device that is located on any interstate highway,
federal highway or state highway that crosses the Kansas border
within 10 miles where such highway crosses the state line.

1 New Sec. 20. (a) All licenses issued pursuant to the medical 2 marijuana regulation act shall:

3

(1) Not be issued to a person:(A) Who is not a citizen of the United States;

4 5

5 (B) who has been convicted of a felony under the laws of this state, 6 any other state or the United States;

7 (C) who has had a license revoked for cause under the provisions of 8 the act or who has had any license issued under the medical marijuana 9 laws of any state revoked for cause, except that a license may be issued to 10 a person whose license was revoked for the conviction of a misdemeanor 11 at any time after the lapse of 10 years following the date of the revocation;

(D) who has been convicted of being the keeper of or is keeping any property, whether real or personal, where sexual relations are being sold or offered for sale by a person who is 18 years of age or older or has forfeited bond to appear in court to answer charges of being a keeper of any property, whether real or personal, where sexual relations are being sold or offered for sale by a person who is 18 years of age or older;

18 (E) who has been convicted of being a proprietor of a gambling 19 house, pandering or any other crime opposed to decency and morality or 20 has forfeited bond to appear in court to answer charges for any of those 21 crimes;

22

(F) who is not at least 18 years of age;

(G) who, other than as a member of the governing body of a city or
county, appoints or supervises any law enforcement officer, who is a law
enforcement officer or who is an employee of the director of alcoholic
beverage control;

(H) who intends to carry on the business authorized by the license asan agent of another;

(I) who at the time of application for renewal of any license issued
under this act would not be eligible for the license upon a first application,
except as provided by subparagraph (L);

(J) who is the holder of a valid and existing license issued under this
act unless the person agrees to and does surrender the license to the officer
issuing the same;

(K) who does not own the premises for which a license is sought or
 does not, at the time of application, have a written lease thereon;

(L) whose spouse would be ineligible to receive a license under this
act for any reason other than citizenship, residence requirements or age,
except that this paragraph shall not apply in determining eligibility for a
renewal license;

(M) whose spouse has been convicted of a felony or other crime that
would disqualify a person from licensure under this section if such felony
or other crime was committed during the time that the spouse held a

1 license under this act;

2 (N) who has not been a resident of this state for at least four years 3 immediately preceding the date of application. A license shall be forfeited 4 if an individual licensee ceases to be a resident of this state at any time 5 after the license is granted;

6 (O) who does not provide any data or information required by the 7 director under this act; or

8 (P) who, after a hearing before the director, has been found to have 9 held an undisclosed beneficial interest in any license issued pursuant to 10 this act that was obtained by means of fraud or any false statement made 11 on the application for such license;

12 (2) not be issued to a corporation, limited liability company, limited partnership or limited liability partnership if less than 75% of the total 13 equity or similar ownership interest in such-corporation entity is owned by 14 individuals who have been residents of this state for at least two four years 15 16 immediately preceding the date of the application. A license shall be 17 forfeited if, for more than 90 consecutive days, less than 75% of the total equity or similar ownership interest in such-corporation entity is owned by 18 19 individuals who are residents of this state at any time after the license is 20 granted: and

21 (3)

(3) require that any:

(A) Transfer of a license shall be reported to and approved by the
 director. The director shall not approve any transfer of a license to any
 individual or entity that does not satisfy the requirements of this section at
 the time of the transfer;

26 (B) change in ownership of a corporation, limited liability company, limited partnership or limited liability partnership shall be reported to 27 28 the director within 30 days after such change occurs. If such change would 29 result in less than 75% of the total equity or similar ownership interest in such-corporation entity being owned by individuals who have been 30 31 residents of this state for at least-two four years, then such entity shall 32 have 90 days to ensure that 75% or greater of such equity or ownership 33 interest is held by individuals who are residents in Kansas or the license of 34 such entity shall be forfeited to the director;

35 (C) compensation, fee, expense or similarly characterized nonequity 36 payment that is contingent on or otherwise determined in a manner that 37 factors in profits, sales, revenue or cash flow of any kind relating to a 38 licensee's operation, including, but not limited to, profit-based consulting 39 fees and percentage rent payments be prohibited. Any licensee that enters 40 into an agreement for any prohibited compensation, fee, expense or payment shall forfeit such entity's license to the director. Such prohibited 41 42 compensation, fee, expense or payment:

43 (i) Includes any distribution that is made by individuals or other

entities to one or more out-of-state individuals holding an equity or similar
 ownership interest in the entity if such distribution is greater than 25% of
 the total distributed amount; and

4 (ii) does not include payments of fixed amounts that are determined 5 prior to the commencement of applicable services or payments of variable 6 amounts based on verifiable quantities multiplied by a predetermined and 7 reasonably fixed rate.

- 8 9
- (b) No retail dispensary license shall be issued to:
- (1) A person who:

(A) Has not been a resident of this state for at least four yearsimmediately preceding the date of application; or

(B) has a beneficial interest in any other dispensary licensed under
this act, except that the spouse of a licensee may own and hold a license
for another dispensary;

15 (2) a copartnership, unless all of the copartners are qualified to obtaina license;

a corporation, limited liability company, limited partnership or
 limited liability partnership; or

19 (4) a trust, if any grantor, beneficiary or trustee would be ineligible to 20 receive a license under this act for any reason, except that the provisions of 21 subsection (a)(b) (a)(1)(F) shall not apply in determining whether a 22 beneficiary would be eligible for a license.

23

(c) No cultivator's license shall be issued to:

(1) A corporation, limited liability company, limited partnership or
 limited liability partnership, if any officer or director thereof, or any
 stockholder owning in the aggregate more than 25% of the stock of <u>the</u>
 <u>corporation</u> such entity would be ineligible to receive a cultivator's
 license;

(2) a copartnership, unless all of the copartners shall have been
residents of this state for at least<u>five</u> four years immediately preceding the
date of application and unless all the members of the copartnership would
be eligible to receive a cultivator's license under this act;

(3) a trust, if any grantor, beneficiary or trustee would be ineligible to
receive a license under this act for any reason, except that the provisions of
subsection (a)(6) (a)(1)(F) shall not apply in determining whether a
beneficiary would be eligible for a license; or

an individual who has not been a resident of this state for at least
 <u>five</u> four years immediately preceding the date of application.

39

(d) No distributor's license shall be issued to:

40 (1) A corporation, limited liability company, limited partnership or
 41 limited liability partnership, if any officer, director or stockholder of <u>the</u>
 42 <u>corporation</u> such entity would be ineligible to receive a distributor's
 43 license for any reason. It shall be unlawful for any stockholder of <u>a</u>

<u>corporation</u> an entity licensed as a distributor to transfer any stock in <u>the</u>
 <u>corporation</u> such entity to any person who would be ineligible to receive a
 distributor's license for any reason, and any such transfer shall be null and
 void, except that if:

5 (A) Any stockholder owning stock in the corporation such entity dies 6 and an heir or devisee to whom stock of the corporation such entity 7 transfers by descent and distribution or by will is ineligible to receive a 8 distributor's license, the legal representatives of the deceased stockholder's estate and the ineligible heir or devisee shall have 14 months from the date 9 10 of the death of the stockholder within which to sell the stock to a person eligible to receive a distributor's license. Any such sale by a legal 11 12 representative shall be made in accordance with the provisions of the 13 probate code; or

14 (B) the stock in any such <u>corporation</u> entity is the subject of any trust and any trustee or beneficiary of the trust who is 18 years of age or older is 15 16 ineligible to receive a distributor's license, the trustee, within 14 months 17 after the effective date of the trust, shall sell the stock to a person eligible to receive a distributor's license and hold and disburse the proceeds in 18 19 accordance with the terms of the trust. If any legal representatives, heirs, 20 devisees or trustees fail, refuse or neglect to sell any stock as required by 21 this subparagraph, the stock shall revert to and become the property of the 22 corporation such entity, and the corporation such entity shall pay to the 23 legal representatives, heirs, devisees or trustees the book value of the 24 stock. During the period of 14 months prescribed by this paragraph, the 25 corporation such entity shall not be denied a distributor's license or have 26 its distributor's license revoked if the corporation such entity meets all of 27 the other requirements necessary to have a distributor's license;

28 (2) a copartnership, unless all of the copartners are eligible to receive29 a distributor's license; or

30 (3) a trust, if any grantor, beneficiary or trustee would be ineligible to
31 receive a license under this act for any reason, except that the provisions of
32 subsection (a)(6) (a)(1)(F) shall not apply in determining whether a
33 beneficiary would be eligible for a license.

34

(e) No processor's license shall be issued to a:

(1) Copartnership, unless all of the copartners are qualified to obtain a
 license;

(2) corporation, limited liability company, limited partnership or
limited liability partnership, unless stockholders owning in the aggregate
50% 75% or more of the stock of the corporation such entity would be
eligible to receive such license and all other stockholders would be eligible
to receive such license except for reason of citizenship or residency; or

42 (3) a trust, if any grantor, beneficiary or trustee would be ineligible to 43 receive a license under this act for any reason, except that the provisions of

1 subsection $\frac{(a)(6)}{(a)(1)(F)}$ shall not apply in determining whether a 2 beneficiary would be eligible for a license. 3 New Sec. 21. (a) Any entity that seeks to cultivate medical marijuana 4 or to conduct laboratory testing of medical marijuana shall submit an-5 application for the appropriate license to the director of alcoholic beverage control in such form and manner as prescribed by the director. A separate 6 7 license application shall be submitted for each location to be operated by 8 the licensee. (b) The director shall issue a license to an applicant if: 9 10 (1) The criminal history record check conducted pursuant to section 11 48, and amendments thereto, with respect to the applicant demonstrates-12 that the applicant is not disqualified from holding a license pursuant to-13 section 20, and amendments thereto; 14 (2) the applicant is not applying for a laboratory license and 15 demonstrates that it does not have an ownership or investment interest in 16 or compensation arrangement with a laboratory licensed under this section 17 or an applicant for such license; (3) the applicant is not applying for a laboratory license and 18 19 demonstrates that it does not share any corporate officers or employees-20 with a laboratory licensed under this section or an applicant for such-21 license: 22 (4) the applicant demonstrates that it will not violate the provisions of 23 section 47, and amendments thereto: (5) the applicant has submitted a tax clearance certificate issued by 24 25 the department of revenue; and 26 (6) the applicant meets all other licensure eligibility conditions 27 established in rules and regulations adopted by the secretary of revenue 28 and has paid all required fees. 29 (c) The director shall issue not less than 15% of cultivator and 30 laboratory licenses to entities that are owned and controlled by United 31 States eitizens who are residents of this state and are members of one of 32 the following economically disadvantaged groups: Blacks or African-33 Americans, American Indians, Hispanics or Latinos and Asians. If no-34 applications or an insufficient number of applications are submitted by 35 such entities that meet the conditions set forth in subsection (b), licenses 36 shall be issued in accordance with subsections (a) and (b). 37 (d) A license shall be valid for a period of one year from the date such 38 license is issued and may be renewed by submitting a license renewal-39 application and paying the required fee. New Sec. 22. 21. (a) A cultivator licensee<u>may</u> shall cultivate medical 40 marijuana in an area-either on open farmland or in a building-and that is 41 42 designated by the licensee. A licensee may deliver or sell medical 43 marijuana to one or more licensed processors, distributors or dispensaries.

1 (b) A licensee may submit an application to the director of alcoholic 2 beverage control for approval of an expansion of such licensee's 3 cultivation area. Expansion approval applications shall be submitted in 4 such form and manner as prescribed by the director and shall include an 5 expansion plan that shall include the following:

6 (1) Specifications for the expansion or alteration that demonstrate 7 compliance with all applicable zoning ordinances, building codes and any 8 other state and local laws and rules and regulations adopted thereunder;

9 (2) a proposed timeline for completion of the expansion that, if 10 approved, will become a mandatory condition; and

(3) a history of compliance with the Kansas medical marijuana
 regulation act and all rules and regulations adopted thereunder, including a
 history of enforcement actions and sanctions issued by the department or
 any law enforcement agency against the licensee.

(c) (1) Unless authorized by this act, a cultivator shall not transfer or 15 16 sell medical marijuana and a processor shall not transfer, sell or process 17 into a concentrate or product any medical marijuana, medical marijuana 18 concentrate or medical marijuana product unless samples from each 19 harvest batch or production batch from which that medical marijuana, 20 medical marijuana concentrate or medical marijuana product was derived 21 has been tested by a licensed laboratory for contaminants and has passed 22 all contaminant tests required by this act.

(2) A licensed cultivator may transfer medical marijuana that has
 failed testing for quality control to a licensed processor only for the
 purposes of decontamination or remediation and only in accordance with
 the provisions of this act.

(d) A licensed cultivator shall not cultivate medical marijuana for
 personal, family or household use or on any public land.

29 New Sec. 23. (a) {(1) Within 45 days of the effective date of 30 this act, the director of alcoholic beverage control shall establish a 31 medical marijuana pilot program and select a company for the 32 purpose of cultivating, testing, processing, distributing and 33 researching medical marijuana. Such company shall operate the pilot 34 program by entering into a public-private partnership with the university of Kansas, Kansas state university and Pittsburg state 35 36 university. Such public-private partnership shall develop and provide 37 the director with recommended best practices for all aspects of the 38 cultivation, processing, dispensing and research and development of 39 medical marijuana.

40 (2) Notwithstanding any provision of this act to the contrary, the
41 director shall issue such company one cultivator license, one
42 laboratory license, one processor license, one distributor license and
43 three retail dispensary licenses that shall be valid for the duration of

1 the public-private partnership.}

2 {(b) (1)} Prior to January 1,<u>2022</u> 2023, the director of alcoholic 3 beverage control shall contract with an operational private laboratory for 4 the purpose of conducting compliance and quality assurance testing of 5 medical marijuana laboratories, processors and cultivators licensed in this 6 state in an effort to provide public safety and ensure quality medical 7 marijuana product is available to registered patients.

8 (b){(2)} Any laboratory under contract with the director for 9 compliance and quality assurance testing shall:

10 (H) Be prohibited from conducting any other commercial 11 medical marijuana testing in this state;

12 (2){(B)} have a minimum of one year of medical marijuana testing
 13 licensure in another state and have contracted for quality assurance testing
 14 with another state;

(3){(C)} not employ, or be owned by any individual:

16 (A){(i)} That has a direct or indirect financial interest in any licensee 17 in this state;

(B){(ii)} whose spouse, parent, child, spouse of a child, sibling or
 spouse of a sibling has an active application for a license from the director;
 or

 (\underline{C}) {(iii)} that is a member of the board of directors of a licensee.

22 (e){(3)} The laboratory under contract with the director for 23 compliance and quality assurance shall be accessible and utilized for any 24 medical marijuana testing needs by any regulatory agency within the state, 25 including, but not limited to, the department of health and environment, 26 the Kansas bureau of investigation and the state fire marshal.

New Sec.<u>24.</u> 23. (a) A laboratory licensee shall:

(1) Not be owned by a person who is a direct or indirect beneficial
owner of a retail dispensary, cultivator, processor or distributor;

(2) comply with all applicable local ordinances, including but not
 limited to zoning, occupancy, licensing and building codes;

32

27

15

21

(3) obtain a separate license for each laboratory;

(4) comply with the application requirements of this section and
 submit any information required by the director of alcoholic beverage
 control;

36 (5) establish policies to prevent the existence of or appearance of 37 undue commercial, financial or other influences that diminish, or have the 38 effect of diminishing the public confidence in, the competency, 39 impartiality and integrity of the testing processes or results of such laboratory. Such policies shall prohibit employees, owners or agents of a 40 41 laboratory who participate in any aspect of the analysis and results of a sample from improperly influencing the testing process, manipulating data 42 43 or benefiting from any ongoing financial, employment, personal or

1 business relationship with the licensee that submitted the sample for 2 testing;

3 (6) not test samples for any licensee in which an owner, employee or 4 agent of the laboratory has any form of ownership or financial interest in 5 the licensee that submitted the sample for testing;

6

(7) promptly provide the director access to:

7 (A) A report of a test and any underlying data that is conducted on a 8 sample at the request of a licensee or registered patient; and

9 (B) laboratory premises and to any material or information requested 10 by the director to determine compliance with the requirements of this 11 section;

(8) retain all results of laboratory tests conducted on medical
marijuana or medical marijuana products for a period of at least two years
and shall make them available to the director upon request;

(9) establish standards, policies and procedures for laboratory testing
 procedures in accordance with rules and regulations adopted under
 section-23 24, and amendments thereto;

(10) (A) test samples from each harvest batch or product batch, as
appropriate, of medical marijuana, medical marijuana concentrate and
medical marijuana product for each of the following categories of testing,
consistent with standards developed by the director:

- 22 (i) Microbials;
- 23 (ii) mycotoxins;
- 24 (iii) residual solvents;
- 25 (iv) pesticides;
- 26 (v) tetrahydrocannabinol and other cannabinoid potency;
- 27 (vi) terpenoid potency type and concentration;
- 28 (vii) moisture content;
- 29 (viii) homogeneity; and
- 30 (ix) heavy metals; and

(B) only accept a test batch of usable medical marijuana or medical
 marijuana product for testing purposes from a:

(i) Cultivator that has separated each harvest lot of usable marijuana
into harvest batches containing no more than 10 pounds, except harvest
batches of fresh, uncured medical marijuana or fresh or frozen medical
marijuana to be sold to a processor in order to make a concentrate may be
separated into batches containing no more than 20 pounds; and

- (ii) processor that has separated each medical marijuana productionlot into production batches containing no more than 10 pounds.
- 40
- (b) A laboratory licensee may:

41 (1) Accept samples of medical marijuana, medical marijuana42 concentrate or medical marijuana product from:

43 (A) A licensee or any entity designated in section <u>50 45</u> {44}, and

1 amendments thereto, for testing and research purposes only, including the 2 provision of testing services for samples submitted by a licensee for 3 product development. A laboratory shall not be prohibited from obtaining a 4 license under this section due to such laboratory performing testing and 5 research on medical marijuana and medical marijuana products for any 6 entity designated in section 50 45 {44}, and amendments thereto; or 7

(B) an individual person for testing if such person is a:

8 (i) Registered patient or caregiver under this act and such person 9 provides the laboratory with the individual's registration identification and 10 a valid photo identification; or

(ii) participant in an approved clinical or observational study 11 12 conducted by a research facility;

(2) transfer samples to another licensed laboratory for testing. All 13 laboratory reports provided to or by a licensee or to a patient or caregiver 14 shall identify the laboratory that performed the testing of the sample that is 15 16 submitted; and

17 (3) utilize a licensed distributor to transport samples of medical 18 marijuana, medical marijuana concentrates and medical marijuana product 19 for testing, in accordance with this act, between the original licensee 20 requesting testing services and the destination licensed laboratory 21 performing testing services.

22 New Sec. 25.24. (a) In consultation with the compliance and quality 23 assurance testing laboratory contracted with pursuant to section $\frac{23}{23}$ 22, and 24 amendments thereto, the director of alcoholic beverage control shall 25 propose rules and regulations as necessary to develop acceptable testing and research practices in consultation with the contracted compliance and 26 27 quality assurance testing laboratory, including, but not limited to, testing, 28 standards, quality control analysis, equipment certification and calibration 29 and chemical identification and substances used in bona fide research 30 methods. After the hearing on a proposed rule and regulation has been held 31 as required by law, the director shall submit any such proposed rule and 32 regulation to the secretary of revenue who, if the secretary approves it, 33 shall adopt the rule and regulation.

34 (b) The director shall recommend rules and regulations for laboratory 35 testing performed under this act concerning:

36 (1) The cleanliness and orderliness of the premises of a licensed 37 laboratory and the establishing of licensed laboratories in secured 38 locations:

39 (2) the inspection, cleaning and maintenance of any equipment or 40 utensils used for the analysis of test samples;

41 (3) testing procedures and standards for cannabinoid and terpenoid potency and safe levels of contaminants and appropriate remediation and 42 43 validation procedures;

1 (4) controlled access areas for storage of medical marijuana and 2 medical marijuana product test samples, **medical marijuana** waste and 3 reference standards;

4 (5) records to be retained and computer systems to be utilized by the 5 laboratory;

6 (6) the possession, storage and use by the laboratory of reagents, 7 solutions and reference standards;

8

(7) a certificate of analysis for each lot of reference standard;

9 (8) the transport and disposal of unused **medical** marijuana, **medical** 10 marijuana products and **medical marijuana** waste;

(9) the mandatory use by a laboratory of an inventory tracking system
to ensure all test harvest and production batches or samples containing
medical marijuana, medical marijuana concentrate or medical marijuana
products are identified and tracked from the point they are transferred from
a licensee or a registered patient or caregiver through the point of transfer,
destruction or disposal. The inventory tracking system reporting shall
include the results of any tests that are conducted;

18

(10) the employment of laboratory personnel;

19 (11) a written standard operating procedure manual to be maintained20 and updated by the laboratory;

(12) the successful participation in a proficiency testing program
 approved by the director for conducting each testing required by section <u>-24</u>
 23, and amendments thereto, in order to obtain and maintain certification;

(13) the establishment of and adherence to a quality assurance and
 quality control program to ensure sufficient monitoring of laboratory
 processes and the quality of results reported;

(14) the immediate recall of medical marijuana or medical marijuana
products that test above allowable thresholds or are otherwise determined
to be unsafe;

(15) the establishment by the laboratory of a system to document the
 complete chain of custody for samples from receipt through disposal;

(16) the establishment by the laboratory of a system to retain and
 maintain all required records, including business records, and processes to
 ensure results are reported in a timely and accurate manner; and

(17) any other aspect of laboratory testing of medical marijuana or
 medical marijuana product deemed necessary by the director.

37

43

New Sec.<u>-26.</u> 25. (a) A laboratory licensee may:

38 (1) Obtain medical marijuana from one or more licensed cultivators,39 processors or retail dispensaries; and

40 (2) conduct medical marijuana testing in accordance with the 41 requirements of section<u>-24</u> 23, and amendments thereto, and rules and 42 regulations adopted by the secretary of revenue.

(b) (1) Licensure of laboratories shall be contingent upon the

successful onsite inspection, participation in proficiency testing and
 ongoing compliance with the requirements of this act.

3 (2) A laboratory shall be inspected prior to initial licensure and up to 4 six times annually by an inspector approved by the director of alcoholic 5 beverage control. The director may enter the licensed premises of a 6 laboratory to conduct investigations and additional inspections when the 7 director believes an investigation or additional inspection is necessary due 8 to a possible violation of this act.

9 (3) After January 1, 2022, accreditation by the national environmental 10 laboratory accreditation program, ANSI/ASQ national accreditation board 11 or another accrediting body approved by the director shall be required for 12 licensure and renewal of licensure of laboratories.

13 <u>New See. 27. (a) The fees for a cultivator license shall be set by rules</u>
 14 <u>and regulations adopted by the secretary of revenue in an amount not to</u>
 15 <u>exceed an annual fee of:</u>

16 (1) \$5,000 for the license application; and

17 (2) \$20 per plant at the time of licensing and each subsequent renewal

18 for the maximum number of flowering medical marijuana plants, based

upon a declaration by the applicant, that are cultivated by the licensee in
 the facility at any given time.

21 (b) The fees for a laboratory license shall be set by rules and 22 regulations adopted by the secretary of revenue in an amount not to 23 exceed:

24 (1) \$2,000 for a laboratory license application;

25 (2) \$18,000 for a laboratory license; and

26 (3) \$20,000 for a renewal of a laboratory license.

27 <u>New Sec. 28. The director of alcoholic beverage control may refuse</u>

28 to issue or renew a license, or may revoke or suspend a license for any of
 29 the following reasons:

30 (a) The applicant has failed to comply with any provision of the-

31 <u>Kansas medical marijuana regulation act or any rules and regulations</u>
 32 <u>adopted thereunder;</u>

33 (b) the applicant has falsified or misrepresented any information 34 submitted to the director in order to obtain a license;

35 (e) the applicant has failed to adhere to any acknowledgment,

36 <u>verification or other representation made to the director when applying for</u>
 37 <u>a license;</u>

38 (d) the applicant has failed to submit or disclose information 39 requested by the director; or

40 (e) the applicant has failed to demonstrate that the person, limited

41 <u>liability company or corporation whose ownership on the date of issuance</u>

- 42 <u>consists of at least 50% residents of Kansas.</u>
- 43 <u>New Sec. 29. (a) In addition to or in lieu of any other civil or criminal</u>

1 penalty as provided by law, the director of alcoholic beverage control may 2 impose a civil penalty or suspend or revoke a license upon a finding that 3 the licensee committed a violation as provided in this section. 4 (b) (1) Upon a finding that a licensee has submitted fraudulent 5 information or otherwise falsified or misrepresented information required 6 to be submitted by such licensee, the director may impose a civil fine not 7 to exceed \$5,000 for a first offense and may suspend or revoke such-8 licensee's license for a second or subsequent offense. 9 (2) Upon a finding that a licensee has sold, transferred or otherwise 10 distributed medical marijuana in violation of this act, the director may-11 impose a civil fine not to exceed \$5,000 for a first offense and may-12 suspend or revoke such licensee's license for a second or subsequent-13 offense. 14 (e) If the director suspends, revokes or refuses to renew any license 15 issued pursuant to this act and determines that there is clear and 16 convincing evidence of a danger of immediate and serious harm to any 17 person, the director may place under seal all medical marijuana owned by 18 or in the possession, custody or control of the affected license holder. 19 Except as provided in this section, the director shall not dispose of the 20 sealed medical marijuana until a final order is issued authorizing such-21 disposition. During the pendency of an appeal from any order by the 22 director, a court may order the director to sell medical marijuana that is 23 perishable, and the proceeds of any such sale shall be deposited with the 24 court. 25 New Sec. 30. (a) There is hereby established the medical marijuana 26 eultivation regulation fund in the state treasury. The director of alcoholie 27 beverage control shall administer the medical marijuana cultivation-28 regulation fund and shall remit all moneys collected from the payment by 29 eultivators and laboratories of all fees and fines imposed by the director-30 pursuant to the Kansas medical marijuana regulation act and any other-31 moneys received by or on behalf of the director pursuant to such act to the 32 state treasurer in accordance with the provisions of K.S.A. 75-4215, and 33 amendments thereto. Upon receipt of each such remittance, the state-34 treasurer shall deposit the entire amount in the state treasury to the credit 35 of the medical marijuana cultivation regulation fund. Moneys credited to 36 the medical marijuana cultivation regulation fund shall only be expended 37 or transferred as provided in this section. Expenditures from such fund-38 shall be made in accordance with appropriation acts upon warrants of the 39 director of accounts and reports issued pursuant to vouchers approved by 40 the director or the director's designee. 41 (b) Moneys in the medical marijuana cultivation regulation fund shall 42 be used for the payment or reimbursement of costs related to the regulation

43 and enforcement of the cultivation, possession, testing and sale of medical

1 marijuana by the division of alcoholic beverage control. New Sec.<u>31.</u> 26. (a) (1) An application for the appropriate 2 license shall be submitted to the director of alcoholic beverage control 3 4 in such form and manner as prescribed by the director by any person 5 or entity that seeks to: 6 (A) Cultivate medical marijuana; 7 (B) conduct laboratory testing of medical marijuana; 8 (C) process or distribute medical marijuana shall submit an 9 application for the appropriate license to the director of alcoholic beverage 10 control in such form and manner as prescribed by the director; dispense medical marijuana at retail; or 11 (D) 12 **(E)** be an associated employee, key employee or support 13 employee. 14 (2) A separate license application shall be submitted for each location 15 to be operated by the licensee. 16 (b) {Except as provided in subsection (e),} the director shall issue a 17 license to an applicant if: 18 (1) The criminal history record check conducted pursuant to section 19 48 - 43 $\{42\}$, and amendments thereto, with respect to the applicant 20 demonstrates that the applicant is not disqualified from holding a license 21 pursuant to section 20, and amendments thereto; 22 (2) the applicant is not applying for a laboratory license and 23 demonstrates that it does not: 24 (A) Have an ownership or investment interest in or compensation 25 arrangement with a licensed laboratory-licensed under section 21, and 26 amendments thereto, or an applicant for such license; or 27 (3) the applicant demonstrates that it does not 28 (B) share any corporate officers or employees with a licensed 29 laboratory-licensed under section 21, and amendments thereto, or an applicant for such license; 30 31 (4)(3) the applicant demonstrates that it will not violate the provisions 32 of section_47-42 {41}, and amendments thereto; 33 (5)(4) the applicant has submitted a tax clearance certificate issued by the department of revenue; and 34 35 (5) the applicant is applying for a cultivator license and 36 demonstrates the ability to grow medical marijuana in a secure indoor 37 facility and maintain adequate control against the diversion, theft and 38 loss of all medical marijuana to be grown by the applicant; 39 (6) the applicant seeking licensure has submitted an attestation to 40 the director under penalty of perjury, in a form and manner prescribed by the director, that confirms or denies the existence of any 41 foreign financial interests associated with the entity applying for such 42 43 license and discloses the identity of such ownership, if applicable; and

1 (<u>(()</u>(7) the applicant meets all other licensure eligibility conditions 2 established in rules and regulations adopted by the secretary of revenue 3 and has paid all required fees.

4 (c) The director shall issue not less than 15% of cultivator, 5 laboratory, processor-and, distributor and retail dispensary licenses to 6 entities that are owned and controlled by United States citizens who are residents of this state and are members of one of the following 7 8 economically disadvantaged groups: Blacks or African Americans, American Indians, Hispanics or Latinos and Asians. If no applications or 9 an insufficient number of applications are submitted by such entities that 10 meet the conditions set forth in subsection (b), licenses shall be issued in 11 12 accordance with subsections (a) and (b).

13

29

(d) (1) A license shall be valid for a period of:

(A) One year from the date such license is issued, and to a cultivator,
 laboratory, processor and distributor; and

16 **(B)** two years from the date such license is issued to a retail 17 dispensary or any associated employee, key employee or support 18 employee.

(2) Any license may be renewed by submitting a license renewalapplication and paying the required fee.

21 {(e) The board of county commissioners of any county may 22 prohibit a licensee from establishing a facility licensed under this act 23 in such county by adoption of a resolution prohibiting the establishment of any facility licensed under this act in such county. 24 Any licensee that is lawfully operating at the time such resolution is 25 adopted shall be permitted to continue operating in such county and 26 shall not be denied renewal of any license based upon the adoption of 27 28 such resolution.

New Sec.<u>32.</u> 27. (a) A processor licensee may:

30 (1) Obtain medical marijuana from one or more licensed cultivators31 or processors;

32 (2) subject to subsection (b), process medical marijuana obtained
33 from one or more licensed cultivators into a form described in section <u>36</u>
34 <u>31</u> (30), and amendments thereto; and

(3) deliver or sell processed medical marijuana to one or morelicensed processors, distributors or retail dispensaries.

(b) When packaging medical marijuana for final retail sale, a licensedprocessor shall:

39 (1) Package the medical marijuana in accordance with child-resistant
40 effectiveness standards described in 16 C.F.R. § 1700.15(b) in effect on
41 July 1, 2021;

42 (2) label the medical marijuana packaging with the product's 43 tetrahydrocannabinol and cannabidiol content; and

1 (3) comply with any packaging or labeling requirements established by rules and regulations adopted by the secretary of revenue. 2 3 New Sec. 33. **28.** (a) A distributor licensee may: (1) Purchase at wholesale medical marijuana from one or more 4 5 licensed processors and cultivators; 6 (2) store medical marijuana obtained from one or more licensed 7 processors in a form described in section 36 31 {30}, and amendments 8 thereto: and 9 (3) deliver, package for finale sale or sell processed medical marijuana to one or more licensed retail dispensaries. 10 (b) When storing or selling medical marijuana, a licensed distributor 11 shall ensure that such medical marijuana meets the packaging and labeling 12 13 requirements established by rules and regulations adopted by the secretary of revenue 14 15 New Sec. 34. 29. (a) Any entity that seeks to dispense at retail 16 medical marijuana shall submit an application for a retail dispensary-17 license in such form and manner as prescribed by the director of alcoholic 18 beverage control. A separate license application shall be submitted for each 19 location to be operated by the licensee. 20 (b) The director shall issue a license to an applicant if: 21 (1) The criminal history record check conducted pursuant to section 22 48, and amendments thereto, with respect to the applicant demonstrates-23 that the applicant is not disqualified from holding a license pursuant to-24 section 20, and amendments thereto: 25 (2) the applicant demonstrates that it does not have an ownership or 26 investment interest in or compensation arrangement with a laboratory-27 licensed under section 21, and amendments thereto, or an applicant for-28 such license; 29 (3) the applicant demonstrates that it does not share any corporate officers or employees with a laboratory licensed under section 21, and-30 31 amendments thereto, or an applicant for such license; 32 (4) the applicant demonstrates that it will not violate the provisions of 33 section 47, and amendments thereto; 34 (5) the applicant has submitted a tax clearance certificate issued by 35 the department of revenue; and 36 (6) the applicant meets all other licensure eligibility conditions-37 established in rules and regulations adopted by the secretary and has paid 38 all required fees. 39 (c) The director shall issue not less than 15% of retail dispensary-40 licenses to entities that are owned and controlled by United States citizens who are residents of this state and are members of one of the following 41 economically disadvantaged groups: Blacks or African Americans.-42 43 American Indians, Hispanics or Latinos and Asians. If no application or an

1 insufficient number of applications are submitted by such entities that meet 2 the conditions set forth in subsection (b), licenses shall be issued in-3 accordance with subsections (a) and (b). (d) Each associated, key and support employee of a licensed retail-4 5 dispensary shall submit an application for an employee license for such 6 employee in such form and manner as prescribed by the director. A-7 separate license application shall be submitted for each employee. The 8 director shall issue a license to an applicant if all of the following-9 conditions are met: 10 (1) The criminal history record check conducted pursuant to section 48 43, and amendments thereto, with respect to the applicant demonstrates 11 that the applicant is not disqualified from holding a license pursuant to-12 13 section 20, and amendments thereto; and 14 (2) the applicant meets all other licensure eligibility conditions established in rules and regulations adopted by the secretary of revenue 15 16 and has paid all required fees. 17 (c)(b) A license shall be valid for a period of two years from the date 18 such license is issued and may be renewed by submitting a license renewal 19 application and paying the required fee. New Sec. <u>35. 30.</u> {29.} (a) A retail dispensary licensee may: 20 21 (1) Obtain medical marijuana from one or more licensed cultivators, 22 processors or distributors; and 23 (2) <u>unless prohibited pursuant to subsection (f)</u>, dispense or sell 24 medical marijuana in accordance with subsection (b). (b) When dispensing or selling medical marijuana, a retail dispensary 25 26 shall: 27 (1) Dispense or sell medical marijuana only to a person who shows 28 provides the dispensary with a current, valid identification card and only 29 in accordance with a written recommendation issued by a physician: 30 (2) report to the prescription monitoring program database the 31 information required by K.S.A. 65-1683, and amendments thereto, and 32 rules and regulations adopted by the board of pharmacy pursuant to section 33 43-38 {37}, and amendments thereto; 34 (3) ensure that the package containing medical marijuana is labeled 35 with the following information: 36 (A) The name and address of the licensed processor that produced the 37 product and the retail dispensary; 38 (B) the name of the patient and caregiver, if any; 39 (C) the name of the physician who recommended treatment with 40 medical marijuana; 41 (D) the directions for use, if any, as recommended by the physician; a health warning as specified in rules and regulations adopted by 42 (E) 43 the secretary of health and environment;

(F) the date on which the medical marijuana was dispensed; and

2 (G) the quantity, strength, kind or form of medical marijuana 3 contained in the package;

4 (4) package the medical marijuana in accordance with child-resistant 5 effectiveness standards described in 16 C.F.R. § 1700.15(b), as in effect on 6 July 1, 2021; and

7 (5) dispense or sell medical marijuana in an official tamper-proof 8 Kansas specific package that is clearly marked and approved by the 9 director.

(c) A retail dispensary shall employ only those individuals who hold a
 current, valid employee license issued pursuant to section<u>-34</u> 26, and
 amendments thereto, and who have completed the training requirements
 established by rules and regulations recommended by the director of
 alcoholic beverage control and adopted by the secretary of revenue.

15 (d) {(1) Each associated, key and support employee of a licensed 16 retail dispensary shall submit an application for an employee license 17 for such employee in such form and manner as prescribed by the 18 director. A separate license application shall be submitted for each 19 employee. The director shall issue a license to an applicant if all of the 20 following conditions are met:

(A) The criminal history record check conducted pursuant to
section 42, and amendments thereto, with respect to the applicant
demonstrates that the applicant is not disqualified from holding a
license pursuant to section 20, and amendments thereto; and

(B) the applicant meets all other licensure eligibility conditions
established in rules and regulations adopted by the secretary of
revenue and has paid all required fees.

(2) A license shall be valid for a period of two years from the date
 such license is issued and may be renewed by submitting a license
 renewal application and paying the required fee.}

31 {(e)} A retail dispensary shall designate a pharmacist consultant who is
32 a pharmacist licensed in this state and registered pursuant to section<u>-44-39</u>
33 {38}, and amendments thereto.

34

1

(e){(f)} A retail dispensary shall{:}

35 {(1) Maintain a 9" by 18" sign that is prominently displayed near 36 the check-out counter and the primary door of entry and exit that 37 includes a warning in accordance with rules and regulations adopted 38 by the board of healing arts that warns pregnant women and anyone 39 with psychiatric or emotional disorders that marijuana of any type 40 can be dangerous to your health; and}

41 {(2)} not make public any information it collects that identifies or 42 would tend to identify any specific patient.

43 (f) The board of county commissioners of any county may-

1 prohibit establishing a dispensary in such county by adoption of a

2 resolution prohibiting the establishment of a dispensary in such-

3 county. Any retail dispensary that is lawfully operating at the time-

4 such resolution is adopted shall be permitted to continue operating in

5 such county and shall not be denied renewal of any license based upon

6 the adoption of such resolution.

New Sec. <u>36. 31.</u> {30.} (a) Only the following forms of medical
marijuana may be dispensed under the Kansas medical marijuana
regulation act:

- 10 (1) Oils;
- 11 (2) tinctures;
- 12 (3) plant material;
- 13 (4) edibles;
- 14 (5) patches; or

15 (6) any other form approved by the secretary of revenue under section 16 $\frac{37 32}{31}$, and amendments thereto.

(b) The smoking, combustion or vaporization of medical marijuana isprohibited.

(c) Any form or method of using medical marijuana that is consideredattractive to children is prohibited.

(d) Plant material shall have a tetrahydrocannabinol content of not
 more than 35% in its final, dispensed form.

(e) Extracts shall have a tetrahydrocannabinol content of not morethan 70% in their final, dispensed form.

(f) No form of medical marijuana shall be dispensed from a vendingmachine or through electronic commerce.

New Sec. <u>37. 32.</u> {31.} (a) Any person may submit a petition to the
director of alcoholic beverage control requesting that a form or method of
using medical marijuana be approved for the purposes of section <u>36-31</u>
{30}, and amendments thereto. The petition shall be submitted in such
form and manner as prescribed by the director.

32 (b) Upon receipt of a petition, the director shall review such petition 33 to determine whether to recommend approval of the form or method of 34 using medical marijuana described in the petition. The director may 35 consolidate the review of petitions for the same or similar forms or 36 methods. The director shall consult with the medical marijuana advisory 37 committee and review any relevant scientific evidence when reviewing a 38 petition. The director shall recommend to the secretary of revenue whether 39 to approve or deny the proposed form or method of using medical 40 marijuana. The secretary shall approve or deny such proposed form or 41 method. The secretary's decision shall be final.

42 (c) Any petition that is<u>recommended for denial</u> **denied** by the 43 <u>director</u> secretary shall not be resubmitted until 12 months have elapsed

since the petition was-submitted denied. 1 2 New Sec. <u>38</u>. <u>33</u>. (a) The fees for a cultivator license shall be: (1) \$5,000 for the nonrefundable license application; and 3 (2) \$20 per plant, for a minimum of 1,000 flowering plants, to be 4 assessed at the time of licensing and each subsequent renewal for the 5 6 maximum number of flowering medical marijuana plants, based upon 7 a declaration by the applicant, that are cultivated by the licensee in 8 the facility at any given time. (b) The fees for a laboratory license shall be: 9 (1) \$2,000 for the nonrefundable laboratory license application; 10 (2) \$18,000 for a laboratory license; and 11 (3) \$20,000 for a renewal of a laboratory license. 12 (c) The fees for a processor license shall be<u>set by rules and</u> 13 regulations adopted by the secretary of revenue in an amount not to-14 15 exceed: 16 (1) \$5,000 for<u>-a</u> the nonrefundable processor license application; 17 and 18 (2) \$40,000 for a processor license and any renewal thereof. 19 (b)(d) The fees for a distributor license shall be set by rules and 20 regulations adopted by the secretary of revenue in an amount not to-21 exceed: 22 (1) \$5,000 for<u>-a</u> the nonrefundable distributor license application; 23 and 24 (2) \$40,000 for a distributor license and any renewal thereof. 25 (e) The fees for a retail dispensary license shall be set by rules and regulations adopted by the secretary of revenue in an amount not to-26 27 exceed: 28 (1) \$5,000 for<u>—a</u> the nonrefundable retail dispensary license 29 application; 30 (2) \$40,000 for a retail dispensary license and any renewal thereof; (3) \$500 for each associated employee license application; 31 32 (4) \$250 for each key employee license application; and (5) \$100 for each support employee license application. 33 New Sec.<u>39.34.</u> {33.} The director of alcoholic beverage control 34 35 may refuse to issue or renew a license, or may revoke or suspend a license 36 if the applicant has: 37 (a) Failed to comply with any provision of the Kansas medical 38 marijuana regulation act or any rules and regulations adopted thereunder; 39 (b) falsified or misrepresented any information submitted to the 40 director in order to obtain a license; 41 (c) failed to adhere to any acknowledgment, verification or other representation made to the director when applying for a license; or 42 43 (d) failed to submit or disclose information requested by the director.

New Sec. <u>40. 35.</u> {34.} (a) In addition to or in lieu of any other civil 1 or criminal penalty as provided by law, the director of alcoholic beverage 2 3 control may impose a civil penalty or suspend or revoke a license upon a 4 finding that the licensee committed a violation as provided in this section.

5 (b) (1) Upon a finding that a licensee has submitted fraudulent 6 information or otherwise falsified or misrepresented information required 7 to be submitted by such licensee, the director may impose a civil fine not 8 to exceed \$5,000 for a first offense and may suspend or revoke such 9 licensee's license for a second or subsequent offense.

10 (2) (A) Except as provided in paragraph (B), upon a finding that a licensee has cultivated, tested, processed, sold, transferred or otherwise 11 distributed medical marijuana in violation of this act, the director may 12 impose a civil fine not to exceed \$5,000 for a first offense and may 13 suspend or revoke such licensee's license for a second or subsequent 14 15 offense.

16 (B) Upon a finding that a retail dispensary licensee has knowingly 17 disclosed patient information to any individual, the director shall impose a 18 civil fine of \$5,000 and revoke such licensee's license.

19 (c) The director may require any licensee to submit a sample of 20 medical marijuana, medical marijuana concentrate or medical marijuana 21 product to a laboratory upon demand.

22 (d) If the director suspends, revokes or refuses to renew any license 23 issued pursuant to this act and determines that there is clear and 24 convincing evidence of a danger of immediate and serious harm to any 25 person, the director may place under seal all medical marijuana owned by or in the possession, custody or control of the affected license holder. 26 27 Except as provided in this section, the director shall not dispose of the 28 sealed medical marijuana until a final order is issued authorizing such 29 disposition. During the pendency of an appeal from any order by the 30 director, a court may order the director to sell medical marijuana that is 31 perishable, and the proceeds of any such sale shall be deposited with the 32 court.

33 New Sec. <u>41. 36.</u> {35.} (a) There is hereby established the medical 34 marijuana business entity regulation fund in the state treasury. The director 35 of alcoholic beverage control shall administer the medical marijuana 36 business entity regulation fund and shall remit all moneys collected from 37 the payment by licensed cultivator, laboratories, processors, distributors and, retail dispensaries, associated employees, key employees and 38 39 support employees of all fees and fines imposed by the director pursuant 40 to the Kansas medical marijuana regulation act and any other moneys 41 received by or on behalf of the director pursuant to such act to the state 42 treasurer in accordance with the provisions of K.S.A. 75-4215, and 43 amendments thereto. Upon receipt of each such remittance, the state

1 treasurer shall deposit the entire amount in the state treasury to the credit 2 of the medical marijuana business entity regulation fund. Moneys credited 3 to the medical marijuana business entity regulation fund shall only be 4 expended or transferred as provided in this section. Expenditures from 5 such fund shall be made in accordance with appropriation acts upon 6 warrants of the director of accounts and reports issued pursuant to 7 vouchers approved by the director or the director's designee.

8 (b) Moneys in the medical marijuana business entity regulation fund 9 shall be used for the payment or reimbursement of costs related to the 10 regulation and enforcement of the **cultivation**, **testing**, **distributing**, 11 possession, processing and sale of medical marijuana by the division of 12 alcoholic beverage control.

13 New Sec. <u>42. 37.</u> {36.} (a) On or before July $1, \frac{2022}{2023}$, the director of alcoholic beverage control shall propose rules and 14 regulations to administer the Kansas medical marijuana regulation 15 16 act, and the secretary of revenue shall, after consulting with the medical 17 marijuana advisory committee, adopt rules and regulations to administer 18 the Kansas medical marijuana regulation program and implement and enforce the provisions of the Kansas medical marijuana regulation this act. 19 20 Such rules and regulations shall:

(1) Establish application procedures and fees for licenses issued
 under<u>sections 21</u>, section 26, <u>31 and 34</u>, and amendments thereto;

(2) specify the conditions for eligibility for licensure;

23

(3) establish a license renewal schedule_z {and} renewal procedures
 and renewal fees;

26 (4) establish standards and procedures for the testing of medical27 marijuana by a licensed laboratory;

(5) establish official packaging requirements that designate the
 package as Kansas medical marijuana and ensure the packaging is tamper proof; and

(6) establish requirements for a cultivator to grow medical
marijuana in a secure indoor facility and maintain adequate control
against the diversion, theft and loss of all medical marijuana to be
grown by the applicant; and

35 (7) establish training requirements for employees of retail36 dispensaries.

(b) The director of alcoholic beverage control shall propose such rules and regulations as necessary to carry out the intent and purposes of this act. After the hearing on a proposed rule and regulation has been held as required by law, the director shall submit the proposed rule and regulation to the secretary of revenue who, if the secretary approves it, shall adopt the rule and regulation.

43 (c) When adopting rules and regulations under this section, the

1 secretary shall consider standards and procedures that have been found to 2 be best practices relative to the use and regulation of medical marijuana.

3 New Sec. 43. 38. {37.} (a) On or before July 1, 2022, the board of pharmacy shall adopt rules and regulations establishing the requirements 4 5 for a.

6 (1) Retail dispensary to report to the prescription monitoring program 7 database, including, but not limited to, the: (A) Methods of transmission:

8 9

10

(B) nationally recognized telecommunications format to be used;

(C) frequency of such reports; and

(D) procedures for the maintenance of information submitted to or 11 12 received from the prescription monitoring program database to ensure such information is treated as confidential and is subject to the requirements of 13 K.S.A. 65-1685 and 65-1687, and amendments thereto; and 14

(2) pharmacist to register as a pharmacist consultant for a retail 15 16 dispensary.

17 (b) Every September 15, December 15, March 15 and June 15, the 18 board of pharmacy shall certify to the director of accounts and reports the 19 amount of moneys expended for operation and maintenance of the Kansas prescription drug monitoring program that is attributable to this act. Upon 20 21 receipt of each such certification, or as soon thereafter as moneys are 22 available, the director of accounts and reports shall transfer the amount 23 certified from the medical marijuana business entity regulation fund to the 24 state board of pharmacy fee fund.

25 New Sec. 44. 39. {38.} (a) Any pharmacist that seeks to operate as a pharmacist consultant for a retail dispensary shall register with the board 26 27 of pharmacy in accordance with rules and regulations adopted by the 28 board.

29 (b) In operating as a pharmacist consultant for a retail dispensary, 30 such pharmacist shall:

31 (1) Not charge a fee for the pharmacist's services that exceeds 1% of 32 the gross receipts of the retail dispensary;

33 (2) audit each recommendation for use of medical marijuana and 34 ensure that each such recommendation is reported to the prescription monitoring system in accordance with K.S.A. 65-1683, and amendments 35 36 thereto, and rules and regulations adopted by the board of pharmacy;

37 (3) develop and provide training to other retail dispensary employees 38 at least once every 12 months that:

39 (A) Establishes guidelines for providing information to registered 40 patients related to risks, benefits and side effects associated with medical 41 marijuana:

42 (B) explains how to identify the signs and symptoms of substance 43 abuse:

1 (C) establishes guidelines for refusing to provide medical marijuana 2 to an individual who appears to be impaired or abusing medical marijuana; 3 and

- 4 (D) assists in the development and implementation of review and 5 improvement processes for patient education and support provided by the 6 retail dispensary;
- 7

(4) provide oversight for the development and dissemination of:

8 (A) Education materials for qualifying patients and designated 9 caregivers that include:

10 (i) Information about possible side effects and contraindications of 11 medical marijuana;

(ii) guidelines for notifying the physician who provided the written
 certification for medical marijuana if side effects or contraindications
 occur;

(iii) a description of the potential effects of differing strengths ofmedical marijuana strains and products;

(iv) information about potential drug-to-drug interactions, including
 interactions with alcohol, prescription drugs, nonprescription drugs and
 supplements;

20 (v) techniques for the use of medical marijuana and marijuana 21 paraphernalia; and

(vi) information about different methods, forms and routes of medical
 marijuana administration;

(B) systems for documentation by a registered patient or designated
 caregiver of the symptoms of a registered patient that includes a logbook,
 rating scale for pain and symptoms and guidelines for a patient's self assessment; and

(C) policies and procedures for refusing to provide medical marijuana
 to an individual who appears to be impaired or abusing medical marijuana;
 and

31 32 (5) be accessible by the retail dispensary or dispensary agent through:

(A) Telephonic means at all times during operating hours; and

(B) telephone or video conference for a patient consultation duringoperating hours.

New Sec. <u>45. 40.</u> **(39.)** (a) The director of alcoholic beverage control shall establish and maintain an electronic database to monitor medical marijuana from its seed source through its cultivation, testing, processing, distribution and dispensing. The director may contract with a separate entity to establish and maintain all or any portion of the electronic database on behalf of the division of alcoholic beverage control.

(b) The electronic database shall allow for information regarding
medical marijuana to be updated instantaneously. Any licensed cultivator,
laboratory, processor, distributor or retail dispensary shall submit such

information to the director as the director determines is necessary for
 maintaining the electronic database.

3 (c) The director, any employee of the division, any entity under 4 contract with the director and any employee or agent thereof shall not 5 make public any information reported to or collected by the director under 6 this section that identifies or would tend to identify any specific patient. 7 Such information shall be kept confidential to protect the privacy of the 8 patient. The provisions of this subsection shall expire on July 1, 2026, 9 unless the legislature reviews and reenacts such provisions in accordance 10 with K.S.A. 45-229, and amendments thereto, prior to July 1, 2026.

New Sec. <u>46. 41.</u> **(40.)** (a) The director of alcoholic beverage control 11 may, in cooperation with the state treasurer, establish a-closed-loop-12 13 payment processing system whereby the state treasurer creates accounts to be used only by registered patients and caregivers at licensed retail 14 dispensaries and all licensed cultivators, laboratories, processors and 15 16 distributors. The system may include record-keeping and accounting 17 functions that identify all parties in transactions involving the purchase and sale of medical marijuana. If established, such system shall be 18 19 designed to prevent:

20 (1) Revenue from the sale of marijuana going to criminal enterprises,21 gangs and cartels;

(2) the diversion of marijuana from a state where it is legal in someform under that state's law to another state;

24

(3) the distribution of marijuana to minors; and

(4) the use of state-authorized marijuana activity as a cover or pretext
for the trafficking of other illegal drugs or for other illegal activity.

(b) The information recorded by the system shall be fully accessible
to the department of health and environment, the director and all state and
federal law enforcement agencies, including the United States department
of the treasury's financial crimes enforcement network.

31 New Sec. 47. 42. {41.} (a) Except as provided in subsections (b) and (c), no licensed cultivator, laboratory, processor, distributor or retail 32 33 dispensary shall be located within 1,000 feet of the boundaries of a parcel 34 of real estate having situated on it a school, religious organization, public 35 library or public park. If the relocation of a licensed cultivator, laboratory, 36 processor, distributor or retail dispensary results in such licensee being 37 located within 1,000 feet of the boundaries of a parcel of real estate having 38 situated on it a school, religious organization, public library or public park, 39 the director shall revoke the license such agency previously issued to such 40 cultivator, laboratory, processor, distributor or retail dispensary.

41 (b) (1) The director may, in the director's discretion, not revoke the
42 license of a cultivator, laboratory, processor, distributor or retail dispensary
43 if such licensee existed at a location prior to the establishment of a school,

religious organization, public library or public park within 1,000 feet of
 such licensee.

3 (2) Any licensee may petition for and receive an exemption from the
 4 provisions of this section upon approval by the secretary of health and
 5 environment and the director of alcoholic beverage control.

6 (c) This section shall not apply to research related to marijuana 7 conducted at a postsecondary educational institution, academic medical 8 center or private research and development organization as part of a 9 research protocol approved by an institutional review board or equivalent 10 entity.

11

(d) As used in this section:

(1) "Public library" means any library established pursuant to article
12 of chapter 12 of the Kansas Statutes Annotated, and amendments
thereto, and any other library that serves the general public and is funded
in whole, or in part, from moneys derived from tax levies;

(2) "public park" means any park or other outdoor recreational area or
facility, including, but not limited to, parks, open spaces, trails, swimming
pools, playgrounds and playing courts and fields, established by the state,
or any political subdivision thereof;

(3) "religious organization" means any organization, church, body of 20 21 communicants or group, gathered in common membership for mutual 22 support and edification in piety, worship and religious observances, or a 23 society of individuals united for religious purposes at a definite place and such religious organization maintains an established place of worship 24 25 within this state and has a regular schedule of services or meetings at least 26 on a weekly basis and has been determined to be organized and created as 27 a bona fide religious organization; and

(4) "school" means any public or private educational institution,
including, but not limited to, any college, university, community college,
technical college, high school, middle school, elementary school, trade
school, vocational school or other professional school providing training
or education.

33 New Sec. 48. 43. {42.} Each applicant for a cultivator license, 34 laboratory license, processor license, distributor license or retail 35 dispensary license shall require any owner, director, officer and any 36 employee or agent of such applicant to be fingerprinted and to submit to a 37 state and national criminal history record check. The director of alcoholic 38 beverage control is authorized to submit the fingerprints to the Kansas 39 bureau of investigation and the federal bureau of investigation for a state 40 and national criminal history record check. The director shall use the information obtained from fingerprinting and the state and national 41 criminal history record check for purposes of verifying the identification 42 43 of the applicant and for making a determination of the qualifications of the

1 applicant for licensure. The Kansas bureau of investigation may charge a

2 reasonable fee to the applicant for fingerprinting and conducting a criminal3 history record check.

4 New Sec.<u>49.44.</u> {43.} (a) A financial institution that provides financial services to any licensed cultivator, laboratory, processor, 5 distributor or retail dispensary shall be exempt from any criminal law of 6 7 this state an element of which may be proven by substantiating that a 8 person provides financial services to a person who possesses, delivers or manufactures medical marijuana or medical marijuana-derived products, 9 including any of the offenses specified in article 57 of chapter 21 of the 10 Kansas Statutes Annotated, and amendments thereto, or any attempt, 11 conspiracy or solicitation specified in article 53 of chapter 21 of the 12 Kansas Statutes Annotated, and amendments thereto, if the cultivator, 13 laboratory, processor, distributor or retail dispensary is in compliance with 14 the provisions of this act and all applicable tax laws of this state. 15

16 (b) (1) Upon the request of a financial institution, the director of 17 alcoholic beverage control shall provide to the financial institution the 18 following information:

(A) Whether a person with whom the financial institution is seeking
 to do business is a licensed cultivator, laboratory, processor, distributor or
 retail dispensary;

(B) the name of any other business or individual affiliated with theperson;

(C) an unredacted copy of such person's application for a license, and
 any supporting documentation, that was submitted by the person;

26 (D) if applicable, information relating to sales and volume of product27 sold by the person;

(E) whether the person is in compliance with the provisions of thisact; and

(F) any past or pending violations of the Kansas medical marijuana
regulation act or any rules and regulations adopted thereunder committed
by such person, and any penalty imposed on the person for such violation.

(2) The director may charge a financial institution a reasonable fee to
 cover the administrative cost of providing information requested under this
 section.

(c) Information received by a financial institution under subsection
(b) is confidential. Except as otherwise permitted by any other state or
federal law, a financial institution shall not make the information available
to any person other than the customer to whom the information applies and
any trustee, conservator, guardian, personal representative or agent of that
customer.

42 (d) As used in this section:

43 (1) "Financial institution" means any bank, trust company, savings

bank, credit union or savings and loan association or any other financial
 institution regulated by the state of Kansas, any agency of the United
 States or other state with an office in Kansas; and

4 (2) "financial services" means services that a financial institution is 5 authorized to provide under chapter nine or article 22 of chapter 17 of the 6 Kansas Statutes Annotated, and amendments thereto, as applicable.

New Sec. 50. 45. {44.} Nothing in this act authorizes the director of
alcoholic beverage control to oversee or limit research conducted at a
postsecondary educational institution, academic medical center or private
research and development organization that is related to marijuana and is
approved by an agency, board, center, department or institute of the United
States government, including any of the following:

- 13
 - (a) The agency for health care research and quality;
- 14 (b) the national institutes of health;
- 15 (c) the national academy of sciences;
- 16 (d) the centers for medicare and medicaid services;

17 (e) the United States department of defense;

- 18 (f) the centers for disease control and prevention;
- 19 (g) the United States department of veterans affairs;
- 20 (h) the drug enforcement administration;
- 21 (i) the food and drug administration; and
- (j) any board recognized by the national institutes of health for thepurpose of evaluating the medical value of health care services.
- New Sec. <u>51. 46.</u> {45.} No provisions of the medical marijuana regulation act shall be construed to:

(a) Require an employer to permit or accommodate the use,
consumption, possession, transfer, display, distribution, transportation, sale
or growing of marijuana or any conduct otherwise allowed by this act in
any workplace or on the employer's property;

(b) prohibit a person, employer, corporation or any other entity that
occupies, owns or controls a property from prohibiting or otherwise
regulating the use, consumption, possession, transfer, display, distribution,
transportation, sale or growing of marijuana on such property;

(c) require any government medical assistance program, a private
health insurer or a workers' compensation carrier or self-insured employer
providing workers' compensation benefits to reimburse a person for costs
associated with the use of medical marijuana;

(d) affect the ability of an employer to implement policies to promote
 workplace health and safety by restricting the use of marijuana by
 employees;

41

(e) prohibit an employer from:

42 (1) Establishing and enforcing a drug testing policy, drug-free43 workplace policy or zero-tolerance drug policy;

(2) disciplining an employee for a violation of a workplace drug 1 2 policy or for working while under the influence of marijuana; or

3 (3) including a provision in any contract that prohibits the use of 4 marijuana; or

5 (f) prevent an employer from, because of a person's violation of a 6 workplace drug policy or because that person was working while under the 7 influence of marijuana: 8

- (1) Refusing to hire;
- (2) discharging;

9

10

(3) disciplining; or

(4) otherwise taking an adverse employment action against a person 11 with respect to hiring decisions, tenure, terms, conditions or privileges of 12 13 employment{.}

New Sec. 52. 47. {46.} The provisions of the Kansas medical 14 marijuana regulation act are hereby declared to be severable. If any part or 15 16 provision of the Kansas medical marijuana regulation act is held to be 17 void, invalid or unconstitutional, such part or provision shall not affect or 18 impair any of the remaining parts or provisions of the Kansas medical 19 marijuana regulation act, and any such remaining provisions shall continue 20 in full force and effect.

21 New Sec. <u>53.</u> 48. {47.} (a) No person shall transport medical 22 marijuana as defined in section 2, and amendments thereto, in any vehicle 23 upon a highway or street unless such medical marijuana is in the:

(1) Original, sealed packaging that is in compliance with the 24 25 requirements of section 35 30 {29}, and amendments thereto, and rules and regulations recommended by the director of alcoholic beverage control 26 27 and adopted by the secretary of revenue, and the seal of which has not 28 been broken and any other means of closure has not been removed;

29 (2) locked rear trunk or rear compartment or any locked outside compartment that is not accessible to any person in the vehicle while it is 30 31 in motion. If a motor vehicle is not equipped with a trunk, then such 32 medical marijuana shall be behind the last upright seat or in an area not 33 normally occupied by the driver or a passenger; or

34 (3) exclusive possession of a passenger in a vehicle that is a recreational vehicle, as defined by K.S.A. 75-1212, and amendments 35 thereto, or a bus, as defined by K.S.A. 8-1406, and amendments thereto, 36 37 who is not in the driving compartment of such vehicle or who is in a 38 portion of such vehicle from which the driver is not directly accessible. 39

(b) Violation of this section is a class C nonperson misdemeanor.

40 New Sec. 54. (a) Subject to the provisions of K.S.A. 44-1018, and 41 amendments thereto, it shall be unlawful for any person:

42 (1) To refuse to sell or rent after the making of a bona fide offer, to

43 fail to transmit a bona fide offer or refuse to negotiate in good faith for the

1	sale or rental of, or otherwise make unavailable or deny, real property to
2	any person because such person consumes medical marijuana in-
3	accordance with section 10, and amendments thereto;
4	(2) to discriminate against any person in the terms, conditions or
5	privileges of sale or rental of real property, or in the provision of services
6	or facilities in connection therewith, because such person consumes_
7	medical marijuana in accordance with section 10, and amendments-
8	thereto; and
9	(3) to discriminate against any person in such person's use or
10	occupancy of real property because such person associates with another
11	person who consumes medical marijuana in accordance with section 10,
12	and amendments thereto.
13	(b) (1) It shall be unlawful for any person or other entity whose
14	business includes engaging in real estate related transactions to-
15	discriminate against any person in making available such a transaction, or
16	in the terms or conditions of such a transaction, because such person or
17	any person associated with such person in connection with any real estate
18	related transaction consumes medical marijuana in accordance with
19	section 10, and amendments thereto.
20	(2) Nothing in this subsection prohibits a person engaged in the
21	business of furnishing appraisals of real property to take into consideration
22	factors other than an individual's consumption of medical marijuana in
23	accordance with section 10, and amendments thereto.
24	(3) As used in this subsection, "real estate related transaction" means
25	the same as that term is defined in K.S.A. 44-1017, and amendments-
26	thereto.
27	(c) It shall be unlawful to coerce, intimidate, threaten or interfere with
28	any person in the exercise or enjoyment of, or on account of such person's
29	having exercised or enjoyed, or on account of such person's having aided
30	or encouraged any other person in the exercise or enjoyment of, any right
31	granted or protected by subsection (a) or (b).
32	(d) Nothing in this section shall be construed to prohibit a person-
33	from taking any action necessary to procure or retain any monetary benefit
34	provided under federal law, or any rules and regulations adopted
35	thereunder, or to obtain or maintain any license, certificate, registration or
36	other legal status issued or bestowed under federal law, or any rules and
37	regulations adopted thereunder.
38	(c) The provisions of this section shall be a part of and supplement to
39	the Kansas act against discrimination.
40	New Sec. <u>49.</u> {48.} (a) It shall be unlawful to store or otherwise
41	leave medical marijuana where it is readily accessible to a child under
42	18 years of age. Such conduct shall be unlawful with no requirement
43	of a culpable mental state.

1

(b) Violation of this section is a class A person misdemeanor.

2 (c) This section shall not apply to any person who stores or otherwise leaves medical marijuana where it is readily accessible to a 3 4 child under 18 years of age if:

5 (1) Such child is a patient registered pursuant to section 8, and 6 amendments thereto; and

7 (2) such medical marijuana is not readily accessible to any child 8 under 18 years of age other than the child described in paragraph (1). 9

(d) As used in this section:

"Medical marijuana" means the same as defined in section 2, 10 (1) and amendments thereto: and 11

"readily accessible" means the medical marijuana is not 12 (2) 13 stored in a locked container that restricts entry to such container solely to individuals who are over 18 years of age or who are registered 14 patients pursuant to section 8, and amendments thereto. 15

16 (e) This section shall be a part of and supplemental to the Kansas 17 criminal code.

18 New Sec. <u>50.</u> {49.} (a) The division of alcoholic beverage control is 19 hereby renamed the division of alcohol and cannabis control. Any 20 reference in law to the division of alcoholic beverage control shall 21 refer to the division of alcohol and cannabis control.

22 (b) Any reference in law to the director, employees or agents of 23 alcoholic beverage control shall refer to the director, employees or 24 agents of alcohol and cannabis control.

25 New Sec. 51. {50.} No law enforcement officer as defined in K.S.A. 74-5602, and amendments thereto, shall enforce any violations 26 27 of 18 U.S.C. § 922(g)(3) if the substance involved in such violation is 28 medical marijuana, as defined in section 2, and amendments thereto, 29 and such person is a registered patient pursuant to the Kansas 30 medical marijuana regulation act, section 1 et seq., and amendments 31 thereto, whose possession is authorized by such act.

32 New Sec. <u>55. 52.</u> {51.} (a) A covered entity, solely on the basis that an 33 individual consumes medical marijuana in accordance with section 10, and 34 amendments thereto, shall not:

35 (1) Consider such individual ineligible to receive an anatomical gift 36 or organ transplant;

37 (2) deny medical and other services related to organ transplantation, 38 including evaluation, surgery, counseling and post-transplantation 39 treatment and services:

40 (3) refuse to refer the individual to a transplant center or a related specialist for the purpose of evaluation or receipt of an organ transplant; 41

42 (4) refuse to place such individual on an organ transplant waiting list; 43 or

1 (5) place such individual at a lower-priority position on an organ 2 transplant waiting list than the position at which such individual would 3 have been placed if not for such individual's consumption of medical 4 marijuana.

5 (b) A covered entity may take into account an individual's 6 consumption of medical marijuana when making treatment or coverage 7 recommendations or decisions, solely to the extent that such consumption 8 has been found by a physician, following an individualized evaluation of 9 the individual, to be medically significant to the provision of the 10 anatomical gift.

(c) Nothing in this section shall be construed to require a covered
 entity to make a referral or recommendation for or perform a medically
 inappropriate organ transplant.

(d) As used in this section, the terms "anatomical gift," "covered
entity" and "organ transplant" mean the same as those terms are defined in
K.S.A. 65-3276, and amendments thereto.

New Sec. <u>56. 53.</u> **{52.}** (a) No order shall be issued pursuant to K.S.A. 2020 Supp. 38-2242, 38-2243 or 38-2244, and amendments thereto, if the sole basis for the threat to the child's safety or welfare is that the child resides with an individual who consumes medical marijuana in accordance with section 10, and amendments thereto, or the child consumes medical marijuana in accordance with section 10, and amendments thereto.

(b) The provisions of this section shall be a part of and supplementalto the revised Kansas code for care of children.

New Sec. <u>57. 54.</u> **{53.}** Notwithstanding the provisions of K.S.A. 65-2836, and amendments thereto, the board shall not revoke, suspend or limit a physician's license, publicly censure a physician or place a physician's license under probationary conditions upon any of the following:

(a) The physician has:

31

32 (1) Advised a patient about the possible benefits and risks of using33 medical marijuana;

34 (2) advised the patient that using medical marijuana may mitigate the35 patient's symptoms; or

36 (3) submitted an application on behalf of a patient or caregiver for
 37 registration as a patient or caregiver under section 8, and amendments
 38 thereto; or

(b) the physician is a registered patient or caregiver pursuant to
section 8, and amendments thereto, possesses or has possessed or uses or
has used medical marijuana in accordance with the Kansas medical
marijuana regulation act, section 1 et seq., and amendments thereto.

43 New Sec. <u>58. 55.</u> {54.} Notwithstanding the provisions of K.S.A. 65-

28a05, and amendments thereto, the board shall not revoke, suspend or 1 limit a physician assistant's license, publicly or privately censure a 2 physician assistant or deny an application for a license or for reinstatement 3 of a license upon any of the following: 4

5

(a) The physician assistant has:

6 (1) Advised a patient about the possible benefits and risks of using 7 medical marijuana; or

8 (2) advised the patient that using medical marijuana may mitigate the 9 patient's symptoms; or

10 (b) the physician assistant is a registered patient or caregiver pursuant to section 8, and amendments thereto, possesses or has possessed or uses 11 or has used medical marijuana in accordance with the Kansas medical 12 13 marijuana regulation act, section 1 et seq., and amendments thereto.

14 New Sec. <u>59. 56.</u> {55.} (a) Notwithstanding any other provision of law, any person, board, commission or similar body that determines the 15 16 qualifications of individuals for licensure, certification or registration shall 17 not:

18 (1) Require an individual who is a registered patient pursuant to 19 section 8, and amendments thereto, to disclose the fact that such 20 person is a registered patient; or

21 (2) disgualify an individual from licensure, certification or 22 registration solely because such individual consumes medical marijiuana 23 in accordance with section 10, and amendments thereto. 24

(b) The provisions of this section shall not apply to the:

(1) Kansas commission on peace officers' standards and training;

26 (2) Kansas highway patrol; 27

(3) office of the attorney general board of healing arts;

28 (4) board of pharmacy; 29

(4)(5) department of health and environment; or

30 (5)(6) division of alcoholic beverage control.

31 Sec. 57. {56.} On and after the effective date of this act, if the 32 secretary of state publishes notice of the certification required pursuant to section-83 {82}, and amendments thereto, Section 2 of this 33 34 act is hereby amended to read as follows: Section 2. As used in the 35 Kansas medical marijuana regulation act, section 1 et seq., and 36 amendments thereto:

37 "Academic medical center" means a medical school and its **(a)** 38 affiliated teaching hospitals and clinics.

39 (b) "Associated employee" means an owner or prospective owner, 40 officer or board member or prospective board member of an entity seeking a retail dispensary license. 41

"Board of healing arts" means the state board of healing arts. 42 (c)

43 "Cannabinoid" means (d) any of the diverse chemical

25

compounds that can act on cannabinoid receptors in cells and alter
 neurotransmitter release in the brain, including phytocannabinoids
 that are produced naturally by marijuana and some other plants.

4 (e) "Caregiver" means an individual registered pursuant to 5 section 8, and amendments thereto, who may purchase and possess 6 medical marijuana in accordance with section 11, and amendments 7 thereto.

8 (f) "Cultivate" means the same as defined in K.S.A. 65-4101, and 9 amendments thereto.

10 (g) "Cultivator" means a person issued a license pursuant to 11 section 26, and amendments thereto, who may grow and sell medical 12 marijuana in accordance with section 21, and amendments thereto.

(h) "Distributor" means a person issued a license pursuant to
section 26, and amendments thereto, who may purchase and sell
medical marijuana in accordance with section 28, and amendments
thereto.

17 (i) "Electronic cigarette" means the same as defined in K.S.A. 79-18 3301, and amendments thereto.

(j) "Key employee" means a manager or other person responsiblefor the daily operation of a licensed retail dispensary.

(k) "Marijuana" means the same as defined in K.S.A. 65-4101,
and amendments thereto.

(1) "Medical marijuana" means marijuana that is cultivated,
 processed, tested, dispensed, possessed or used for a medical purpose.

(m) "Medical marijuana product" means a product that contains
 cannabinoids that have been extracted from plant material or the
 resin therefrom by physical or chemical means and is intended for
 administration to a registered patient.

29 30 (n) "Medical marijuana waste" means:

- (1) Unused, surplus, returned or out-of-date marijuana;
- 31

(2) recalled marijuana;

32 (3) plant debris of the plant of the genus cannabis, including dead
33 plants and all unused plant parts and roots; and

34

(4) any wastewater generated during growing and processing.

(o) "Owned and controlled" means ownership of at least 51% of
the business, including corporate stock if a corporation, control over
the management and day-to-day operations of the business and an
interest in the capital, assets and profits and losses of the business
proportionate to such owner's percentage of ownership.

40 (p) "Patient" means an individual registered pursuant to section
41 8, and amendments thereto, who may purchase and possess medical
42 marijuana in accordance with section 10, and amendments thereto.

43 (q) "Person" means any natural person, corporation,

1 partnership, trust or association.

(r) "Plant material" means the leaves, stems, buds and flowers of
the marijuana plant and does not include seedlings, seeds, clones,
stalks or roots of the plant or the weight of any non-marijuana
ingredients combined with marijuana.

6 (s) "Postsecondary educational institution" means the same as 7 defined in K.S.A. 74-3201b, and amendments thereto.

8 (t) "Processor" means a person issued a license pursuant to 9 section<u>-31</u> {30}, and amendments thereto, who may purchase, process 10 and sell medical marijuana in accordance with section 27, and 11 amendments thereto.

12 (u) "Physician" means an individual licensed to practice 13 medicine and surgery in this state and who is certified by the board of 14 healing arts to recommend *prescribe* treatment with medical marijuana 15 pursuant to section 17, and amendments thereto.

16

31

(v) "Physician's designee" means:

17 (1) A registered nurse, licensed practical nurse, respiratory 18 therapist, emergency medical responder, paramedic, dental hygienist, 19 pharmacy technician or pharmacy intern who has registered for 20 access to the program database as an agent of a practitioner or 21 pharmacist to request program data on behalf of the practitioner or 22 pharmacist;

(2) a death investigator who has registered for limited access to
 the program database as an agent of a medical examiner, coroner or
 another person authorized under law to investigate or determine
 causes of death; or

(3) an individual authorized by rules and regulations adopted by
the board of healing arts to access the prescription monitoring
program database by the board of healing arts in rules and
regulations.

(w) "Qualifying medical condition" means any of the following:

- 32 (1) Acquired immune deficiency syndrome;
- 33 (2) Alzheimer's disease;
- 34 (3) amyotrophic lateral sclerosis;
- 35 (4) cancer;
- 36 **(5)** chronic traumatic encephalopathy;
- 37 (6) Crohn's disease;
- 38 (7) epilepsy or another seizure disorder;
- 39 (8) fibromyalgia;
- 40 **(9)** glaucoma;
- 41 (10) hepatitis C;
- 42 (11) inflammatory bowel disease;
- 43 (12) multiple sclerosis;

- 1 (13) Parkinson's disease;
- 2 (14) positive status for human immunodeficiency virus;
- 3 (15) post-traumatic stress disorder;
- 4 (16) sickle cell anemia;
- 5 (17) spinal cord disease or injury;
- 6 (18) Tourette's syndrome;
- 7 (19) traumatic brain injury;
- 8 (20) ulcerative colitis;
 - (21) pain that is either chronic and severe or intractable; and

(22) any other disease or condition adopted by the secretary of
 health and environment upon petition recommended for approval by
 the medical marijuana advisory commitee pursuant to section 5, and
 amendments thereto.

(x) "Retail dispensary" means a person issued a license pursuant
 to section 26, and amendments thereto, who may purchase and sell
 medical marijuana in accordance with section<u>30</u> {29}, and
 amendments thereto.

(y) "Smoking" means the use of a lighted cigarette, cigar or pipe
 or otherwise burning marijuana in any other form for the purpose of
 consuming such marijuana.

(z) "Support employee" means an individual employed by a
 licensed retail dispensary who does not have authority to make
 operational decisions.

(aa) "Tetrahydrocannabinol" means the primary psychoactive
 cannabinoid in marijuana formed by decarboxylation of naturally
 occurring tetrahydrocannabinolic acid that generally takes place by
 heating.

(bb) "Tetrahydrocannabinolic acid" means the dominant
 cannabinoid that occurs naturally in most varieties of marijuana.

(cc) "Tetrahydrocannabinol content" means the sum of the
 amount of tetrahydrocannabinol and 87.7% of the amount of
 tetrahydrocannabinolic acid present in the product or plant material.

(dd) "Vaporization" means the use of an electronic cigarette for
the purpose of consuming medical marijuana in which such medical
marijuana comes into direct contact with a heating element.

36

9

(ee) "Veteran" means a person who:

(1) Has served in the army, navy, marine corps, air force, coast
guard, space force, any state air or army national guard or any branch
of the military reserves of the United States; and

40 (2) has been separated from the branch of service in which the
41 person was honorably discharged or received a general discharge
42 under honorable conditions.

43 Sec. <u>58.</u> {57.} On and after the effective date of this act, if the

secretary of state publishes notice of the certification required 1 2 pursuant to section 83 {82}, and amendments thereto, Section 3 of this 3 act is hereby amended to read as follows: Section 3. (a) No person 4 shall grow, harvest, process, sell, barter, transport, deliver, furnish or 5 otherwise possess any form of marijuana, except as specifically 6 provided in the Kansas medical marijuana regulation act or the 7 commercial industrial hemp act, K.S.A. 2020 Supp. 2-3901 et seq., and 8 amendments thereto.

9 (b) Nothing in the Kansas medical marijuana regulation act shall 10 be construed to:

(1) Require a physician to recommend prescribe that a patient use
 medical marijuana to treat a qualifying medical condition;

13 (2) permit the use, possession or administration of medical
 14 marijuana other than as authorized by this act;

15 (3) permit the use, possession or administration of medical
 16 marijuana on federal land located in this state;

17 (4) require any public place to accommodate a registered18 patient's use of medical marijuana;

19 (5) prohibit any public place from accommodating a registered20 patient's use of medical marijuana;

(6) authorize any limitation on the number of any licenses awarded under this act to otherwise qualified applicants or authorize any state agency through rules and regulations to effectively limit the number of licenses available to otherwise qualified applicants for any type of license awarded under this act; or

(7) restrict research related to marijuana conducted at a
 postsecondary educational institution, academic medical center or
 private research and development organization as part of a research
 protocol approved by an institutional review board or equivalent
 entity.

Sec.<u>59.</u> {58.} On and after the effective date of this act, if the secretary of state publishes notice of the certification required pursuant to section<u>83</u> {82}, and amendments thereto, Section 4 of this act is hereby amended to read as follows: Section 4. (a) There is hereby established a Kansas medical marijuana regulation program.

(b) The secretary of health and environment shall administer the
 program in accordance with the provisions of this act and provide for
 the registration of patients and caregivers, including the issuance of
 identification cards to registered patients and caregivers.

40 (c) The board of healing arts shall administer the program in 41 accordance with the provisions of this act and provide for the 42 certification authorizing physicians to-recommend *prescribe* medical 43 marijuana. 1 (d) The board of pharmacy shall administer the program in 2 accordance with the provisions of this act and provide for the registration of pharmacist consultants and the reporting to the 3 4 prescription monitoring program database.

5

(e) The director of alcoholic beverage control shall administer the 6 program in accordance with the provisions of this act and provide for 7 the licensure of cultivators, laboratories that test medical marijuana, 8 processors, distributors and retail dispensaries.

9 Sec. <u>60.</u> {59.} On and after the effective date of this act, if the secretary of state publishes notice of the certification required 10 pursuant to section_83 {82}, and amendments thereto, Section 17 of 11 this act is hereby amended to read as follows: Section 17. (a) Except as 12 13 provided in subsection (j), a physician seeking to recommend prescribe treatment with medical marijuana shall apply to the board of healing arts 14 for a certificate authorizing such physician to-recommend prescribe 15 treatment with medical marijuana. The application shall be submitted in 16 17 such form and manner as prescribed by the board. The board shall grant a certificate to-recommend prescribe if the following conditions are 18 19 satisfied:

20 (1) The application is complete and meets the requirements 21 established in rules and regulations adopted by the board of healing 22 arts; and

23 (2) the applicant demonstrates that the applicant does not have 24 an ownership or investment interest in or compensation arrangement 25 with an entity licensed by the department of health and environment 26 or the director of alcoholic beverage control under this act or an applicant for such licensure. 27

28 (b) Pursuant to rules and regulations adopted by the board of 29 healing arts, a certificate to recommend prescribe shall:

30 (A) Expire annually unless renewed in the manner prescribed by 31 the board; and

32 (B) be accompanied by an annual fee in an amount not to exceed 33 \$175.

34 (2) Renewal of a certificate to recommend prescribe shall be 35 conditioned upon the holder's certification of having met the 36 requirements in subsection (a) and having completed at least two 37 hours of continuing medical education in medical marijuana annually 38 in accordance with subsection (g).

39 (c) A physician licensed in this state who holds a certificate to 40 recommend prescribe treatment with medical marijuana may recommend prescribe that a patient be treated with medical marijuana 41 42 if:

43 (1) The patient has been diagnosed with a qualifying medical 1 condition;

2 (2) an ongoing physician-patient relationship has existed for a
3 minimum of six months, or as specified by rules and regulations
4 adopted by the board, unless the patient:

5

(A) Has recently moved from out-of-state, and:

6 (i) Previously had medical marijuana recommended prescribed by 7 a physician in another state; and

8 (ii) the patient's previous physician contacts the new physician to
 9 share the patient's medical history and verify that the patient has a
 10 qualifying medical condition;

(B) currently has a recommendation prescription for medical
 marijuana pursuant to this act and the:

(i) Patient no longer has a relationship with the recommending
 prescribing physician and the patient's previous physician contacts the
 new physician to share the patient's medical history and verify that
 the patient has a qualifying medical condition; or

17 (ii

(ii) recommending prescribing physician is deceased; or

(C) is a veteran and has not previously received a recommendation
 prescription for medical marijuana;

(3) a review of all old medical records, particularly relating to the
 medical indication for the tetrahydrocannabinol—recommendation—
 prescription, and a physical exam have been performed;

(4) the recommending prescribing physician has a certification to
 recommend prescribe pursuant to section 18, and amendments
 thereto;

(5) the recommending prescribing physician, or physician's
 designee, reports all medical marijuana recommendations prescriptions
 for all patients to the prescription monitoring program in accordance
 with K.S.A. 65-1683, and amendments thereto; and

30 **(6) for a patient who has previously had medical marijuana** 31 recommended *prescribed* for use by another physician, the patient:

(A) Has maintained a physician-patient relationship with the new
 recommending prescribing physician for at least six months with either
 inpatient visits or via telephonic or electronic means; or

(B) no longer has the previous physician-patient relationship on
 account of death or discontinuance of care by the physician.

(d) In the case of a patient who is a minor, the physician may
recommend *prescribe* treatment with medical marijuana only after
obtaining the consent of the patient's parent or other person
responsible for providing consent to treatment.

41 (e) When issuing a written recommendation prescription to a
42 patient, the physician shall specify any information required by rules
43 and regulations adopted by the board of healing arts. A written

1 recommendation prescription issued to a patient under this section is 2 valid for a period of not more than 90 days. The physician may renew 3 the recommendation for issue not more than three additional periods of 4 written prescriptions for not more than 90 days each. Thereafter, the 5 physician may issue another recommendation prescription to the patient 6 only upon a physical examination of the patient.

7 (f) Each year a physician holding a certificate to <u>recommend</u> 8 prescribe treatment with medical marijuana shall submit to the board 9 of healing arts a report that describes the physician's observations 10 regarding the effectiveness of medical marijuana in treating the 11 physician's patients during the year covered by the report. When 12 submitting reports, a physician shall not include any information that 13 identifies or would tend to identify any specific patient.

14 (g) Annually, each physician who holds a certificate to recommend 15 prescribe treatment with medical marijuana shall complete at least two 16 hours of continuing medical education in the treatment with and use 17 of medical marijuana as approved by the board of healing arts.

18 (h) A physician shall not issue a recommendation prescription for 19 treatment with medical marijuana for a family member or the 20 physician's self, or personally furnish or otherwise dispense medical 21 marijuana.

(i) A physician who holds a certificate to-recommend prescribe
 treatment with medical marijuana shall be immune from civil liability,
 shall not be subject to professional disciplinary action by the board of
 healing arts and shall not be subject to criminal prosecution for any of
 the following actions:

(1) Advising a patient, patient representative or caregiver about
 the benefits and risks of medical marijuana to treat a qualifying
 medical condition;

30 (2) recommending prescribing that a patient use medical 31 marijuana to treat or alleviate a qualifying medical condition; and

32

(3) monitoring a patient's treatment with medical marijuana.

(j) This section shall not apply to a physician who-recommendsprescribes treatment with marijuana or a drug derived from marijuana under any of the following that is approved by an institutional review board or equivalent entity, the United States food and drug administration or the national institutes of health or one of its cooperative groups or centers under the United States department of health and human services:

- 40 (1) A research protocol;
- 41 (2) a clinical trial;
- 42 (3) an investigational new drug application; or
- 43 (4) an expanded access submission.

1 Sec. <u>61.</u> {60.} On and after the effective date of this act, if the secretary of state publishes notice of the certification required 2 3 pursuant to section-83 {82}, and amendments thereto, Section 18 of 4 this act is hereby amended to read as follows: Section 18. (a) On or 5 before July 1, 2022, the board of healing arts shall adopt rules and regulations to implement and enforce the provisions of section 17, and 6 7 amendments thereto. Such rules and regulations shall include: (1) The procedures and fees for applying for a certificate to 8 9 recommend prescribe treatment with medical marijuana; 10 (2) the conditions for eligibility for a certificate to-recommend-11 prescribe treatment with medical marijuana; (3) the schedule, fees and procedures for renewing such a 12 13 certificate: 14 (4) the reasons for which a certificate may be suspended or 15 revoked: 16 (5) the standards under which a certificate suspension may be 17 lifted: and 18 (6) the minimum standards of care when recommending 19 prescribing treatment with medical marijuana. 20 (b) The board of healing arts shall approve one or more 21 continuing medical education courses of study that assist physicians 22 holding certificates to-recommend prescribe treatment with medical 23 marijuana in diagnosing and treating qualifying medical conditions 24 with medical marijuana. 25 Sec. <u>62.</u> {61.} On and after the effective date of this act, if the secretary of state publishes notice of the certification required 26 27 pursuant to section 83 {82}, and amendments thereto, Section 30 {29} 28 of this act is hereby amended to read as follows: Section 30 {29}. (a) A 29 retail dispensary licensee may: 30 (1) Obtain medical marijuana from one or more licensed cultivators, processors or distributors; and 31 32 (2) unless prohibited pursuant to subsection (f), dispense or sell 33 medical marijuana in accordance with subsection (b). 34 (b) When dispensing or selling medical marijuana, a retail 35 dispensary shall: 36 (1) Dispense or sell medical marijuana only to a person who 37 provides the dispensary with a current, valid identification card and 38 only in accordance with a written-recommendation prescription issued 39 by a physician; 40 (2) report to the prescription monitoring program database the information required by K.S.A. 65-1683, and amendments thereto, 41 and rules and regulations adopted by the board of pharmacy pursuant 42

43 to section <u>38</u> {37}, and amendments thereto;

- 1 (3) ensure that the package containing medical marijuana is 2 labeled with the following information:
- 3 (A) The name and address of the licensed processor that 4 produced the product and the retail dispensary;
- 5

(B) the name of the patient and caregiver, if any;

6 (C) the name of the physician who-recommended prescribed 7 treatment with medical marijuana;

8 (D) the directions for use, if any, as-recommended prescribed by 9 the physician;

10 (E) a health warning as specified in rules and regulations adopted
11 by the secretary of health and environment;

12

(F) the date on which the medical marijuana was dispensed; and

13 (G) the quantity, strength, kind or form of medical marijuana 14 contained in the package;

(4) package the medical marijuana in accordance with childresistant effectiveness standards described in 16 C.F.R. § 1700.15(b),
as in effect on July 1, 2021; and

(5) dispense or sell medical marijuana in an official tamper-proof
 Kansas specific package that is clearly marked and approved by the
 director.

(c) A retail dispensary shall employ only those individuals who
 hold a current, valid employee license issued pursuant to section 26,
 and amendments thereto, and who have completed the training
 requirements established by rules and regulations recommended by
 the director of alcoholic beverage control and adopted by the secretary
 of revenue.

(d) {(1) Each associated, key and support employee of a licensed retail dispensary shall submit an application for an employee license for such employee in such form and manner as prescribed by the director. A separate license application shall be submitted for each employee. The director shall issue a license to an applicant if all of the following conditions are met:

(A) The criminal history record check conducted pursuant to
section 42, and amendments thereto, with respect to the applicant
demonstrates that the applicant is not disqualified from holding a
license pursuant to section 20, and amendments thereto; and

(B) the applicant meets all other licensure eligibility conditions
established in rules and regulations adopted by the secretary of
revenue and has paid all required fees.

40 (2) A license shall be valid for a period of two years from the date
41 such license is issued and may be renewed by submitting a license
42 renewal application and paying the required fee.}

43 {(e)} A retail dispensary shall designate a pharmacist consultant

who is a pharmacist licensed in this state and registered pursuant to
 section-<u>39</u> {38}, and amendments thereto.

3 (e){(f)} A retail dispensary shall not make public any information
 4 it collects that identifies or would tend to identify any specific patient.

5 (f) Pursuant to K.S.A. 19-101a, and amendments thereto, the board of 6 county commissioners of any county may prohibit the establishing of 7 dispensaries in such county by adoption of a resolution prohibiting the 8 establishing of dispensaries in such county. Any retail dispensary that is 9 lawfully operating at the time such resolution is adopted shall be permitted 10 to continue operating in such county and shall not be denied renewal of 11 any license based upon the adoption of such resolution.

12 Sec.<u>-63.</u> {62.} On and after the effective date of this act, if the 13 secretary of state publishes notice of the certification required 14 pursuant to section<u>-83</u> {82}, and amendments thereto, Section<u>-39</u> {38} 15 of this act is hereby amended to read as follows: Section<u>-39</u> {38}. (a) 16 Any pharmacist that seeks to operate as a pharmacist consultant for a 17 retail dispensary shall register with the board of pharmacy in 18 accordance with rules and regulations adopted by the board.

19 (b) In operating as a pharmacist consultant for a retail 20 dispensary, such pharmacist shall:

(1) Not charge a fee for the pharmacist's services that exceeds 1%
of the gross receipts of the retail dispensary;

(2) audit each recommendation prescription for use of medical
 marijuana and ensure that each such recommendation prescription is
 reported to the prescription monitoring system in accordance with
 K.S.A. 65-1683, and amendments thereto, and rules and regulations
 adopted by the board of pharmacy;

(3) develop and provide training to other retail dispensary
 employees at least once every 12 months that:

30 (A) Establishes guidelines for providing information to registered 31 patients related to risks, benefits and side effects associated with 32 medical marijuana;

(B) explains how to identify the signs and symptoms of substance
 abuse;

(C) establishes guidelines for refusing to provide medical
 marijuana to an individual who appears to be impaired or abusing
 medical marijuana; and

(D) assists in the development and implementation of review and
 improvement processes for patient education and support provided by
 the retail dispensary;

(4) provide oversight for the development and dissemination of:

42 (A) Education materials for qualifying patients and designated 43 caregivers that include:

41

1 (i) Information about possible side effects and contraindications 2 of medical marijuana;

3 (ii) guidelines for notifying the physician who provided the 4 written-certification prescription for medical marijuana if side effects or 5 contraindications occur;

6 (iii) a description of the potential effects of differing strengths of 7 medical marijuana strains and products;

8 (iv) information about potential drug-to-drug interactions,
 9 including interactions with alcohol, prescription drugs,
 10 nonprescription drugs and supplements;

(v) techniques for the use of medical marijuana and marijuanaparaphernalia; and

(vi) information about different methods, forms and routes ofmedical marijuana administration;

(B) systems for documentation by a registered patient or
designated caregiver of the symptoms of a registered patient that
includes a logbook, rating scale for pain and symptoms and guidelines
for a patient's self-assessment; and

(C) policies and procedures for refusing to provide medical
 marijuana to an individual who appears to be impaired or abusing
 medical marijuana; and

(5) be accessible by the retail dispensary or dispensary agentthrough:

(A) Telephonic means at all times during operating hours; and

25 **(B)** telephone or video conference for a patient consultation 26 during operating hours.

27 Sec.<u>-64.</u> {63.} K.S.A. 2020 Supp. 19-101a is hereby amended to 28 read as follows: 19-101a. (a) The board of county commissioners may 29 transact all county business and perform all powers of local legislation 30 and administration it deems appropriate, subject only to the following 31 limitations, restrictions or prohibitions:

32 (1) Counties shall be subject to all acts of the legislature which33 apply uniformly to all counties.

34

24

(2) Counties may not affect the courts located therein.

35 (3) Counties shall be subject to acts of the legislature prescribing
 36 limits of indebtedness.

(4) In the exercise of powers of local legislation and
administration authorized under provisions of this section, the home
rule power conferred on cities to determine their local affairs and
government shall not be superseded or impaired without the consent
of the governing body of each city within a county which may be
affected.

43

(5) Counties may not legislate on social welfare administered

under state law enacted pursuant to or in conformity with public law
 No. 271 – 74th congress, or amendments thereof.

3 (6) Counties shall be subject to all acts of the legislature 4 concerning elections, election commissioners and officers and their 5 duties as such officers and the election of county officers.

6 (7) Counties shall be subject to the limitations and prohibitions 7 imposed under K.S.A. 12-187 through 12-195, and amendments 8 thereto, prescribing limitations upon the levy of retailers' sales taxes 9 by counties.

(8) Counties may not exempt from or effect changes in statutes
 made nonuniform in application solely by reason of authorizing
 exceptions for counties having adopted a charter for county
 government.

(9) No county may levy ad valorem taxes under the authority of this section upon real property located within any redevelopment project area established under the authority of K.S.A. 12-1772, and amendments thereto, unless the resolution authorizing the same specifically authorized a portion of the proceeds of such levy to be used to pay the principal of and interest upon bonds issued by a city under the authority of K.S.A. 12-1774, and amendments thereto.

(10) Counties shall have no power under this section to exempt from any statute authorizing or requiring the levy of taxes and providing substitute and additional provisions on the same subject, unless the resolution authorizing the same specifically provides for a portion of the proceeds of such levy to be used to pay a portion of the principal and interest on bonds issued by cities under the authority of K.S.A. 12-1774, and amendments thereto.

(11) Counties may not exempt from or effect changes in the
 provisions of K.S.A. 19-4601 through 19-4625, and amendments
 thereto.

(12) Except as otherwise specifically authorized by K.S.A. 121,101 through 12-1,109, and amendments thereto, counties may not
levy and collect taxes on incomes from whatever source derived.

(13) Counties may not exempt from or effect changes in K.S.A.
19-430, and amendments thereto.

(14) Counties may not exempt from or effect changes in K.S.A.
19-302, 19-502b, 19-503, 19-805 or 19-1202, and amendments thereto.

(15) Counties may not exempt from or effect changes in K.S.A.
19-15,139, 19-15,140 and 19-15,141, and amendments thereto.

40 (16) Counties may not exempt from or effect changes in the
41 provisions of K.S.A. 12-1223, 12-1225, 12-1225a, 12-1225b, 12-1225c
42 and 12-1226, and amendments thereto, or the provisions of K.S.A. 1243 1260 through 12-1270 and 12-1276, and amendments thereto.

4

- 1 (17) Counties may not exempt from or effect changes in the 2 provisions of K.S.A. 19-211, and amendments thereto.
- 3 (18) Counties may not exempt from or effect changes in the 4 provisions of K.S.A. 19-4001 through 19-4015, and amendments 5 thereto.
- (19) Counties may not regulate the production or drilling of any 6 7 oil or gas well in any manner which would result in the duplication of regulation by the state corporation commission and the Kansas 8 department of health and environment pursuant to chapter 55 and 9 chapter 65 of the Kansas Statutes Annotated, and amendments 10 thereto, and any rules and regulations adopted pursuant thereto. 11 Counties may not require any license or permit for the drilling or 12 production of oil and gas wells. Counties may not impose any fee or 13 charge for the drilling or production of any oil or gas well. 14
- (20) Counties may not exempt from or effect changes in K.S.A.
 79-41a04, and amendments thereto.
- 17 (21) Counties may not exempt from or effect changes in K.S.A.
 18 79-1611, and amendments thereto.
- (22) Counties may not exempt from or effect changes in K.S.A.
 79-1494, and amendments thereto.
- (23) Counties may not exempt from or effect changes in K.S.A.
 19-202(b), and amendments thereto.
- 23 (24) Counties may not exempt from or effect changes in K.S.A.
 24 19-204(b), and amendments thereto.
- (25) Counties may not levy or impose an excise, severance or any
 other tax in the nature of an excise tax upon the physical severance
 and production of any mineral or other material from the earth or
 water.
- (26) Counties may not exempt from or effect changes in K.S.A.
 79-2017 or 79-2101, and amendments thereto.
- 31(27)Counties may not exempt from or effect changes in K.S.A. 2-323302, 2-3305, 2-3307, 2-3318, 17-5904, 17-5908, 47-1219, 65-171d, 65-331,178 through 65-1,199, 65-3001 through 65-3028, and amendments34thereto.
- 35 (28) Counties may not exempt from or effect changes in K.S.A.
 36 80-121, and amendments thereto.
- 37 (29) Counties may not exempt from or effect changes in K.S.A.
 38 19-228, and amendments thereto.
- 39 (30) Counties may not exempt from or effect changes in the40 Kansas 911 act.
- 41 (31) Counties may not exempt from or effect changes in K.S.A.
 42 2020 Supp. 26-601, and amendments thereto.
- 43 (32) (A) Counties may not exempt from or effect changes in the

1 Kansas liquor control act except as provided by paragraph (B).

2 (B) Counties may adopt resolutions which are not in conflict with 3 the Kansas liquor control act.

- 4 (33) (A) Counties may not exempt from or effect changes in the 5 Kansas cereal malt beverage act except as provided by paragraph (B).
- 6 **(B)** Counties may adopt resolutions which are not in conflict with 7 the Kansas cereal malt beverage act.
- 8 (34) Counties may not exempt from or effect changes in the 9 Kansas lottery act.

10 (35) Counties may not exempt from or effect changes in the 11 Kansas expanded lottery act.

12 (36) Counties may neither exempt from nor effect changes to the 13 eminent domain procedure act.

(37) Any county granted authority pursuant to the provisions of
K.S.A. 19-5001 through 19-5005, and amendments thereto, shall be
subject to the limitations and prohibitions imposed under K.S.A. 195001 through 19-5005, and amendments thereto.

(38) Except as otherwise specifically authorized by K.S.A. 195001 through 19-5005, and amendments thereto, counties may not
exercise any authority granted pursuant to K.S.A. 19-5001 through
19-5005, and amendments thereto, including the imposition or levy of
any retailers' sales tax.

23 (39) Counties may not exempt from or effect changes in K.S.A.
24 65-201 and 65-202, and amendments thereto.

(40) Counties may not exempt from or effect changes in the medical
marijuana regulation act except as provided in section <u>-30</u> {26 29}, and
amendments thereto.

28 (b) Counties shall apply the powers of local legislation granted in 29 subsection (a) by resolution of the board of county commissioners. If no statutory authority exists for such local legislation other than that 30 31 set forth in subsection (a) and the local legislation proposed under the 32 authority of such subsection is not contrary to any act of the 33 legislature, such local legislation shall become effective upon passage 34 of a resolution of the board and publication in the official county 35 newspaper. If the legislation proposed by the board under authority of 36 subsection (a) is contrary to an act of the legislature which is 37 applicable to the particular county but not uniformly applicable to all 38 counties, such legislation shall become effective by passage of a 39 charter resolution in the manner provided in K.S.A. 19-101b, and 40 amendments thereto.

41 (c) Any resolution adopted by a county which conflicts with the 42 restrictions in subsection (a) is null and void.

43 Sec. <u>60. 65.</u> {64.} K.S.A. 2020 Supp. 21-5703 is hereby amended to

read as follows: 21-5703. (a) It shall be unlawful for any person to
 manufacture any controlled substance or controlled substance analog.

3

(b) Violation or attempted violation of subsection (a) is a:

4 (1) Drug severity level 2 felony, except as provided in subsections (b) 5 (2) and (b)(3);

6

(2) drug severity level 1 felony if:

7 (A) The controlled substance is not methamphetamine, as defined by 8 subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and 9 amendments thereto, or an analog thereof; and

10 (B) the offender has a prior conviction for unlawful manufacturing of 11 a controlled substance under this section, K.S.A. 65-4159, prior to its 12 repeal, K.S.A. 2010 Supp. 21-36a03, prior to its transfer, or a substantially 13 similar offense from another jurisdiction and the substance was not 14 methamphetamine, as defined by-subsection (d)(3) or (f)(1) of K.S.A. 65-15 4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, in any 16 such prior conviction; and

17 (3) drug severity level 1 felony if the controlled substance is 18 methamphetamine, as defined by-subsection (d)(3) or (f)(1) of K.S.A. 65-19 4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof.

20 (c) The provisions of subsection (d) of K.S.A. 2020 Supp. 21-21 5301(*d*), and amendments thereto, shall not apply to a violation of 22 attempting to unlawfully manufacture any controlled substance or 23 controlled substance analog pursuant to this section.

(d) For persons arrested and charged under this section, bail shall be
at least \$50,000 cash or surety, and such person shall not be released upon
the person's own recognizance pursuant to K.S.A. 22-2802, and
amendments thereto, unless the court determines, on the record, that the
defendant is not likely to re-offend, the court imposes pretrial supervision,
or the defendant agrees to participate in a licensed or certified drug
treatment program.

(e) The sentence of a person who violates this section shall not be
subject to statutory provisions for suspended sentence, community service
work or probation.

(f) The sentence of a person who violates this section, K.S.A. 654159, prior to its repeal or K.S.A. 2010 Supp. 21-36a03, prior to its
transfer, shall not be reduced because these sections prohibit conduct
identical to that prohibited by K.S.A. 65-4161 or 65-4163, prior to their
repeal, K.S.A. 2010 Supp. 21-36a05, prior to its transfer, or K.S.A. 2020
Supp. 21-5705, and amendments thereto.

40 (g) The provisions of this section shall not apply to a cultivator or 41 processor licensed by the director of alcoholic beverage control pursuant

42 to section -21 26, and amendments thereto, <u>or a processor licensed by the</u>

43 director of alcoholic beverage control pursuant to section 31, and -

1 amendments thereto, that is producing medical marijuana, as defined in section 2, and amendments thereto, when used for acts authorized by the 2 3 Kansas medical marijuana regulation act, section 1 et seq., and 4 amendments thereto. 5 Sec.<u>61.66.</u> {65.} K.S.A. 2020 Supp. 21-5705 is hereby amended to 6 read as follows: 21-5705. (a) It shall be unlawful for any person to 7 distribute or possess with the intent to distribute any of the following 8 controlled substances or controlled substance analogs thereof: 9 (1) Opiates, opium or narcotic drugs, or any stimulant designated in 10 subsection (d)(1), (d)(3) or (f)(1) of K.S.A. 65-4107(d)(1), (d)(3) or (f)(1), 11 and amendments thereto; 12 (2) any depressant designated in subsection (e) of K.S.A. 65-4105(e), subsection (e) of K.S.A. 65-4107(e), subsection (b) or (c) of K.S.A. 65-13 4109(b) or (c) or subsection (b) of K.S.A. 65-4111(b), and amendments 14 15 thereto: 16 (3) any stimulant designated in subsection (f) of K.S.A. 65-4105(f), subsection (d)(2), (d)(4), (d)(5) or (f)(2) of K.S.A. 65-4107(d)(2), (d)(4), 17 18 (d)(5) or (f)(2) or subsection (e) of K.S.A. 65-4109(e), and amendments 19 thereto: 20 (4) any hallucinogenic drug designated in subsection (d) of K.S.A. 21 65-4105(d), subsection (g) of K.S.A. 65-4107(g) or subsection (g) of 22 K.S.A. 65-4109(g), and amendments thereto; 23 (5) any substance designated in subsection (g) of K.S.A. 65-4105(g)24 and subsection (c), (d), (e), (f) or (g) of K.S.A. 65-4111(c), (d), (e), (f) or 25 (g), and amendments thereto; 26 (6) any anabolic steroids as defined in subsection (f) of K.S.A. 65-27 4109(f), and amendments thereto; or 28 (7) any substance designated in subsection (h) of K.S.A. 65-4105(h), 29 and amendments thereto. 30 (b) It shall be unlawful for any person to distribute or possess with 31 the intent to distribute a controlled substance or a controlled substance 32 analog designated in K.S.A. 65-4113, and amendments thereto. 33 (c) It shall be unlawful for any person to cultivate any controlled 34 substance or controlled substance analog listed in subsection (a). 35 (d) (1) Except as provided further, violation of subsection (a) is a: 36 (A) Drug severity level 4 felony if the quantity of the material was 37 less than 3.5 grams; 38 (B) drug severity level 3 felony if the quantity of the material was at 39 least 3.5 grams but less than 100 grams; 40 (C) drug severity level 2 felony if the quantity of the material was at 41 least 100 grams but less than 1 kilogram; and 42 (D) drug severity level 1 felony if the quantity of the material was 1 43 kilogram or more.

1 (2) Violation of subsection (a) with respect to material containing any 2 quantity of marijuana, or an analog thereof, is a:

3 (A) Drug severity level 4 felony if the quantity of the material was 4 less than 25 grams;

5 (B) drug severity level 3 felony if the quantity of the material was at 6 least 25 grams but less than 450 grams;

7 (C) drug severity level 2 felony if the quantity of the material was at 8 least 450 grams but less than 30 kilograms; and

9 (D) drug severity level 1 felony if the quantity of the material was 30 kilograms or more.

11 (3) Violation of subsection (a) with respect to material containing any 12 quantity of heroin, as defined by-subsection (c)(1) of K.S.A. 65-4105(c)13 (1), and amendments thereto, or methamphetamine, as defined by 14 subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and 15 amendments thereto, or an analog thereof, is a:

16 (A) Drug severity level 4 felony if the quantity of the material was17 less than 1 gram;

(B) drug severity level 3 felony if the quantity of the material was atleast 1 gram but less than 3.5 grams;

20 (C) drug severity level 2 felony if the quantity of the material was at 21 least 3.5 grams but less than 100 grams; and

(D) drug severity level 1 felony if the quantity of the material was100 grams or more.

(4) Violation of subsection (a) with respect to material containing any
quantity of a controlled substance designated in K.S.A. 65-4105, 65-4107,
65-4109 or 65-4111, and amendments thereto, or an analog thereof,
distributed by dosage unit, is a:

(A) Drug severity level 4 felony if the number of dosage units wasfewer than 10;

(B) drug severity level 3 felony if the number of dosage units was at
least 10 but less than 100;

32 (C) drug severity level 2 felony if the number of dosage units was at
 33 least 100 but less than 1,000; and

(D) drug severity level 1 felony if the number of dosage units was1,000 or more.

(5) For any violation of subsection (a), the severity level of the
offense shall be increased one level if the controlled substance or
controlled substance analog was distributed or possessed with the intent to
distribute on or within 1,000 feet of any school property.

40

(6) Violation of subsection (b) is a:

41 (A) Class A person misdemeanor, except as provided in subsection 42 (d)(6)(B) subparagraph (B); and

43 (B) nondrug severity level 7, person felony if the substance was

- distributed to or possessed with the intent to distribute to a minor. 1 (7) Violation of subsection (c) is a:
- 2

(A) Drug severity level 3 felony if the number of plants cultivated 3 4 was more than 4 but fewer than 50;

5 (B) drug severity level 2 felony if the number of plants cultivated was 6 at least 50 but fewer than 100; and

7 (C) drug severity level 1 felony if the number of plants cultivated was 8 100 or more

- 9 (e) In any prosecution under this section, there shall be a rebuttable presumption of an intent to distribute if any person possesses the following 10 quantities of controlled substances or analogs thereof: 11 12
 - (1) 450 grams or more of marijuana;

13

14

(2) 3.5 grams or more of heroin or methamphetamine; (3) 100 dosage units or more containing a controlled substance; or

15

(4) 100 grams or more of any other controlled substance.

16 (f) It shall not be a defense to charges arising under this section that 17 the defendant.

18 (1) Was acting in an agency relationship on behalf of any other party 19 in a transaction involving a controlled substance or controlled substance 20 analog;

21 (2) did not know the quantity of the controlled substance or 22 controlled substance analog; or

23 (3) did not know the specific controlled substance or controlled substance analog contained in the material that was distributed or 24 25 possessed with the intent to distribute.

26 (g) The provisions of subsections (a)(4) and (a)(5) shall not apply for 27 medical marijuana as defined in section 2, and amendments thereto, 28 to:

29 (1) Any cultivator licensed by the director of alcoholic beverage control pursuant to section -21 26, and amendments thereto, or any 30 31 employee or agent thereof, that is growing medical marijuana for the 32 purpose of sale to a licensed processor as authorized by section $\frac{-22}{2}$ 21, 33 and amendments thereto:

34 (2) any processor licensed by the director of alcoholic beverage control pursuant to section 31 26, and amendments thereto, or any 35 36 employee or agent thereof, that is processing medical marijuana for the 37 purpose of sale or distribution to a licensed processor, distributor or retail 38 dispensary as authorized by section $\frac{32}{27}$, and amendments thereto;

39 (3) any distributor licensed by the director of alcoholic beverage control pursuant to section $\underline{31}$ 26, and amendments thereto, or any 40 employee or agent thereof, that is storing or distributing medical 41 marijuana for the purpose of wholesale or distribution to a licensed retail 42 43 dispensary as authorized by section <u>33</u> 28, and amendments thereto; or

(4) any retail dispensary licensed by the director of alcoholic
beverage control pursuant to section <u>34</u> 26, and amendments thereto, or
any employee or agent thereof, that is engaging in the sale of medical
marijuana in a manner authorized by section <u>35 30</u> {29}, and amendments
thereto.

6

(*h*) As used in this section:

7 (1) "Material" means the total amount of any substance, including a
8 compound or a mixture, which that contains any quantity of a controlled
9 substance or controlled substance analog.

10 (2) "Dosage unit" means a controlled substance or controlled 11 substance analog distributed or possessed with the intent to distribute as a 12 discrete unit, including, but not limited to, one pill, one capsule or one 13 microdot, and not distributed by weight.

(A) For steroids, or controlled substances in liquid solution legally
manufactured for prescription use, or an analog thereof, "dosage unit"
means the smallest medically approved dosage unit, as determined by the
label, materials provided by the manufacturer, a prescribing authority,
licensed health care professional or other qualified health authority.

19 (B) For illegally manufactured controlled substances in liquid 20 solution, or controlled substances in liquid products not intended for 21 ingestion by human beings, or an analog thereof, "dosage unit" means 10 22 milligrams, including the liquid carrier medium, except as provided in 23 subsection (g)(2)(C) subparagraph (C).

(C) For lysergic acid diethylamide (LSD) in liquid form, or an analog
 thereof, a dosage unit is defined as 0.4 milligrams, including the liquid
 medium.

(3) "Medical marijuana" means the same as defined in section 2, and
amendments thereto.

Sec. <u>62. 67.</u> **(66.)** K.S.A. 2020 Supp. 21-5706 is hereby amended to read as follows: 21-5706. (a) It shall be unlawful for any person to possess any opiates, opium or narcotic drugs, or any stimulant designated in K.S.A. 65-4107(d)(1), (d)(3) or (f)(1), and amendments thereto, or a controlled substance analog thereof.

(b) It shall be unlawful for any person to possess any of the followingcontrolled substances or controlled substance analogs thereof:

36 (1) Any depressant designated in K.S.A. 65-4105(e), 65-4107(e), 6537 4109(b) or (c) or 65-4111(b), and amendments thereto;

38 (2) any stimulant designated in K.S.A. 65-4105(f), 65-4107(d)(2), (d)
39 (4), (d)(5) or (f)(2) or 65-4109(e), and amendments thereto;

40 (3) any hallucinogenic drug designated in K.S.A. 65-4105(d), 65-41 4107(g) or 65-4109(g), and amendments thereto;

42 (4) any substance designated in K.S.A. 65-4105(g) and 65-4111(c),

43 (d), (e), (f) or (g), and amendments thereto;

(5) any anabolic steroids as defined in K.S.A. 65-4109(f), and 1 2 amendments thereto:

3 (6) any substance designated in K.S.A. 65-4113, and amendments 4 thereto; or

5 (7) any substance designated in K.S.A. 65-4105(h), and amendments 6 thereto.

7 8 (c) (1) Violation of subsection (a) is a drug severity level 5 felony.

(2) Except as provided in subsection (c)(3):

9 (A) Violation of subsection (b) is a class A nonperson misdemeanor, 10 except as provided in subparagraph (B); and

(B) violation of subsection (b)(1) through (b)(5) or (b)(7) is a drug 11 severity level 5 felony if that person has a prior conviction under such 12 subsection, under K.S.A. 65-4162, prior to its repeal, under a substantially 13 similar offense from another jurisdiction, or under any city ordinance or 14 county resolution for a substantially similar offense if the substance 15 16 involved was 3, 4-methylenedioxymethamphetamine (MDMA), marijuana 17 as designated in K.S.A. 65-4105(d), and amendments thereto, or any substance designated in K.S.A. 65-4105(h), and amendments thereto, or an 18 19 analog thereof.

20 (3) If the substance involved is marijuana, as designated in K.S.A. 21 65-4105(d), and amendments thereto, or tetrahydrocannabinols, as 22 designated in K.S.A. 65-4105(h), and amendments thereto, violation of 23 subsection (b) is a:

24 (A) Class B nonperson misdemeanor, except as provided in subparagraphs (B)-and, (C) and (D); 25

(B) class A nonperson misdemeanor if that person has a prior 26 27 conviction under such subsection, under K.S.A. 65-4162, prior to its 28 repeal, under a substantially similar offense from another jurisdiction, or 29 under any city ordinance or county resolution for a substantially similar 30 offense;-and

31 (C) drug severity level 5 felony if that person has two or more prior 32 convictions under such subsection, under K.S.A. 65-4162, prior to its 33 repeal, under a substantially similar offense from another jurisdiction, or 34 under any city ordinance or county resolution for a substantially similar 35 offense: and

36 (D) nonperson misdemeanor punishable by a fine not to exceed \$400, 37 if that person is not a registered patient or caregiver under the Kansas medical marijuana regulation act, section 1 et seq., and amendments 38 39 thereto, is found in possession of not more than 1.5 ounces of marijuana 40 and provides a statement from such person's physician recommending the 41 use of medical marijuana to treat such person's symptoms.

42 (d) It shall be an affirmative defense to prosecution under this section 43 arising out of a person's possession of any cannabidiol treatment-

1 preparation if the person:

(1) Has a debilitating medical condition, as defined in K.S.A.2020
 Supp. 65-6235, and amendments thereto, or is the parent or guardian of a
 minor child who has such debilitating medical condition;

5 (2) is possessing a cannabidiol treatment preparation, as defined in
 6 K.S.A. 2020 Supp. 65-6235, and amendments thereto, that is being used to
 7 treat such debilitating medical condition; and

8 (3) has possession of a letter, at all times while the person has 9 possession of the cannabidiol treatment preparation, that:

10 (A) Shall be shown to a law enforcement officer on such officer's-11 request;

(B) is dated within the preceding 15 months and signed by the
 physician licensed to practice medicine and surgery in Kansas who diagnosed the debilitating medical condition;

15

(C) is on such physician's letterhead; and

(D) identifies the person or the person's minor child as suchphysician's patient and identifies the patient's debilitating medicalcondition If the substance involved is medical marijuana, as defined in section 2, and amendments thereto, the provisions of subsections (b) and (c) shall not apply to any person who is registered or licensed pursuant to the Kansas medical marijuana regulation act, section 1 et seq., and amendments thereto, whose possession is authorized by such act.

(e) It shall not be a defense to charges arising under this section that
the defendant was acting in an agency relationship on behalf of any other
party in a transaction involving a controlled substance or controlled
substance analog.

27 Sec. <u>68.</u> {67.} On and after the effective date of this act, if the 28 secretary of state publishes notice of the certification required 29 pursuant to section-83 {82}, and amendments thereto, K.S.A. 2020 Supp. 21-5706, as amended by section-67 {66} of this act, is hereby 30 amended to read as follows: 21-5706. (a) It shall be unlawful for any 31 person to possess any opiates, opium or narcotic drugs, or any 32 stimulant designated in K.S.A. 65-4107(d)(1), (d)(3) or (f)(1), and 33 34 amendments thereto, or a controlled substance analog thereof.

(b) It shall be unlawful for any person to possess any of the
 following controlled substances or controlled substance analogs
 thereof:

38 (1) Any depressant designated in K.S.A. 65-4105(e), 65-4107(e),
39 65-4109(b) or (c) or 65-4111(b), and amendments thereto;

40 (2) any stimulant designated in K.S.A. 65-4105(f), 65-4107(d)(2),
41 (d)(4), (d)(5) or (f)(2) or 65-4109(e), and amendments thereto;

42 (3) any hallucinogenic drug designated in K.S.A. 65-4105(d), 654107(g) or 65-4109(g), and amendments thereto;

1 (4) any substance designated in K.S.A. 65-4105(g) and 65-4111(c), 2 (d), (e), (f) or (g), and amendments thereto;

3 (5) any anabolic steroids as defined in K.S.A. 65-4109(f), and 4 amendments thereto;

5 (6) any substance designated in K.S.A. 65-4113, and amendments 6 thereto; or

7 (7) any substance designated in K.S.A. 65-4105(h), and 8 amendments thereto.

(c) (1) Violation of subsection (a) is a drug severity level 5 felony.

9

10

(2) Except as provided in subsection (c)(3):

11 (A) Violation of subsection (b) is a class A nonperson
12 misdemeanor, except as provided in subparagraph (B); and

- 13 (B) violation of subsection (b)(1) through (b)(5) or (b)(7) is a drug severity level 5 felony if that person has a prior conviction under such 14 subsection, under K.S.A. 65-4162, prior to its repeal, under a 15 substantially similar offense from another jurisdiction, or under any 16 city ordinance or county resolution for a substantially similar offense 17 18 if the substance involved was 3, 4-methylenedioxymethamphetamine 19 (MDMA), marijuana as designated in K.S.A. 65-4105(d), and amendments thereto, or any substance designated in K.S.A. 65-20 21 4105(h), and amendments thereto, or an analog thereof.
- (3) If the substance involved is marijuana, as designated in K.S.A.
 65-4105(d), and amendments thereto, or tetrahydrocannabinols, as
 designated in K.S.A. 65-4105(h), and amendments thereto, violation of
 subsection (b) is a:

26 (A) Class B nonperson misdemeanor, except as provided in
27 subparagraphs (B), (C) and (D);

(B) class A nonperson misdemeanor if that person has a prior
conviction under such subsection, under K.S.A. 65-4162, prior to its
repeal, under a substantially similar offense from another jurisdiction,
or under any city ordinance or county resolution for a substantially
similar offense;

(C) drug severity level 5 felony if that person has two or more prior convictions under such subsection, under K.S.A. 65-4162, prior to its repeal, under a substantially similar offense from another jurisdiction, or under any city ordinance or county resolution for a substantially similar offense; and

(D) nonperson misdemeanor punishable by a fine not to exceed \$400, if that person is not a registered patient or caregiver under the Kansas medical marijuana regulation act, section 1 et seq., and amendments thereto, is found in possession of not more than 1.5 ounces of marijuana and provides a statement from such person's physician-recommending prescribing the use of medical marijuana to 1 treat such person's symptoms.

2 (d) If the substance involved is medical marijuana, as defined in 3 section 2, and amendments thereto, the provisions of subsections (b) 4 and (c) shall not apply to any person who is registered or licensed 5 pursuant to the Kansas medical marijuana regulation act, section 1 et 6 seq., and amendments thereto, whose possession is authorized by such 7 act.

8 (e) It shall not be a defense to charges arising under this section 9 that the defendant was acting in an agency relationship on behalf of 10 any other party in a transaction involving a controlled substance or 11 controlled substance analog.

12 Sec.<u>68.69.</u> **(68.)** K.S.A. 2020 Supp. 21-5707 is hereby amended to 13 read as follows: 21-5707. (a) It shall be unlawful for any person to 14 knowingly or intentionally use any communication facility:

15 (1) In committing, causing, or facilitating the commission of any 16 felony under K.S.A. 2020 Supp. 21-5703, 21-5705 or 21-5706, and 17 amendments thereto; or

(2) in any attempt to commit, any conspiracy to commit, or any
criminal solicitation of any felony under K.S.A. 2020 Supp. 21-5703, 215705 or 21-5706, and amendments thereto. Each separate use of a
communication facility may be charged as a separate offense under this
subsection.

(b) Violation of subsection (a) is a nondrug severity level 8,nonperson felony.

(c) The provisions of this section shall not apply to any person using
 communication facilities for those activities authorized by the Kansas
 medical marijuana regulation act, section 1 et seq., and amendments
 thereto.

(d) As used in this section, "communication facility" means any and
all public and private instrumentalities used or useful in the transmission
of writing, signs, signals, pictures or sounds of all kinds and includes
telephone, wire, radio, computer, computer networks, beepers, pagers and
all other means of communication.

34 Sec.<u>64. 70.</u> **(69.)** K.S.A. 2020 Supp. 21-5709 is hereby amended to 35 read as follows: 21-5709. (a) It shall be unlawful for any person to possess 36 ephedrine, pseudoephedrine, red phosphorus, lithium metal, sodium metal, 37 anhydrous pressurized iodine. ammonia, ammonia or 38 phenylpropanolamine, or their salts, isomers or salts of isomers with an 39 intent to use the product to manufacture a controlled substance.

40 (b) It shall be unlawful for any person to use or possess with intent to 41 use any drug paraphernalia to:

42 (1) Manufacture, cultivate, plant, propagate, harvest, test, analyze or43 distribute a controlled substance; or

1 (2) store, contain, conceal, inject, ingest, inhale or otherwise 2 introduce a controlled substance into the human body.

3 (c) It shall be unlawful for any person to use or possess with intent to 4 use anhydrous ammonia or pressurized ammonia in a container not 5 approved for that chemical by the Kansas department of agriculture.

6 (d) It shall be unlawful for any person to purchase, receive or 7 otherwise acquire at retail any compound, mixture or preparation 8 containing more than 3.6 grams of pseudoephedrine base or ephedrine 9 base in any single transaction or any compound, mixture or preparation 10 containing more than nine grams of pseudoephedrine base or ephedrine 11 base within any 30-day period.

12

13

(e) (1) Violation of subsection (a) is a drug severity level 3 felony;

(2) violation of subsection (b)(1) is a:

14 (A) Drug severity level 5 felony, except as provided in subsection (e)15 (2)(B); and

(B) class B nonperson misdemeanor if the drug paraphernalia wasused to cultivate fewer than five marijuana plants;

18 (3) violation of subsection (b)(2) is a class B nonperson19 misdemeanor;

20

(4) violation of subsection (c) is a drug severity level 5 felony; and

21

(5) violation of subsection (d) is a class A nonperson misdemeanor.

(f) For persons arrested and charged under subsection (a) or (c), bail shall be at least \$50,000 cash or surety, and such person shall not be released upon the person's own recognizance pursuant to K.S.A. 22-2802, and amendments thereto, unless the court determines, on the record, that the defendant is not likely to reoffend, the court imposes pretrial supervision or the defendant agrees to participate in a licensed or certified drug treatment program.

(g) The provisions of subsection (b) shall not apply to any person registered or licensed pursuant to the Kansas medical marijuana regulation act, section 1 et seq., and amendments thereto, whose possession of such equipment or material is used solely to produce or for the administration of medical marijuana, as defined in section 2, and amendments thereto, in a manner authorized by the Kansas medical marijuana regulation act, section 1 et seq., and amendments thereto.

Sec. <u>65. 71.</u> {70.} K.S.A. 2020 Supp. 21-5710 is hereby amended to read as follows: 21-5710. (a) It shall be unlawful for any person to advertise, market, label, distribute or possess with the intent to distribute:

(1) Any product containing ephedrine, pseudoephedrine, red phosphorus, lithium metal, sodium metal, iodine, anhydrous ammonia, pressurized ammonia or phenylpropanolamine or their salts, isomers or salts of isomers if the person knows or reasonably should know that the purchaser will use the product to manufacture a controlled substance or

1 controlled substance analog; or

2 (2) any product containing ephedrine, pseudoephedrine or 3 phenylpropanolamine, or their salts, isomers or salts of isomers for 4 indication of stimulation, mental alertness, weight loss, appetite control, 5 energy or other indications not approved pursuant to the pertinent federal 6 over-the-counter drug final monograph or tentative final monograph or 7 approved new drug application.

(b) It shall be unlawful for any person to distribute, possess with the
intent to distribute or manufacture with intent to distribute any drug
paraphernalia, knowing or under circumstances where one reasonably
should know that it will be used to manufacture or distribute a controlled
substance or controlled substance analog in violation of K.S.A. 2020 Supp.
21-5701 through 21-5717, and amendments thereto.

(c) It shall be unlawful for any person to distribute, possess with
intent to distribute or manufacture with intent to distribute any drug
paraphernalia, knowing or under circumstances where one reasonably
should know, that it will be used as such in violation of K.S.A. 2020 Supp.
21-5701 through 21-5717, and amendments thereto, except subsection (b)
of K.S.A. 2020 Supp. 21-5706(b), and amendments thereto.

(d) It shall be unlawful for any person to distribute, possess with
intent to distribute or manufacture with intent to distribute any drug
paraphernalia, knowing, or under circumstances where one reasonably
should know, that it will be used as such in violation of subsection (b) of
K.S.A. 2020 Supp. 21-5706(b), and amendments thereto.

(e) (1) Violation of subsection (a) is a drug severity level 3 felony;

25 26

(A) Drug severity level 5 felony, except as provided in subsection (e)
 (2)(B) subparagraph (B); and

(B) drug severity level 4 felony if the trier of fact makes a finding that
the offender distributed or caused drug paraphernalia to be distributed to a
minor or on or within 1,000 feet of any school property;

32

(3) violation of subsection (c) is a:

(2) violation of subsection (b) is a:

(A) Nondrug severity level 9, nonperson felony, except as provided in
 subsection (e)(3)(B) subparagraph (B); and

(B) drug severity level 5 felony if the trier of fact makes a finding that
the offender distributed or caused drug paraphernalia to be distributed to a
minor or on or within 1,000 feet of any school property; and

38

(4) violation of subsection (d) is a:

39 (A) Class A nonperson misdemeanor, except as provided in
 40 subsection (e)(4)(B) subparagraph (B); and

(B) nondrug severity level 9, nonperson felony if the trier of fact
makes a finding that the offender distributed or caused drug paraphernalia
to be distributed to a minor or on or within 1,000 feet of any school

1 property.

2 (f) For persons arrested and charged under subsection (a), bail shall 3 be at least \$50,000 cash or surety, and such person shall not be released 4 upon the person's own recognizance pursuant to K.S.A. 22-2802, and 5 amendments thereto, unless the court determines, on the record, that the 6 defendant is not likely to re-offend, the court imposes pretrial supervision 7 or the defendant agrees to participate in a licensed or certified drug 8 treatment program.

9 (g) The provisions of subsection (c) shall not apply to any person 10 licensed pursuant to the Kansas medical marijuana regulation act, section 11 l et seq., and amendments thereto, whose distribution or manufacture is 12 used solely to distribute or produce medical marijuana, as defined in 13 section 2, and amendments thereto, in a manner authorized by the Kansas 14 medical marijuana regulation act, section 1 et seq., and amendments 15 thereto.

(h) As used in this section, "or under circumstances where one
 reasonably should know" that an item will be used in violation of this
 section, shall include, but not be limited to, the following:

19 (1) Actual knowledge from prior experience or statements by 20 customers;

21

(2) inappropriate or impractical design for alleged legitimate use;

(3) receipt of packaging material, advertising information or other
 manufacturer supplied information regarding the item's use as drug
 paraphernalia; or

(4) receipt of a written warning from a law enforcement or
prosecutorial agency having jurisdiction that the item has been previously
determined to have been designed specifically for use as drug
paraphernalia.

Sec.<u>66.72.</u> **(71.)** K.S.A. 2020 Supp. 23-3201 is hereby amended to read as follows: 23-3201. *(a)* The court shall determine legal custody, residency and parenting time of a child in accordance with the best interests of the child.

(b) The court shall not consider the fact that a parent or a child
consumes medical marijuana in accordance with section 10, and
amendments thereto, when determining the legal custody, residency or
parenting time of a child.

Sec.<u>-67.73.</u> {72.} K.S.A. 2020 Supp. 38-2269 is hereby amended to read as follows: 38-2269. (a) When the child has been adjudicated to be a child in need of care, the court may terminate parental rights or appoint a permanent custodian when the court finds by clear and convincing evidence that the parent is unfit by reason of conduct or condition which renders the parent unable to care properly for a child and the conduct or condition is unlikely to change in the foreseeable future.

1 (b) In making a determination of unfitness the court shall consider, 2 but is not limited to, the following, if applicable:

- 3 (1) Emotional illness, mental illness, mental deficiency or physical 4 disability of the parent, of such duration or nature as to render the parent 5 unable to care for the ongoing physical, mental and emotional needs of the 6 child:
- 7 (2) conduct toward a child of a physically, emotionally or sexually 8 cruel or abusive nature;

9 (3) the use of intoxicating liquors or narcotic or dangerous drugs of 10 such duration or nature as to render the parent unable to care for the 11 ongoing physical, mental or emotional needs of the child, *except that the* 12 *use of medical marijuana in accordance with section 10, and amendments* 13 *thereto, shall not be considered to render the parent unable to care for the* 14 *ongoing physical, mental or emotional needs of the child*;

15 (4) physical, mental or emotional abuse or neglect or sexual abuse of 16 a child;

17

(5) conviction of a felony and imprisonment;

(6) unexplained injury or death of another child or stepchild of theparent or any child in the care of the parent at the time of injury or death;

(7) failure of reasonable efforts made by appropriate public or private
 agencies to rehabilitate the family;

(8) lack of effort on the part of the parent to adjust the parent'scircumstances, conduct or conditions to meet the needs of the child; and

(9) whether, as a result of the actions or inactions attributable to the parent and one or more of the factors listed in subsection (c) apply, the child has been in the custody of the secretary and placed with neither parent for 15 of the most recent 22 months beginning 60 days after the date on which a child in the secretary's custody was removed from the child's home.

30 (c) In addition to the foregoing, when a child is not in the physical 31 custody of a parent, the court, shall consider, but is not limited to, the 32 following:

(1) Failure to assure care of the child in the parental home when ableto do so;

(2) failure to maintain regular visitation, contact or communicationwith the child or with the custodian of the child;

(3) failure to carry out a reasonable plan approved by the courtdirected toward the integration of the child into a parental home; and

(4) failure to pay a reasonable portion of the cost of substitutephysical care and maintenance based on ability to pay.

In making the above determination, the court may disregard incidentalvisitations, contacts, communications or contributions.

43 (d) A finding of unfitness may be made as provided in this section if

the court finds that the parents have abandoned the child, the custody of the child was surrendered pursuant to K.S.A. 2020 Supp. 38-2282, and amendments thereto, or the child was left under such circumstances that the identity of the parents is unknown and cannot be ascertained, despite diligent searching, and the parents have not come forward to claim the child within three months after the child is found.

7 (e) If a person is convicted of a felony in which sexual intercourse 8 occurred, or if a juvenile is adjudicated a juvenile offender because of an 9 act which, if committed by an adult, would be a felony in which sexual 10 intercourse occurred, and as a result of the sexual intercourse, a child is 11 conceived, a finding of unfitness may be made.

(f) The existence of any one of the above factors standing alone may,
but does not necessarily, establish grounds for termination of parental
rights.

15 (g) (1) If the court makes a finding of unfitness, the court shall 16 consider whether termination of parental rights as requested in the petition 17 or motion is in the best interests of the child. In making the determination, 18 the court shall give primary consideration to the physical, mental and 19 emotional health of the child. If the physical, mental or emotional needs of 20 the child would best be served by termination of parental rights, the court 21 shall so order. A termination of parental rights under the code shall not 22 terminate the right of a child to inherit from or through a parent. Upon 23 such termination all rights of the parent to such child, including, such 24 parent's right to inherit from or through such child, shall cease.

(2) If the court terminates parental rights, the court may authorize
adoption pursuant to K.S.A. 2020 Supp. 38-2270, and amendments
thereto, appointment of a permanent custodian pursuant to K.S.A. 2020
Supp. 38-2272, and amendments thereto, or continued permanency
planning.

(3) If the court does not terminate parental rights, the court may
authorize appointment of a permanent custodian pursuant to K.S.A. 2020
Supp. 38-2272, and amendments thereto, or continued permanency
planning.

(h) If a parent is convicted of an offense as provided in K.S.A. 2020
Supp. 38-2271(a)(7), and amendments thereto, or is adjudicated a juvenile
offender because of an act which if committed by an adult would be an
offense as provided in K.S.A. 2020 Supp. 38-2271(a)(7), and amendments
thereto, and if the victim was the other parent of a child, the court may
disregard such convicted or adjudicated parent's opinions or wishes in
regard to the placement of such child.

41

(i) A record shall be made of the proceedings.

42 (j) When adoption, proceedings to appoint a permanent custodian or 43 continued permanency planning has been authorized, the person or agency

awarded custody of the child shall within 30 days submit a written plan for
 permanent placement which shall include measurable objectives and time
 schedules.

4 Sec.<u>-68. 74.</u> {73.} K.S.A. 2020 Supp. 44-501 is hereby amended to 5 read as follows: 44-501. (a) (1) Compensation for an injury shall be 6 disallowed if such injury to the employee results from:

7

(A) The employee's deliberate intention to cause such injury;

8 (B) the employee's willful failure to use a guard or protection against 9 accident or injury which is required pursuant to any statute and provided 10 for the employee;

11 (C) the employee's willful failure to use a reasonable and proper 12 guard and protection voluntarily furnished the employee by the employer;

(D) the employee's reckless violation of their employer's workplacesafety rules or regulations; or

15 (E) the employee's voluntary participation in fighting or horseplay 16 with a co-employee for any reason, work related or otherwise.

17 (2) Subparagraphs (B) and (C) of paragraph (1) of subsection-18 (a)Subsections (a)(1)(B) and (a)(1)(C) shall not apply when it was 19 reasonable under the totality of the circumstances to not use such 20 equipment, or if the employer approved the work engaged in at the time of 21 an accident or injury to be performed without such equipment.

22 (b) (1) (A) The employer shall not be liable under the workers 23 compensation act where the injury, disability or death was contributed to 24 by the employee's use or consumption of alcohol or any drugs, chemicals 25 or any other compounds or substances, including, but not limited to, any drugs or medications-which that are available to the public without a 26 27 prescription from a health care provider, prescription drugs or medications, 28 any form or type of narcotic drugs, marijuana, stimulants, depressants or 29 hallucinogens.

30 (B) *(i)* In the case of drugs or medications which are available to the 31 public without a prescription from a health care provider and prescription 32 drugs or medications, compensation shall not be denied if the employee 33 can show that such drugs or medications were being taken or used in 34 therapeutic doses and there have been no prior incidences of the 35 employee's impairment on the job as the result of the use of such drugs or 36 medications within the previous 24 months.

(ii) In the case of marijuana or any other form of cannabis, including any cannabis derivatives, compensation shall not be denied if the employee is registered as a patient pursuant to section 8, and amendments thereto, such cannabis or cannabis derivative was used in accordance with the Kansas medical marijuana regulation act, section 1 et seq., and amendments thereto, and there has been no prior incidence of the employee's impairment on the job as a result of the use of such cannabis

1 or cannabis derivative within the previous 24 months.

2 It shall be conclusively presumed that the employee was impaired (C) due to alcohol or drugs if it is shown that, at the time of the injury, the 3 employee had an alcohol concentration of .04 or more, or a GCMS 4 confirmatory test by quantitative analysis showing a concentration at or 5 6 above the levels shown on the following chart for the drugs of abuse listed: 7 Confirmatory 8 test cutoff 9 levels (ng/ml) Marijuana metabolite¹..... 10 15 Cocaine metabolite²..... 150 11 12 Opiates: 13 Morphine 2000 14 Codeine 2000 6-Acetylmorphine⁴ 15 10 ng/ml 16 Phencyclidine 25 17 Amphetamines: 18 Amphetamine 500 19 Methamphetamine³..... 500 Delta-9-tetrahydrocannabinol-9-carboxylic acid. 20 1

21² Benzoylecgonine.

Specimen must also contain amphetamine at a concentration greater
 than or equal to 200 ng/ml.

⁴ Test for 6-AM when morphine concentration exceeds 2,000 ng/ml.

(D) If it is shown that the employee was impaired pursuant to subsection (b)(1)(C) at the time of the injury, there shall be a rebuttable presumption that the accident, injury, disability or death was contributed to by such impairment. The employee may overcome the presumption of contribution by clear and convincing evidence.

30 (E) An employee's refusal to submit to a chemical test at the request 31 of the employer shall result in the forfeiture of benefits under the workers 32 compensation act if the employer had sufficient cause to suspect the use of 33 alcohol or drugs by the claimant or if the employer's policy clearly 34 authorizes post-injury testing.

(2) The results of a chemical test shall be admissible evidence to
 prove impairment if the employer establishes that the testing was done
 under any of the following circumstances:

(A) As a result of an employer mandated drug testing policy, in place
in writing prior to the date of accident or injury, requiring any worker to
submit to testing for drugs or alcohol;

(B) during an autopsy or in the normal course of medical treatment
for reasons related to the health and welfare of the injured worker and not
at the direction of the employer;

1 (C) the worker, prior to the date and time of the accident or injury, 2 gave written consent to the employer that the worker would voluntarily 3 submit to a chemical test for drugs or alcohol following any accident or 4 injury;

5 (D) the worker voluntarily agrees to submit to a chemical test for 6 drugs or alcohol following any accident or injury; or

7 (E) as a result of federal or state law or a federal or state rule or 8 regulation having the force and effect of law requiring a post-injury testing 9 program and such required program was properly implemented at the time 10 of testing.

(3) Notwithstanding subsection (b)(2), the results of a chemical test
performed on a sample collected by an employer shall not be admissible
evidence to prove impairment unless the following conditions are met:

14 (A) The test sample was collected within a reasonable time following15 the accident or injury;

(B) the collecting and labeling of the test sample was performed by orunder the supervision of a licensed health care professional;

18 (C) the test was performed by a laboratory approved by the United 19 States department of health and human services or licensed by the 20 department of health and environment, except that a blood sample may be 21 tested for alcohol content by a laboratory commonly used for that purpose 22 by state law enforcement agencies;

(D) the test was confirmed by gas chromatography-mass
 spectroscopy or other comparably reliable analytical method, except that
 no such confirmation is required for a blood alcohol sample;

(E) the foundation evidence must establish, beyond a reasonable
doubt, that the test results were from the sample taken from the employee;
and

(F) a split sample sufficient for testing shall be retained and madeavailable to the employee within 48 hours of a positive test.

(c) (1) Except as provided in paragraph (2), compensation shall not
be paid in case of coronary or coronary artery disease or cerebrovascular
injury unless it is shown that the exertion of the work necessary to
precipitate the disability was more than the employee's usual work in the
course of the employee's regular employment.

36 (2) For events occurring on or after July 1, 2014, in the case of a 37 firefighter as defined by K.S.A. 40-1709(b)(1), and amendments thereto, 38 or a law enforcement officer as defined by K.S.A. 74-5602, and 39 amendments thereto, coronary or coronary artery disease or 40 cerebrovascular injury shall be compensable if:

(A) The injury can be identified as caused by a specific eventoccurring in the course and scope of employment;

43 (B) the coronary or cerebrovascular injury occurred within 24 hours

1 of the specific event; and

2 (C) the specific event was the prevailing factor in causing the 3 coronary or coronary artery disease or cerebrovascular injury.

4 (d) Except as provided in the workers compensation act, no 5 construction design professional who is retained to perform professional 6 services on a construction project or any employee of a construction 7 design professional who is assisting or representing the construction 8 design professional in the performance of professional services on the site 9 of the construction project, shall be liable for any injury resulting from the 10 employer's failure to comply with safety standards on the construction project for which compensation is recoverable under the workers 11 12 compensation act, unless responsibility for safety practices is specifically assumed by contract. The immunity provided by this subsection to any 13 14 construction design professional shall not apply to the negligent 15 preparation of design plans or specifications.

16 (e) An award of compensation for permanent partial impairment, 17 work disability, or permanent total disability shall be reduced by the amount of functional impairment determined to be preexisting. Any such 18 19 reduction shall not apply to temporary total disability, nor shall it apply to 20 compensation for medical treatment.

21 (1) Where workers compensation benefits have previously been 22 awarded through settlement or judicial or administrative determination in 23 Kansas, the percentage basis of the prior settlement or award shall 24 conclusively establish the amount of functional impairment determined to 25 be preexisting. Where workers compensation benefits have not previously awarded through settlement or judicial or administrative 26 been 27 determination in Kansas, the amount of preexisting functional impairment 28 shall be established by competent evidence.

29 (2) In all cases, the applicable reduction shall be calculated as 30 follows:

31 (A) If the preexisting impairment is the result of injury sustained 32 while working for the employer against whom workers compensation 33 benefits are currently being sought, any award of compensation shall be 34 reduced by the current dollar value attributable under the workers 35 compensation act to the percentage of functional impairment determined to 36 be preexisting. The "current dollar value" shall be calculated by 37 multiplying the percentage of preexisting impairment by the compensation 38 rate in effect on the date of the accident or injury against which the 39 reduction will be applied.

40 (B) In all other cases, the employer against whom benefits are 41 currently being sought shall be entitled to a credit for the percentage of preexisting impairment. 42 43

(f) If the employee receives, whether periodically or by lump sum,

retirement benefits under the federal social security act or retirement 1 2 benefits from any other retirement system, program, policy or plan-which 3 *that* is provided by the employer against which the claim is being made, 4 any compensation benefit payments which the employee is eligible to 5 receive under the workers compensation act for such claim shall be 6 reduced by the weekly equivalent amount of the total amount of all such 7 retirement benefits, less any portion of any such retirement benefit, other 8 than retirement benefits under the federal social security act, that is 9 attributable to payments or contributions made by the employee, but in no 10 event shall the workers compensation benefit be less than the workers compensation benefit payable for the employee's percentage of functional 11 12 impairment. Where the employee elects to take retirement benefits in a 13 lump sum, the lump sum payment shall be amortized at the rate of 4% per 14 year over the employee's life expectancy to determine the weekly 15 equivalent value of the benefits.

Sec.<u>-69.75.</u> **{74.}** K.S.A. 2020 Supp. 44-706 is hereby amended to read as follows: 44-706. The secretary shall examine whether an individual has separated from employment for each week claimed. The secretary shall apply the provisions of this section to the individual's most recent employment prior to the week claimed. An individual shall be disqualified for benefits:

22 (a) If the individual left work voluntarily without good cause 23 attributable to the work or the employer, subject to the other provisions of 24 this subsection. For purposes of this subsection, "good cause" is cause of 25 such gravity that would impel a reasonable, not supersensitive, individual exercising ordinary common sense to leave employment. Good cause 26 27 requires a showing of good faith of the individual leaving work, including 28 the presence of a genuine desire to work. Failure to return to work after 29 expiration of approved personal or medical leave, or both, shall be 30 considered a voluntary resignation. After a temporary job assignment, 31 failure of an individual to affirmatively request an additional assignment on the next succeeding workday, if required by the employment 32 33 agreement, after completion of a given work assignment, shall constitute 34 leaving work voluntarily. The disqualification shall begin the day 35 following the separation and shall continue until after the individual has 36 become reemployed and has had earnings from insured work of at least 37 three times the individual's weekly benefit amount. An individual shall not 38 be disgualified under this subsection if:

(1) The individual was forced to leave work because of illness or injury upon the advice of a licensed and practicing health care provider and, upon learning of the necessity for absence, immediately notified the employer thereof, or the employer consented to the absence, and after recovery from the illness or injury, when recovery was certified by a

practicing health care provider, the individual returned to the employer and
 offered to perform services and the individual's regular work or
 comparable and suitable work was not available. As used in this paragraph
 "health care provider" means any person licensed by the proper licensing
 authority of any state to engage in the practice of medicine and surgery,
 osteopathy, chiropractic, dentistry, optometry, podiatry or psychology;

7 (2) the individual left temporary work to return to the regular 8 employer;

9 (3) the individual left work to enlist in the armed forces of the United 10 States, but was rejected or delayed from entry;

(4) the spouse of an individual who is a member of the armed forces 11 12 of the United States who left work because of the voluntary or involuntary 13 transfer of the individual's spouse from one job to another job, which is for the same employer or for a different employer, at a geographic location 14 which makes it unreasonable for the individual to continue work at the 15 16 individual's job. For the purposes of this provision the term "armed forces" 17 means active duty in the army, navy, marine corps, air force, coast guard or 18 any branch of the military reserves of the United States;

19 (5) the individual left work because of hazardous working conditions; 20 in determining whether or not working conditions are hazardous for an 21 individual, the degree of risk involved to the individual's health, safety and 22 morals, the individual's physical fitness and prior training and the working 23 conditions of workers engaged in the same or similar work for the same 24 and other employers in the locality shall be considered; as used in this 25 paragraph, "hazardous working conditions" means working conditions that could result in a danger to the physical or mental well-being of the 26 27 individual; each determination as to whether hazardous working 28 conditions exist shall include, but shall not be limited to, a consideration 29 of: (A) The safety measures used or the lack thereof; and (B) the condition 30 of equipment or lack of proper equipment; no work shall be considered 31 hazardous if the working conditions surrounding the individual's work are the same or substantially the same as the working conditions generally 32 33 prevailing among individuals performing the same or similar work for 34 other employers engaged in the same or similar type of activity;

(6) the individual left work to enter training approved under section 236(a)(1) of the federal trade act of 1974, provided the work left is not of a substantially equal or higher skill level than the individual's past adversely affected employment, as defined for purposes of the federal trade act of 1974, and wages for such work are not less than 80% of the individual's average weekly wage as determined for the purposes of the federal trade act of 1974;

42 (7) the individual left work because of unwelcome harassment of the 43 individual by the employer or another employee of which the employing unit had knowledge and that would impel the average worker to give up
 such worker's employment;

(8) the individual left work to accept better work; each determination 3 4 as to whether or not the work accepted is better work shall include, but 5 shall not be limited to, consideration of: (A) The rate of pay, the hours of 6 work and the probable permanency of the work left as compared to the 7 work accepted; (B) the cost to the individual of getting to the work left in 8 comparison to the cost of getting to the work accepted; and (C) the 9 distance from the individual's place of residence to the work accepted in 10 comparison to the distance from the individual's residence to the work left;

(9) the individual left work as a result of being instructed or requested
by the employer, a supervisor or a fellow employee to perform a service or
commit an act in the scope of official job duties which is in violation of an
ordinance or statute;

15 (10) the individual left work because of a substantial violation of the 16 work agreement by the employing unit and, before the individual left, the 17 individual had exhausted all remedies provided in such agreement for the 18 settlement of disputes before terminating. For the purposes of this 19 paragraph, a demotion based on performance does not constitute a 20 violation of the work agreement;

(11) after making reasonable efforts to preserve the work, the
individual left work due to a personal emergency of such nature and
compelling urgency that it would be contrary to good conscience to
impose a disqualification; or

(12) (A) the individual left work due to circumstances resulting from
 domestic violence, including:

(i) The individual's reasonable fear of future domestic violence at oren route to or from the individual's place of employment;

(ii) the individual's need to relocate to another geographic area inorder to avoid future domestic violence;

(iii) the individual's need to address the physical, psychological and
 legal impacts of domestic violence;

(iv) the individual's need to leave employment as a condition of
 receiving services or shelter from an agency which provides support
 services or shelter to victims of domestic violence; or

(v) the individual's reasonable belief that termination of employment
is necessary to avoid other situations which may cause domestic violence
and to provide for the future safety of the individual or the individual's
family.

40 (B) An individual may prove the existence of domestic violence by 41 providing one of the following:

42 (i) A restraining order or other documentation of equitable relief by a43 court of competent jurisdiction;

1

(ii) a police record documenting the abuse;

2 (iii) documentation that the abuser has been convicted of one or more 3 of the offenses enumerated in articles 34 and 35 of chapter 21 of the 4 Kansas Statutes Annotated, prior to their repeal, or articles 54 or 55 of 5 chapter 21 of the Kansas Statutes Annotated, *and amendments thereto*, or 6 K.S.A. 2020 Supp. 21-6104, 21-6325, 21-6326 or 21-6418 through 21-6422, and amendments thereto, where the victim was a family or 8 household member;

9

(iv) medical documentation of the abuse;

10 (v) a statement provided by a counselor, social worker, health care 11 provider, clergy, shelter worker, legal advocate, domestic violence or 12 sexual assault advocate or other professional who has assisted the 13 individual in dealing with the effects of abuse on the individual or the 14 individual's family; or

15

(vi) a sworn statement from the individual attesting to the abuse.

16 (C) No evidence of domestic violence experienced by an individual, 17 including the individual's statement and corroborating evidence, shall be 18 disclosed by the department of labor unless consent for disclosure is given 19 by the individual.

20 (b) If the individual has been discharged or suspended for misconduct 21 connected with the individual's work. The disgualification shall begin the 22 day following the separation and shall continue until after the individual 23 becomes reemployed and in cases where the disqualification is due to 24 discharge for misconduct has had earnings from insured work of at least 25 three times the individual's determined weekly benefit amount, except that if an individual is discharged for gross misconduct connected with the 26 27 individual's work, such individual shall be disqualified for benefits until 28 such individual again becomes employed and has had earnings from 29 insured work of at least eight times such individual's determined weekly 30 benefit amount. In addition, all wage credits attributable to the employment from which the individual was discharged for gross 31 32 misconduct connected with the individual's work shall be canceled. No 33 such cancellation of wage credits shall affect prior payments made as a 34 result of a prior separation.

(1) (A) For the purposes of this subsection, "misconduct" is defined as
a violation of a duty or obligation reasonably owed the employer as a
condition of employment including, but not limited to, a violation of a
company rule, including a safety rule, if:

- 39 (A)(i) The individual knew or should have known about the rule;
- 40 $(\mathbf{B})(ii)$ the rule was lawful and reasonably related to the job; and
- 41 (C)(iii) the rule was fairly and consistently enforced.
- 42 (B) The term "misconduct":
- 43 (i) Does not include any violation of a duty, obligation or company

1 rule, if:

2 (a) The individual is a registered patient pursuant to section 8, and 3 amendments thereto; and

4 (b) the basis for the violation is the possession of an identification 5 card issued under section 8, and amendments thereto, or the possession or 6 use of medical marijuana in accordance with the Kansas medical 7 marijuana regulation act, section 1 et seq., and amendments thereto; and

8 (ii) includes any violation of a duty, obligation or company rule if the 9 individual ingested marijuana in the workplace, worked while under the 10 influence of marijuana or tested positive for a controlled substance.

(2) (A) Failure of the employee to notify the employer of an absence
and an individual's leaving work prior to the end of such individual's
assigned work period without permission shall be considered prima facie
evidence of a violation of a duty or obligation reasonably owed the
employer as a condition of employment.

16 (B) For the purposes of this subsection, misconduct shall include, but 17 not be limited to, violation of the employer's reasonable attendance 18 expectations if the facts show:

19

(i) The individual was absent or tardy without good cause;

20 (ii) the individual had knowledge of the employer's attendance 21 expectation; and

(iii) the employer gave notice to the individual that future absence ortardiness may or will result in discharge.

(C) For the purposes of this subsection, if an employee disputes being absent or tardy without good cause, the employee shall present evidence that a majority of the employee's absences or tardiness were for good cause. If the employee alleges that the employee's repeated absences or tardiness were the result of health related issues, such evidence shall include documentation from a licensed and practicing health care provider as defined in subsection (a)(1).

(3) (A) (i) The term "gross misconduct" as used in this subsection
shall be construed to mean conduct evincing extreme, willful or wanton
misconduct as defined by this subsection. Gross misconduct shall include,
but not be limited to:

- 35 (i)(a) Theft;
- (ii)(b) fraud;
- 37 (iii)(c) intentional damage to property;
- 38 (iv)(d) intentional infliction of personal injury; or
- $\frac{(v)}{(e)}$ any conduct that constitutes a felony.
- 40 *(ii)* The term "gross misconduct":
- 41 *(a)* Does not include any conduct of an individual, if:
- 42 (1) The individual is a registered patient pursuant to section 8, and
- 43 amendments thereto; and

1 (2) the basis for such conduct is the possession of an identification 2 card issued under section 8, and amendments thereto, or the possession or 3 use of medical marijuana in accordance with the Kansas medical 4 marijuana regulation act, section 1 et seq., and amendments thereto; and

5 (b) includes any conduct of an individual if the individual ingested 6 marijuana in the workplace, worked while under the influence of 7 marijuana or tested positive for a controlled substance.

8 (B) For the purposes of this subsection, the following shall be 9 conclusive evidence of gross misconduct:

10 (i) The use of alcoholic liquor, cereal malt beverage or a 11 nonprescribed controlled substance by an individual while working;

12 (ii) the impairment caused by alcoholic liquor, cereal malt beverage 13 or a nonprescribed controlled substance by an individual while working;

14 (iii) a positive breath alcohol test or a positive chemical test,15 provided:

16

(a) The test was either:

17 (1) Required by law and was administered pursuant to the drug free18 workplace act, 41 U.S.C. § 701 et seq.;

(2) administered as part of an employee assistance program or other
 drug or alcohol treatment program in which the employee was
 participating voluntarily or as a condition of further employment;

(3) requested pursuant to a written policy of the employer of which
 the employee had knowledge and was a required condition of
 employment;

(4) required by law and the test constituted a required condition ofemployment for the individual's job; or

(5) there was reasonable suspicion to believe that the individual used,
had possession of, or was impaired by alcoholic liquor, cereal malt
beverage or a nonprescribed controlled substance while working;

30 (b) the test sample was collected either:

31 (1) As prescribed by the drug free workplace act, 41 U.S.C. § 701 et
32 seq.;

(2) as prescribed by an employee assistance program or other drug or
 alcohol treatment program in which the employee was participating
 voluntarily or as a condition of further employment;

36 (3) as prescribed by the written policy of the employer of which the
37 employee had knowledge and which constituted a required condition of
38 employment;

39 (4) as prescribed by a test which was required by law and which40 constituted a required condition of employment for the individual's job; or

41 (5) at a time contemporaneous with the events establishing probable 42 cause;

43 (c) the collecting and labeling of a chemical test sample was

performed by a licensed health care professional or any other individual certified pursuant to-paragraph (b)(3)(A)(iii)(f) subsection (b)(3)(B)(iii)(f) or authorized to collect or label test samples by federal or state law, or a federal or state rule or regulation having the force or effect of law, including law enforcement personnel;

6 (d) the chemical test was performed by a laboratory approved by the 7 United States department of health and human services or licensed by the 8 department of health and environment, except that a blood sample may be 9 tested for alcohol content by a laboratory commonly used for that purpose 10 by state law enforcement agencies;

(e) the chemical test was confirmed by gas chromatography, gas
chromatography-mass spectroscopy or other comparably reliable
analytical method, except that no such confirmation is required for a blood
alcohol sample or a breath alcohol test;

15 (f) the breath alcohol test was administered by an individual trained 16 to perform breath tests, the breath testing instrument used was certified 17 and operated strictly according to a description provided by the 18 manufacturers and the reliability of the instrument performance was 19 assured by testing with alcohol standards; and

(g) the foundation evidence establishes, beyond a reasonable doubt,
that the test results were from the sample taken from the individual;

(iv) an individual's refusal to submit to a chemical test or breathalcohol test, provided:

(a) The test meets the standards of the drug free workplace act, 41
U.S.C. § 701 et seq.;

(b) the test was administered as part of an employee assistance
program or other drug or alcohol treatment program in which the
employee was participating voluntarily or as a condition of further
employment;

30 (c) the test was otherwise required by law and the test constituted a 31 required condition of employment for the individual's job;

(d) the test was requested pursuant to a written policy of the employer
 of which the employee had knowledge and was a required condition of
 employment; or

(e) there was reasonable suspicion to believe that the individual used,
 possessed or was impaired by alcoholic liquor, cereal malt beverage or a
 nonprescribed controlled substance while working;

38 39 (v) an individual's dilution or other tampering of a chemical test.(C) For purposes of this subsection:

40 (i) "Alcohol concentration" means the number of grams of alcohol 41 per 210 liters of breath;

42 (ii) "alcoholic liquor"-shall be defined means the same as provided in
43 K.S.A. 41-102, and amendments thereto;

1 (iii) "cereal malt beverage"-shall be defined means the same as 2 provided in K.S.A. 41-2701, and amendments thereto;

3 (iv) "chemical test"-shall include *includes*, but is not limited to, tests 4 of urine, blood or saliva;

5 6

(v) "controlled substance"—shall be defined means the same as provided in K.S.A. 2020 Supp. 21-5701, and amendments thereto;

7 (vi) "required by law" means required by a federal or state law, a 8 federal or state rule or regulation having the force and effect of law, a 9 county resolution or municipal ordinance, or a policy relating to public 10 safety adopted in an open meeting by the governing body of any special 11 district or other local governmental entity;

"positive breath test"-shall mean means a test result showing an 12 (vii) alcohol concentration of 0.04 or greater, or the levels listed in 49 C.F.R. 13 part 40, if applicable, unless the test was administered as part of an 14 employee assistance program or other drug or alcohol treatment program 15 16 in which the employee was participating voluntarily or as a condition of further employment, in which case "positive chemical test"-shall mean-17 18 *means* a test result showing an alcohol concentration at or above the levels 19 provided for in the assistance or treatment program;

20 (viii) "positive chemical test"-shall mean means a chemical result 21 showing a concentration at or above the levels listed in K.S.A. 44-501, and 22 amendments thereto, or 49 C.F.R. part 40, as applicable, for the drugs or 23 abuse listed therein, unless the test was administered as part of an 24 employee assistance program or other drug or alcohol treatment program 25 in which the employee was participating voluntarily or as a condition of further employment, in which case "positive chemical test"-shall mean-26 27 *means* a chemical result showing a concentration at or above the levels 28 provided for in the assistance or treatment program.

(4) An individual shall not be disqualified under this subsection if theindividual is discharged under the following circumstances:

(A) The employer discharged the individual after learning the individual was seeking other work or when the individual gave notice of future intent to quit, except that the individual shall be disqualified after the time at which such individual intended to quit and any individual who commits misconduct after such individual gives notice to such individual's intent to quit shall be disqualified;

(B) the individual was making a good-faith effort to do the assignedwork but was discharged due to:

39 (i) Inefficiency;

40 (ii) unsatisfactory performance due to inability, incapacity or lack of 41 training or experience;

- 42 (iii) isolated instances of ordinary negligence or inadvertence;
- 43 (iv) good-faith errors in judgment or discretion; or

1 (v) unsatisfactory work or conduct due to circumstances beyond the 2 individual's control; or

3 4 (C) the individual's refusal to perform work in excess of the contract of hire.

5 (c) If the individual has failed, without good cause, to either apply for 6 suitable work when so directed by the employment office of the secretary 7 of labor, or to accept suitable work when offered to the individual by the 8 employment office, the secretary of labor, or an employer, such 9 disqualification shall begin with the week in which such failure occurred 10 and shall continue until the individual becomes reemployed and has had earnings from insured work of at least three times such individual's 11 12 determined weekly benefit amount. In determining whether or not any 13 work is suitable for an individual, the secretary of labor, or a person or persons designated by the secretary, shall consider the degree of risk 14 15 involved to health, safety and morals, physical fitness and prior training, 16 experience and prior earnings, length of unemployment and prospects for 17 securing local work in the individual's customary occupation or work for 18 which the individual is reasonably fitted by training or experience, and the 19 distance of the available work from the individual's residence. 20 Notwithstanding any other provisions of this act, an otherwise eligible 21 individual shall not be disgualified for refusing an offer of suitable 22 employment, or failing to apply for suitable employment when notified by 23 an employment office, or for leaving the individual's most recent work 24 accepted during approved training, including training approved under 25 section 236(a)(1) of the trade act of 1974, if the acceptance of or applying for suitable employment or continuing such work would require the 26 27 individual to terminate approved training and no work shall be deemed 28 suitable and benefits shall not be denied under this act to any otherwise eligible individual for refusing to accept new work under any of the 29 following conditions: (1) If the position offered is vacant due directly to a 30 31 strike, lockout or other labor dispute; (2) if the remuneration, hours or 32 other conditions of the work offered are substantially less favorable to the 33 individual than those prevailing for similar work in the locality; (3) if as a 34 condition of being employed, the individual would be required to join or to 35 resign from or refrain from joining any labor organization; and (4) if the 36 individual left employment as a result of domestic violence, and the 37 position offered does not reasonably accommodate the individual's 38 physical, psychological, safety, or legal needs relating to such domestic 39 violence

(d) For any week with respect to which the secretary of labor, or a
person or persons designated by the secretary, finds that the individual's
unemployment is due to a stoppage of work which exists because of a
labor dispute or there would have been a work stoppage had normal

operations not been maintained with other personnel previously and 1 2 currently employed by the same employer at the factory, establishment or 3 other premises at which the individual is or was last employed, except that 4 this subsection (d) shall not apply if it is shown to the satisfaction of the secretary of labor, or a person or persons designated by the secretary, that: 5 6 (1) The individual is not participating in or financing or directly interested 7 in the labor dispute which caused the stoppage of work; and (2) the 8 individual does not belong to a grade or class of workers of which, 9 immediately before the commencement of the stoppage, there were 10 members employed at the premises at which the stoppage occurs any of whom are participating in or financing or directly interested in the dispute. 11 12 If in any case separate branches of work which are commonly conducted as separate businesses in separate premises are conducted in separate 13 departments of the same premises, each such department shall, for the 14 purpose of this subsection be deemed to be a separate factory, 15 establishment or other premises. For the purposes of this subsection, 16 17 failure or refusal to cross a picket line or refusal for any reason during the 18 continuance of such labor dispute to accept the individual's available and 19 customary work at the factory, establishment or other premises where the individual is or was last employed shall be considered as participation and 20 21 interest in the labor dispute.

(e) For any week with respect to which or a part of which the individual has received or is seeking unemployment benefits under the unemployment compensation law of any other state or of the United States, except that if the appropriate agency of such other state or the United States finally determines that the individual is not entitled to such unemployment benefits, this disqualification shall not apply.

(f) For any week with respect to which the individual is entitled to
receive any unemployment allowance or compensation granted by the
United States under an act of congress to ex-service men and women in
recognition of former service with the military or naval services of the
United States.

33 (g) For the period of five years beginning with the first day following 34 the last week of unemployment for which the individual received benefits, 35 or for five years from the date the act was committed, whichever is the 36 later, if the individual, or another in such individual's behalf with the 37 knowledge of the individual, has knowingly made a false statement or 38 representation, or has knowingly failed to disclose a material fact to obtain 39 or increase benefits under this act or any other unemployment 40 compensation law administered by the secretary of labor. In addition to the penalties set forth in K.S.A. 44-719, and amendments thereto, an 41 42 individual who has knowingly made a false statement or representation or 43 who has knowingly failed to disclose a material fact to obtain or increase

benefits under this act or any other unemployment compensation law
 administered by the secretary of labor shall be liable for a penalty in the
 amount equal to 25% of the amount of benefits unlawfully received.
 Notwithstanding any other provision of law, such penalty shall be
 deposited into the employment security trust fund.

6 (h) For any week with respect to which the individual is receiving 7 compensation for temporary total disability or permanent total disability 8 under the workmen's compensation law of any state or under a similar law 9 of the United States.

10 (i) For any week of unemployment on the basis of service in an instructional, research or principal administrative capacity for an 11 educational institution as defined in K.S.A. 44-703(v), and amendments 12 13 thereto, if such week begins during the period between two successive academic years or terms or, when an agreement provides instead for a 14 15 similar period between two regular but not successive terms during such 16 period or during a period of paid sabbatical leave provided for in the 17 individual's contract, if the individual performs such services in the first of 18 such academic years or terms and there is a contract or a reasonable 19 assurance that such individual will perform services in any such capacity 20 for any educational institution in the second of such academic years or 21 terms.

22 (i) For any week of unemployment on the basis of service in any 23 capacity other than service in an instructional, research, or administrative 24 capacity in an educational institution, as defined in K.S.A. 44-703(v), and 25 amendments thereto, if such week begins during the period between two successive academic years or terms if the individual performs such 26 27 services in the first of such academic years or terms and there is a 28 reasonable assurance that the individual will perform such services in the 29 second of such academic years or terms, except that if benefits are denied 30 to the individual under this subsection and the individual was not offered 31 an opportunity to perform such services for the educational institution for 32 the second of such academic years or terms, such individual shall be 33 entitled to a retroactive payment of benefits for each week for which the 34 individual filed a timely claim for benefits and for which benefits were 35 denied solely by reason of this subsection.

36 (k) For any week of unemployment on the basis of service in any 37 capacity for an educational institution as defined in K.S.A. 44-703(v), and 38 amendments thereto, if such week begins during an established and 39 customary vacation period or holiday recess, if the individual performs 40 services in the period immediately before such vacation period or holiday 41 recess and there is a reasonable assurance that such individual will perform 42 such services in the period immediately following such vacation period or 43 holiday recess.

(1) For any week of unemployment on the basis of any services,
 substantially all of which consist of participating in sports or athletic
 events or training or preparing to so participate, if such week begins during
 the period between two successive sport seasons or similar period if such
 individual performed services in the first of such seasons or similar periods
 and there is a reasonable assurance that such individual will perform such
 services in the later of such seasons or similar periods.

8 (m) For any week on the basis of services performed by an alien 9 unless such alien is an individual who was lawfully admitted for 10 permanent residence at the time such services were performed, was lawfully present for purposes of performing such services, or was 11 12 permanently residing in the United States under color of law at the time 13 such services were performed, including an alien who was lawfully present 14 in the United States as a result of the application of the provisions of 15 section 212(d)(5) of the federal immigration and nationality act. Any data 16 or information required of individuals applying for benefits to determine 17 whether benefits are not payable to them because of their alien status shall 18 be uniformly required from all applicants for benefits. In the case of an 19 individual whose application for benefits would otherwise be approved, no 20 determination that benefits to such individual are not payable because of 21 such individual's alien status shall be made except upon a preponderance 22 of the evidence.

23 (n) For any week in which an individual is receiving a governmental 24 or other pension, retirement or retired pay, annuity or other similar 25 periodic payment under a plan maintained by a base period employer and to which the entire contributions were provided by such employer, except 26 27 that: (1) If the entire contributions to such plan were provided by the base 28 period employer but such individual's weekly benefit amount exceeds such 29 governmental or other pension, retirement or retired pay, annuity or other 30 similar periodic payment attributable to such week, the weekly benefit 31 amount payable to the individual shall be reduced, but not below zero, by 32 an amount equal to the amount of such pension, retirement or retired pay, 33 annuity or other similar periodic payment which is attributable to such 34 week; or (2) if only a portion of contributions to such plan were provided 35 by the base period employer, the weekly benefit amount payable to such 36 individual for such week shall be reduced, but not below zero, by the 37 prorated weekly amount of the pension, retirement or retired pay, annuity 38 or other similar periodic payment after deduction of that portion of the 39 pension, retirement or retired pay, annuity or other similar periodic 40 payment that is directly attributable to the percentage of the contributions 41 made to the plan by such individual; or (3) if the entire contributions to the plan were provided by such individual, or by the individual and an 42 43 employer, or any person or organization, who is not a base period

1 employer, no reduction in the weekly benefit amount payable to the 2 individual for such week shall be made under this subsection; or (4) 3 whatever portion of contributions to such plan were provided by the base 4 period employer, if the services performed for the employer by such 5 individual during the base period, or remuneration received for the 6 services, did not affect the individual's eligibility for, or increased the 7 amount of, such pension, retirement or retired pay, annuity or other similar 8 periodic payment, no reduction in the weekly benefit amount payable to 9 the individual for such week shall be made under this subsection. No 10 reduction shall be made for payments made under the social security act or 11 railroad retirement act of 1974

12 (o) For any week of unemployment on the basis of services 13 performed in any capacity and under any of the circumstances described in subsection (i), (j) or (k) which that an individual performed in an 14 15 educational institution while in the employ of an educational service 16 agency. For the purposes of this subsection, the term "educational service 17 agency" means a governmental agency or entity which is established and operated exclusively for the purpose of providing such services to one or 18 19 more educational institutions.

20 (p) For any week of unemployment on the basis of service as a school 21 bus or other motor vehicle driver employed by a private contractor to 22 transport pupils, students and school personnel to or from school-related 23 functions or activities for an educational institution, as defined in K.S.A. 24 44-703(v), and amendments thereto, if such week begins during the period 25 between two successive academic years or during a similar period between 26 two regular terms, whether or not successive, if the individual has a 27 contract or contracts, or a reasonable assurance thereof, to perform 28 services in any such capacity with a private contractor for any educational institution for both such academic years or both such terms. An individual 29 30 shall not be disqualified for benefits as provided in this subsection for any 31 week of unemployment on the basis of service as a bus or other motor 32 vehicle driver employed by a private contractor to transport persons to or 33 from nonschool-related functions or activities.

34 (q) For any week of unemployment on the basis of services 35 performed by the individual in any capacity and under any of the 36 circumstances described in subsection (i), (j), (k) or (o)-which that are 37 provided to or on behalf of an educational institution, as defined in K.S.A. 38 44-703(v), and amendments thereto, while the individual is in the employ 39 of an employer which is a governmental entity, Indian tribe or any 40 employer described in section 501(c)(3) of the federal internal revenue 41 code of 1986 which is exempt from income under section 501(a) of the 42 code.

43 (r) For any week in which an individual is registered at and attending

an established school, training facility or other educational institution, or is
 on vacation during or between two successive academic years or terms. An
 individual shall not be disqualified for benefits as provided in this
 subsection provided:

5 (1) The individual was engaged in full-time employment concurrent 6 with the individual's school attendance;

7 (2) the individual is attending approved training as defined in K.S.A.
8 44-703(s), and amendments thereto; or

9 (3) the individual is attending evening, weekend or limited day time 10 classes, which would not affect availability for work, and is otherwise 11 eligible under K.S.A. 44-705(c), and amendments thereto.

(s) For any week with respect to which an individual is receiving or has received remuneration in the form of a back pay award or settlement. The remuneration shall be allocated to the week or weeks in the manner as specified in the award or agreement, or in the absence of such specificity in the award or agreement, such remuneration shall be allocated to the week or weeks in which such remuneration, in the judgment of the secretary, would have been paid.

19 (1) For any such weeks that an individual receives remuneration in 20 the form of a back pay award or settlement, an overpayment will be 21 established in the amount of unemployment benefits paid and shall be 22 collected from the claimant.

(2) If an employer chooses to withhold from a back pay award or
settlement, amounts paid to a claimant while they claimed unemployment
benefits, such employer shall pay the department the amount withheld.
With respect to such amount, the secretary shall have available all of the
collection remedies authorized or provided in K.S.A. 44-717, and
amendments thereto.

29 (t) (1) Any applicant for or recipient of unemployment benefits who 30 tests positive for unlawful use of a controlled substance or controlled 31 substance analog shall be required to complete a substance abuse treatment 32 program approved by the secretary of labor, secretary of commerce or 33 secretary for children and families, and a job skills program approved by 34 the secretary of labor, secretary of commerce or the secretary for children 35 and families. Subject to applicable federal laws, any applicant for or 36 recipient of unemployment benefits who fails to complete or refuses to 37 participate in the substance abuse treatment program or job skills program 38 as required under this subsection shall be ineligible to receive 39 unemployment benefits until completion of such substance abuse 40 treatment and job skills programs. Upon completion of both substance abuse treatment and job skills programs, such applicant for or recipient of 41 unemployment benefits may be subject to periodic drug screening, as 42 43 determined by the secretary of labor. Upon a second positive test for

unlawful use of a controlled substance or controlled substance analog, an 1 2 applicant for or recipient of unemployment benefits shall be ordered to 3 complete again a substance abuse treatment program and job skills 4 program, and shall be terminated from unemployment benefits for a period of 12 months, or until such applicant for or recipient of unemployment 5 6 benefits completes both substance abuse treatment and job skills programs, 7 whichever is later. Upon a third positive test for unlawful use of a 8 controlled substance or controlled substance analog, an applicant for or a 9 recipient of unemployment benefits shall be terminated from receiving 10 unemployment benefits, subject to applicable federal law.

(2) Any individual who has been discharged or refused employment for failing a preemployment drug screen required by an employer may request that the drug screening specimen be sent to a different drug testing facility for an additional drug screening. Any such individual who requests an additional drug screening at a different drug testing facility shall be required to pay the cost of drug screening.

(3) The provisions of this subsection shall not apply to any individual
who is a registered patient pursuant to section 8, and amendments thereto,
for activities authorized by the Kansas medical marijuana regulation act,
section 1 et seq., and amendments thereto.

21 (u) If the individual was found not to have a disqualifying 22 adjudication or conviction under K.S.A. 39-970 or 65-5117, and 23 amendments thereto, was hired and then was subsequently convicted of a 24 disqualifying felony under K.S.A. 39-970 or 65-5117, and amendments 25 thereto, and discharged pursuant to K.S.A. 39-970 or 65-5117, and amendments thereto. The disgualification shall begin the day following the 26 27 separation and shall continue until after the individual becomes 28 reemployed and has had earnings from insured work of at least three times 29 the individual's determined weekly benefit amount.

(v) Notwithstanding the provisions of any subsection, an individual shall not be disqualified for such week of part-time employment in a substitute capacity for an educational institution if such individual's most recent employment prior to the individual's benefit year begin date was for a non-educational institution and such individual demonstrates application for work in such individual's customary occupation or for work for which the individual is reasonably fitted by training or experience.

37 See. 70. K.S.A. 44-1009 is hereby amended to read as follows: 44 1009. (a) It shall be an unlawful employment practice:

39 (1) For an employer, because of the race, religion, color, sex,
 40 disability, national origin or ancestry of any person to refuse to hire or
 41 employ such person to bar or discharge such person from employment or
 42 to otherwise discriminate against such person in compensation or in terms,

43 <u>conditions or privileges of employment; to limit, segregate, separate,</u>

1 elassify or make any distinction in regards to employees; or to follow any 2 employment procedure or practice which, in fact, results in discrimination. 3 segregation or separation without a valid business necessity. 4 (2) For a labor organization, because of the race, religion, color, sex, 5 disability, national origin or ancestry of any person, to exclude or to expel 6 from its membership such person or to discriminate in any way against any 7 of its members or against any employer or any person employed by an 8 employer. 9 (3) For any employer, employment agency or labor organization to 10 print or circulate or cause to be printed or circulated any statement,-11 advertisement or publication, or to use any form of application for-12 employment or membership or to make any inquiry in connection with 13 prospective employment or membership, which expresses, directly or-14 indirectly, any limitation, specification or discrimination as to race, 15 religion, color, sex, disability, national origin or ancestry, or any intent to 16 make any such limitation, specification or discrimination, unless based on 17 a bona fide occupational qualification. 18 (4) For any employer, employment agency or labor organization to 19 discharge, expel or otherwise discriminate against any person because such 20 person has opposed any practices or acts forbidden under this act or-21 because such person has filed a complaint, testified or assisted in any 22 proceeding under this act. 23 (5) For an employment agency to refuse to list and properly classify 24 for employment or to refuse to refer any person for employment or 25 otherwise discriminate against any person because of such person's race. religion, color, sex, disability, national origin or ancestry; or to comply-26 27 with a request from an employer for a referral of applicants for-28 employment if the request expresses, either directly or indirectly, any-29 limitation, specification or discrimination as to race, religion, color, sex, 30 disability, national origin or ancestry. 31 (6) For an employer, labor organization, employment agency, or-32 school which provides, coordinates or controls apprenticeship, on-the-job, 33 or other training or retraining program, to maintain a practice of-34 discrimination, segregation or separation because of race, religion, color, 35 sex, disability, national origin or ancestry, in admission, hiring, 36 assignments, upgrading, transfers, promotion, layoff, dismissal, 37 apprenticeship or other training or retraining program, or in any other 38 terms, conditions or privileges of employment, membership, 39 apprenticeship or training; or to follow any policy or procedure which, in 40 fact, results in such practices without a valid business motive. 41 (7) For any person, whether an employer or an employee or not, to aid, abet, incite, compel or coerce the doing of any of the acts forbidden 42 43 under this act, or attempt to do so.

4	
1	(8) For an employer, labor organization, employment agency or joint
2	<u>labor-management committee to:</u>
3	(A) Limit, segregate or classify a job applicant or employee in a way
4	that adversely affects the opportunities or status of such applicant or
5	employee because of the disability of such applicant or employee;
6	(B) participate in a contractual or other arrangement or relationship,
7	including a relationship with an employment or referral agency, labor
8 9	union, an organization providing fringe benefits to an employee or an
9 10	organization providing training and apprenticeship programs that has the effect of subjecting a qualified applicant or employee with a disability to
11	the discrimination prohibited by this act;
12	<u>(C) utilize standards criteria, or methods of administration that have</u>
13	the effect of discrimination on the basis of disability or that perpetuate the
14	discrimination of others who are subject to common administrative
15	control;
16	(D) exclude or otherwise deny equal jobs or benefits to a qualified
17	individual because of the known disability of an individual with whom the
18	gualified individual is known to have a relationship or association;
19	(E) not make reasonable accommodations to the known physical or
20	mental limitations of an otherwise qualified individual with a disability
21	who is an applicant or employee, unless such employer, labor organization,
22	employment agency or joint labor-management committee can
23	demonstrate that the accommodation would impose an undue hardship on
24	the operation of the business thereof;
25	(F) deny employment opportunities to a job applicant or employee
26	who is an otherwise qualified individual with a disability, if such denial is
27	based on the need to make reasonable accommodation to the physical or
28	mental impairments of the employee or applicant;
29	(G) use qualification standards, employment tests or other selection
30	eriteria that sereen out or tend to sereen out an individual with a disability
31	or a class of individuals with disabilities unless the standard, test or other
32	selection criteria, as used, is shown to be job-related for the position in
33	question and is consistent with business necessity; or
34	(H) fail to select and administer tests concerning employment in the
35	most effective manner to ensure that, when such test is administered to a
36	job applicant or employee who has a disability that impairs sensory,
37	manual or speaking skills, the test results accurately reflect the skills,-
38	aptitude or whatever other factor of such applicant or employee that such
39	test purports to measure, rather than reflecting the impaired sensory,-
40	manual or speaking skills of such employee or applicant (, except where
41	such skills are the factors that the test purports to measure).
42	(9) For any employer to:

43 (A) Seek to obtain, to obtain or to use genetic screening or testing-

1	information of an employee or a prospective employee to distinguish-		
2	between or discriminate against or restrict any right or benefit otherwise		
3	due or available to an employee or a prospective employee; or		
4	(B) subject, directly or indirectly, any employee or prospective-		
5	employee to any genetic screening or test.		
6	(10) (A) For an employer, because a person is a registered patient or		
7	caregiver pursuant to section 8, and amendments thereto, or possesses or		
8	uses medical marijuana in accordance with the Kansas medical marijuana		
9	regulation act, section 1 et seq., and amendments thereto, to:		
10	<u>(i) Refuse to hire or employ a person;</u>		
11	(ii) bar or discharge such person from employment; or		
12	(iii) otherwise discriminate against such person in compensation or		
13	in terms, conditions or privileges of employment without a valid business		
14	<u>necessity.</u>		
15	(B) For a labor organization, because a person is a registered patient		
16	or caregiver pursuant to section 8, and amendments thereto, or possesses		
17	or uses medical marijuana in accordance with the Kansas medical-		
18	marijuana regulation act, section 1 et seq., and amendments thereto, to:		
19	exclude or expel such person from its membership.		
20	(C) Nothing in this paragraph shall be construed to prohibit a person		
21	from taking any action necessary to procure or retain any monetary-		
22	benefit provided under federal law, or any rules and regulations adopted		
23	thereunder, or to obtain or maintain any license, certificate, registration:		
24	or other legal status issued or bestowed under federal law, or any rules:		
25	and regulations adopted thereunder.		
26	(D) Nothing in this paragraph shall be construed to provide a cause		
27	of action against an employer for wrongful discharge or discrimination for		
28	<u>the unlawful use of marijuana.</u>		
29	(b) It shall not be an unlawful employment practice to fill vacancies		
30	in such way as to eliminate or reduce imbalance with respect to race,		
31	religion, color, sex, disability, national origin or ancestry.		
32	(c) It shall be an unlawful discriminatory practice:		
33	(1) For any person, as defined herein being the owner, operator,		
34	lessee, manager, agent or employee of any place of public accommodation		
35	to refuse, deny or make a distinction, directly or indirectly, in offering its		
36	goods, services, facilities, and accommodations to any person as covered		
37	by this act because of race, religion, color, sex, disability, national origin or		
38	ancestry, except where a distinction because of sex is necessary because of		
39	the intrinsic nature of such accommodation.		
40	(2) For any person, whether or not specifically enjoined from		
41	discriminating under any provisions of this act, to aid, abet, ineite, compel		
42	or coerce the doing of any of the acts forbidden under this act, or to-		
43	attempt to do so.		

attempt to do so.

1	(3) For any person, to refuse, deny, make a distinction, directly or
2	indirectly, or discriminate in any way against persons because of the race,
3	religion, color, sex, disability, national origin or ancestry of such persons
4	in the full and equal use and enjoyment of the services, facilities,
5	privileges and advantages of any institution, department or agency of the
6	state of Kansas or any political subdivision or municipality thereof.
7	Sec. 71. K.S.A. 44-1015 is hereby amended to read as follows: 44-
8	1015. As used in this act, unless the context otherwise requires:
9	(a) "Commission" means the Kansas human rights commission.
10	(b) "Real property" means and includes:
11	(1) All vacant or unimproved land; and
12	(2) any building or structure which that is occupied or designed or
13	intended for occupancy, or any building or structure having a portion-
14	thereof which that is occupied or designed or intended for occupancy.
15	<u>(c) "Family" includes a single individual.</u>
16	(d) "Person" means an individual, corporation, partnership,
17	association, labor organization, legal representative, mutual company,
18	joint-stock company, trust, unincorporated organization, trustee, trustee in
19	bankruptcy, receiver and fiduciary.
20	(c) "To rent" means to lease, to sublease, to let and otherwise to grant
21	for a consideration the right to occupy premises not owned by the
22	occupant.
23	(f) "Discriminatory housing practice" means any act that is unlawful
24	under K.S.A. 44-1016, 44-1017 or 44-1026, and amendments thereto, or
25	section 54, and amendments thereto.
26	(g) "Person aggrieved" means any person who elaims to have been
27	injured by a discriminatory housing practice or believes that such person
28	will be injured by a discriminatory housing practice that is about to occur.
29	(h) "Disability" has the meaning provided by means the same as-
30	defined in K.S.A. 44-1002, and amendments thereto.
31	(i) "Familial status" means having one or more individuals less than
32	18 years of age domiciled with:
33	(1) A parent or another person having legal custody of such
34	individual or individuals; or
35	(2) the designee of such parent or other person having such eustody,
36	with the written permission of such parent or other person.
37	Sec. <u>72.76.</u> {75.} K.S.A. 2020 Supp. 65-1120 is hereby amended to
38	read as follows: 65-1120. (a) Grounds for disciplinary actions. The board
39	may deny, revoke, limit or suspend any license or authorization to practice
40	nursing as a registered professional nurse, as a licensed practical nurse, as
41	an advanced practice registered nurse or as a registered nurse anesthetist
42	that is issued by the board or applied for under this act, or may require the
43	licensee to attend a specific number of hours of continuing education in

addition to any hours the licensee may already be required to attend or
 may publicly or privately censure a licensee or holder of a temporary
 permit or authorization, if the applicant, licensee or holder of a temporary
 permit or authorization is found after hearing:

5 6 (1) To be guilty of fraud or deceit in practicing nursing or in procuring or attempting to procure a license to practice nursing;

7 (2) to have been guilty of a felony or to have been guilty of a 8 misdemeanor involving an illegal drug offense unless the applicant or licensee establishes sufficient rehabilitation to warrant the public trust, 9 except that notwithstanding K.S.A. 74-120, and amendments thereto, no 10 license or authorization to practice nursing as a licensed professional 11 12 nurse, as a licensed practical nurse, as an advanced practice registered 13 nurse or registered nurse anesthetist shall be granted to a person with a felony conviction for a crime against persons as specified in article 34 of 14 chapter 21 of the Kansas Statutes Annotated, prior to their repeal, or article 15 16 54 of chapter 21 of the Kansas Statutes Annotated, and amendments 17 thereto, or K.S.A. 2020 Supp. 21-6104, 21-6325, 21-6326 or 21-6418, and 18 amendments thereto:

(3) has been convicted or found guilty or has entered into an agreed
disposition of a misdemeanor offense related to the practice of nursing as
determined on a case-by-case basis;

(4) to have committed an act of professional incompetency as definedin subsection (e);

(5) to be unable to practice with skill and safety due to current abuseof drugs or alcohol;

(6) to be a person who has been adjudged in need of a guardian or
conservator, or both, under the act for obtaining a guardian or conservator,
or both, and who has not been restored to capacity under that act;

(7) to be guilty of unprofessional conduct as defined by rules andregulations of the board;

(8) to have willfully or repeatedly violated the provisions of the
 Kansas nurse practice act or any rules and regulations adopted pursuant to
 that act, including K.S.A. 65-1114 and 65-1122, and amendments thereto;

34 (9) to have a license to practice nursing as a registered nurse or as a 35 practical nurse denied, revoked, limited or suspended, or to be publicly or 36 privately censured, by a licensing authority of another state, agency of the 37 United States government, territory of the United States or country or to 38 have other disciplinary action taken against the applicant or licensee by a 39 licensing authority of another state, agency of the United States 40 government, territory of the United States or country. A certified copy of the record or order of public or private censure, denial, suspension, 41 limitation, revocation or other disciplinary action of the licensing authority 42 43 of another state, agency of the United States government, territory of the

United States or country shall constitute prima facie evidence of such a
 fact for purposes of this paragraph-(9); or

3 (10) to have assisted suicide in violation of K.S.A. 21-3406, prior to 4 its repeal, or K.S.A. 2020 Supp. 21-5407, and amendments thereto, as 5 established by any of the following:

6 (A) A copy of the record of criminal conviction or plea of guilty for a 7 felony in violation of K.S.A. 21-3406, prior to its repeal, or K.S.A. 2020 8 Supp. 21-5407, and amendments thereto.

9 (B) A copy of the record of a judgment of contempt of court for 10 violating an injunction issued under K.S.A. 2020 Supp. 60-4404, and 11 amendments thereto.

12 (C) A copy of the record of a judgment assessing damages under13 K.S.A. 2020 Supp. 60-4405, and amendments thereto.

(b) Proceedings. Upon filing of a sworn complaint with the board 14 15 charging a person with having been guilty of any of the unlawful practices 16 specified in subsection (a), two or more members of the board shall 17 investigate the charges, or the board may designate and authorize an 18 employee or employees of the board to conduct an investigation. After 19 investigation, the board may institute charges. If an investigation, in the 20 opinion of the board, reveals reasonable grounds for believing the 21 applicant or licensee is guilty of the charges, the board shall fix a time and 22 place for proceedings, which shall be conducted in accordance with the 23 provisions of the Kansas administrative procedure act.

(c) *Witnesses.* No person shall be excused from testifying in any proceedings before the board under this act or in any civil proceedings under this act before a court of competent jurisdiction on the ground that such testimony may incriminate the person testifying, but such testimony shall not be used against the person for the prosecution of any crime under the laws of this state except the crime of perjury as defined in K.S.A. 2020 Supp. 21-5903, and amendments thereto.

31 (d) Costs. If final agency action of the board in a proceeding under 32 this section is adverse to the applicant or licensee, the costs of the board's 33 proceedings shall be charged to the applicant or licensee as in ordinary 34 civil actions in the district court, but if the board is the unsuccessful party, 35 the costs shall be paid by the board. Witness fees and costs may be taxed 36 by the board according to the statutes relating to procedure in the district 37 court. All costs accrued by the board, when it is the successful party, and 38 which that the attorney general certifies cannot be collected from the 39 applicant or licensee shall be paid from the board of nursing fee fund. All 40 moneys collected following board proceedings shall be credited in full to 41 the board of nursing fee fund.

42 (e) *Professional incompetency defined.* As used in this section, 43 "professional incompetency" means: 1 (1) One or more instances involving failure to adhere to the 2 applicable standard of care to a degree—which *that* constitutes gross 3 negligence, as determined by the board;

4 (2) repeated instances involving failure to adhere to the applicable 5 standard of care to a degree which *that* constitutes ordinary negligence, as 6 determined by the board; or

7 (3) a pattern of practice or other behavior-which *that* demonstrates a
8 manifest incapacity or incompetence to practice nursing.

9 (f) *Criminal justice information.* The board upon request shall receive 10 from the Kansas bureau of investigation such criminal history record 11 information relating to arrests and criminal convictions as necessary for 12 the purpose of determining initial and continuing qualifications of 13 licensees of and applicants for licensure by the board.

14

(g) Medical marijuana exemption. The board shall not:

(1) Deny, revoke, limit or suspend the license of any licensee<u>under</u>:
 the Kansas medical marijuana regulation act, section 1 et seq., and
 amendments thereto;

(2) or publicly or privately censure any licensee for any actions as a
 registered patient or caregiver pursuant to section 8, and amendments
 thereto, including whether the licensee possesses or has possessed, or uses
 or has used medical marijuana in accordance with the Kansas medical
 marijuana regulation act, section 1 et seq., and amendments thereto; or

23 (3)(2) deny, revoke, limit or suspend an advanced practice registered
 24 nurse's license or publicly or privately censure an advanced practice
 25 registered nurse for any of the following:

26

(A) The advanced practice registered nurse has:

(i) Advised a patient about the possible benefits and risks of using
 medical marijuana; or

(ii) advised a patient that using medical marijuana may mitigate the
 patient's symptoms; or

(B) the advanced practice registered nurse is a registered patient or
caregiver pursuant to section 8, and amendments thereto, possesses or has
possessed, or uses or has used medical marijuana in accordance with the
Kansas medical marijuana regulation act, section 1 et seq., and
amendments thereto.

Sec.<u>73.77.</u> {76.} K.S.A. 65-28b08 is hereby amended to read as follows: 65-28b08. (a) The board may deny, revoke, limit or suspend any license or authorization issued to a certified nurse-midwife to engage in the independent practice of midwifery that is issued by the board or applied for under this act, or may publicly censure a licensee or holder of a temporary permit or authorization, if the applicant or licensee is found after a hearing:

43 (1) To be guilty of fraud or deceit while engaging in the independent

practice of midwifery or in procuring or attempting to procure a license to
 engage in the independent practice of midwifery;

3 (2) to have been found guilty of a felony or to have been found guilty of a misdemeanor involving an illegal drug offense unless the applicant or 4 5 licensee establishes sufficient rehabilitation to warrant the public trust, 6 except that notwithstanding K.S.A. 74-120, and amendments thereto, no 7 license or authorization to practice and engage in the independent practice 8 of midwifery shall be granted to a person with a felony conviction for a 9 crime against persons as specified in article 34 of chapter 21 of the Kansas Statutes Annotated, prior to its repeal, or article 54 of chapter 21 of the 10 Kansas Statutes Annotated, and amendments thereto, or K.S.A. 2020 Supp. 11 12 21-6104, 21-6325, 21-6326 or 21-6418, and amendments thereto;

(3) to have committed an act of professional incompetence as definedin subsection (c);

15 (4) to be unable to practice the healing arts with reasonable skill and 16 safety by reason of impairment due to physical or mental illness or condition or use of alcohol, drugs or controlled substances. All 17 18 information, reports, findings and other records relating to impairment 19 shall be confidential and not subject to discovery or release to any person or entity outside of a board proceeding. The provisions of this paragraph 20 21 providing confidentiality of records shall expire on July 1, 2022, unless the 22 legislature reviews and reenacts such provisions pursuant to K.S.A. 45-23 229, and amendments thereto, prior to July 1, 2022;

(5) to be a person who has been adjudged in need of a guardian or
conservator, or both, under the act for obtaining a guardian or conservator,
or both, and who has not been restored to capacity under that act;

(6) to be guilty of unprofessional conduct as defined by rules andregulations of the board;

(7) to have willfully or repeatedly violated the provisions of the
Kansas nurse practice act or any rules and regulations adopted pursuant to
that act;

32 (8) to have a license to practice nursing as a registered nurse or as a 33 practical nurse denied, revoked, limited or suspended, or to have been 34 publicly or privately censured, by a licensing authority of another state, 35 agency of the United States government, territory of the United States or 36 country, or to have other disciplinary action taken against the applicant or 37 licensee by a licensing authority of another state, agency of the United 38 States government, territory of the United States or country. A certified copy of the record or order of public or private censure, denial, suspension, 39 limitation, revocation or other disciplinary action of the licensing authority 40 41 of another state, agency of the United States government, territory of the 42 United States or country shall constitute prima facie evidence of such a 43 fact for purposes of this paragraph; or

1 (9) to have assisted suicide in violation of K.S.A. 21-3406, prior to its 2 repeal, or K.S.A. 2020 Supp. 21-5407, and amendments thereto, as 3 established by any of the following:

4 (A) A copy of the record of criminal conviction or plea of guilty to a 5 felony in violation of K.S.A. 21-3406, prior to its repeal, or K.S.A. 2020 6 Supp. 21-5407, and amendments thereto;

7 (B) a copy of the record of a judgment of contempt of court for 8 violating an injunction issued under K.S.A. 60-4404, and amendments 9 thereto; or

(C) a copy of the record of a judgment assessing damages underK.S.A. 60-4405, and amendments thereto.

(b) No person shall be excused from testifying in any proceedings before the board under this act or in any civil proceedings under this act before a court of competent jurisdiction on the ground that such testimony may incriminate the person testifying, but such testimony shall not be used against the person for the prosecution of any crime under the laws of this state, except the crime of perjury as defined in K.S.A. 2020 Supp. 21-5903, and amendments thereto.

(c) The board shall not deny, revoke, limit or suspend any license or
 authorization issued to a certified nurse-midwife or publicly censure a
 certified nurse-midwife upon any of the following:

22

(1) The certified nurse-midwife has:

23 (A) Advised a patient about the possible benefits and risks of using
 24 medical marijuana; or

25 *(B)* advised the patient that using medical marijuana may mitigate 26 the patient's symptoms; or

(2) the certified nurse-midwife is a registered patient or caregiver
pursuant to section 8, and amendments thereto, possesses or has
possessed, or uses or has used medical marijuana in accordance with the
Kansas medical marijuana regulation act, section 1 et seq., and
amendments thereto.

32

(d) As used in this section, "professional incompetency" means:

(1) One or more instances involving failure to adhere to the
applicable standard of care to a degree-which *that* constitutes gross
negligence, as determined by the board;

36 (2) repeated instances involving failure to adhere to the applicable
37 standard of care to a degree-which *that* constitutes ordinary negligence, as
38 determined by the board; or

(3) a pattern of practice or other behavior which that demonstrates a
 manifest incapacity or incompetence to engage in the independent practice
 of midwifery.

42 (d)(e) The board, upon request, shall receive from the Kansas bureau 43 of investigation such criminal history record information relating to arrests and criminal convictions, as necessary, for the purpose of determining
 initial and continuing qualifications of licensees and applicants for
 licensure by the board.

4 (c) The provisions of this section shall become effective on January 1, 5 2017.

6 Sec.<u>-78.</u> {77.} On and after the effective date of this act, if the 7 secretary of state publishes notice of the certification required 8 pursuant to section<u>-83</u> {82}, and amendments thereto, K.S.A. 2020 9 Supp. 65-4105 is hereby amended to read as follows: 65-4105. (a) The 10 controlled substances listed in this section are included in schedule I 11 and the number set forth opposite each drug or substance is the DEA 12 controlled substances code that has been assigned to it.

(b) Any of the following opiates, including their isomers, esters,
 ethers, salts, and salts of isomers, esters and ethers, unless specifically
 excepted, whenever the existence of these isomers, esters, ethers and
 salts is possible within the specific chemical designation:

-		Free Free Free Free Free Free Free Free
17	(1)	Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
18		phenylacetamide)9821
19	(2)	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
20		piperidinyl]-N-phenylacetamide)
21	(3)	Acetylmethadol9601
22	(4)	Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
23		phenylacrylamide; acryloylfentanyl)9811
24	(5)	AH-7921 (3,4-dichloro-N-[(1-
25	. /	dimethylamino)cyclohexylmethyl]benzamide)9551
26	(6)	Allylprodine
27	(7)	Alphacetylmethadol
28	. /	(except levo-alphacetylmethadol also known as levo-alpha-
29		acetylmethadol, levomethadyl acetate or LAAM)
30	(8)	Alphameprodine
31	(9)	Alphamethadol
32	(10)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-
33	. ,	piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
34		propanilido) piperidine)
35	(11)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
36		piperidinyl]-N-phenylpropanamide)
37	(12)	Benzethidine
38	(13)	Betacetylmethadol9607
39	(14)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
40		piperidinyl]-N-phenylpropanamide)
41	(15)	Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-
42		phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)9831
43	(16)	Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-
		· · · · · · ·

1		ulathullninguidin 4 wll N nhonulnuonignamida) 0926
1	(17)	yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)9836 Betameprodine9608
2		
3		Betamethadol
4		Betaprodine
5	(20)	Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
6	(31)	phenylbutyramide)
7		Clonitazene
8 9	(22)	Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
-	(22)	phenylcyclopentanecarboxamide)
10 11	(23)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopropanecarboxamide)
11	(24)	Dextromoramide
13		Diampromide
14		Diethylthiambutene
15 16		Difenoxin
10		Dimenoxadol
17		Dimepheptanoi
-		Dimethylthiambutene
19 20	· · ·	1 0 0
20 21	(32)	Dipipanone
21 22		Etonitazene
22		Etomtazene
23 24	(35)	Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-
24 25	(30)	2-carboxamide)
23 26	(37)	Furethidine
20		Furetinane
28		Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
28 29	(3))	phenylisobutyramide)
30	(40)	Ketobemidone
31		Levomoramide
32		Levophenacylmorphan
33		Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-
34	(10)	vl)-N-phenylacetamide)
35	(44)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-
36	()	phenylpropanamide)
37	(45)	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-
38	(10)	piperidinyl]-N-phenylpropanamide)
39	(46)	Morpheridine
40		Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-
41	()	phenethylpiperidin-4-yl)acetamide)
42	(48)	O-desmethyltramadol
43	()	Some trade or other names: 2-((dimethylamino)methyl-1-(3-

1		hydroxyphenyl)cyclohexanol;3-(2-((dimethylamino)methyl)-1-
2		hydroxycyclohexyl)phenol
3	(49)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)
4		MT-45 (1-cychohexyl-4-(1,2-diphenylethyl)piperazine)
5		Noracymethadol
6	(52)	Norlevorphanol
7	(53)	Normethadone9635
8		Norpipanone9636
9	(55)	Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-
10		phenethylpiperidin-4-yl)propionamide; 2-fluorofentanyl)9816
11	(56)	Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-
12		phenethylpiperidin-4-yl)isobutyramide)
13	(57)	Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
14		phenethylpiperidin-4-yl)butyramide)
15	(58)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
16		piperidinyl]propanamide)9812
17	(59)	Para-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
18		phenethylpiperidin-4-yl)isobutyramide,
19	(10)	4-fluoroisobutyryl fentanyl)
20	(60)	Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-
21	((1))	phenethylpiperidin-4-yl)butyramide)
22		PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine)9663
23		Phenadoxone
24		Phenampromide
25		Phenomorphan
26		Phenoperidine
27		Piritramide
28		Proheptazine
29		Properidine
30		Propiram
31 32		Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
32	(71)	phenyltetrahydrofuran-2-carboxamide)
33 34	(72)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
34 35	(12)	propanamide)
35 36	(73)	Tilidine
37		Trimeperidine
38		U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
39	(13)	methylbenzamide)
40	(76)	Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
40	(10)	phenylpentanamide)
42	((c) Any of the following opium derivatives, their salts, isomers
43		salts of isomers, unless specifically excepted, whenever the
15	and	suits of isomers, amess specificany excepted, whenever the

1		tence of these salts, isomers and salts of isomers is possible within
2	the s	specific chemical designation:
3	(1)	Acetorphine9319
4	(2)	Acetyldihydrocodeine9051
5	(3)	Benzylmorphine9052
6	(4)	Codeine methylbromide9070
7	(5)	Codeine-N-Oxide9053
8	(6)	Cyprenorphine9054
9	(7)	Desomorphine9055
10	(8)	Dihydromorphine9145
11	(9)	Drotebanol9335
12	(10)	Etorphine (except hydrochloride salt)9056
13	(11)	Heroin
14		Hydromorphinol9301
15		Methyldesorphine9302
16		Methyldihydromorphine9304
17		Morphine methylbromide9305
18		Morphine methylsulfonate9306
19		Morphine-N-Oxide9307
20		Myrophine9308
21	· · ·	Nicocodeine
22		Nicomorphine9312
23		Normorphine9313
24		Pholcodine
25		Thebacon
26		d) Any material, compound, mixture or preparation that
27		ains any quantity of the following hallucinogenic substances, their
28		, isomers and salts of isomers, unless specifically excepted,
29		never the existence of these salts, isomers and salts of isomers is
30	-	ible within the specific chemical designation:
31	(1)	Alpha-ethyltryptamine 7249 Some trade or other names:
32		etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3-(2-
33		aminobutyl) indole; α-ET; and AET.
34	(2)	4-bromo-2,5-dimethoxy-amphetamine
35		Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-
36		methylphenethylamine; 4-bromo-2,5-DMA.
37	(3)	2,5-dimethoxyamphetamine7396
38		Some trade or other names: 2,5-dimethoxy-alpha-methyl-
39		phenethylamine; 2,5-DMA.
40	(4)	4-methoxyamphetamine
41		Some trade or other names: 4-methoxy-alpha-methylphene-
42		thylamine; paramethoxyamphetamine; PMA.
43	(5)	5-methoxy-3,4-methylenedioxy-amphetamine7401

1	(6)	4-methyl-2,5-dimethoxy-amphetamine7395
2		Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-
3		methylphenethylamine; "DOM"; and "STP".
4	(7)	3,4-methylenedioxy amphetamine7400
5	(8)	3,4-methylenedioxymethamphetamine (MDMA)7405
6	(9)	3,4-methylenedioxy-N-ethylamphetamine (also known as N-
7		ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-
8		ethyl MDA, MDE, and MDEA)7404
9	(10)	N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-
10		hydroxy-alpha-methyl-3,4-(methylenedioxy) phenethylamine,
11		and N-hydroxy MDA)7402
12	(11)	3,4,5-trimethoxy amphetamine7390
13	(12)	Bufotenine7433
14		Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-
15		hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-
16		dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
17		mappine.
18	(13)	Diethyltryptamine7434
19		Some trade or other names: N,N-Diethyltryptamine; DET.
20	(14)	Dimethyltryptamine7435
21		Some trade or other names: DMT.
22	(15)	Ibogaine7260
23		Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-
24		octahydro-2-methoxy-6,9-methano-5H-
25		pyrido[1',2':1,2]azepino[5,4-b]indole; Tabernanthe iboga
26		Lysergic acid diethylamide7315
27		Marijuana
28		17) Mescaline7381
29	(19) (<i>18)</i> Parahexyl7374
30		Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-
31		tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.
32	(20) (<i>19)</i> Peyote
33		Meaning all parts of the plant presently classified botanically as
34		Lophophora williamsii Lemaire, whether growing or not, the
35		seeds thereof, any extract from any part of such plant, and every
36		compound, manufacture, salts, derivative, mixture or
37	(01)	preparation of such plant, its seeds or extracts.
38		20) N-ethyl-3-piperidyl benzilate
39		21) N-methyl-3-piperidyl benzilate
40		22) Psilocybin
41	(24) (23) Psilocyn
42	(25)	Some trade or other names: Psilocin.
43	(23) (.	24) Ethylamine analog of phencyclidine7455

1		e trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine;
2		henylcyclohexyl)ethylamine; N-(1-
3		ylcyclohexyl)ethylamine; cyclohexamine; PCE.
4	(26) (25)]	Pyrrolidine analog of phencyclidine7458
5	Som	e trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine;
6	PCP	y; PHP.
7		Thiophene analog of phencyclidine7470
8		e trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-
9		ridine; 2-thienyl analog of phencyclidine; TPCP; TCP.
10		1-[1-(2-thienyl)-cyclohexyl] pyrrolidine7473
11	Som	e other names: TCPy.
12	(29) (28) 2	2,5-dimethoxy-4-ethylamphetamine7399
13		e trade or other names: DOET.
14		Salvia divinorum or salvinorum A; all parts of the plant
15		ently classified botanically as salvia divinorum, whether
16		ing or not, the seeds thereof, any extract from any part of
17		plant, and every compound, manufacture, salts, derivative,
18		ure or preparation of such plant, its seeds or extracts.
19		Datura stramonium, commonly known as gypsum weed or
20		on weed; all parts of the plant presently classified botanically
21	as da	atura stramonium, whether growing or not, the seeds
22		eof, any extract from any part of such plant, and every
23	comj	pound, manufacture, salts, derivative, mixture or
24		aration of such plant, its seeds or extracts.
25	(32) (31) 1	N-benzylpiperazine7493
26	Som	e trade or other names: BZP.
27	(33) (32) 1	1-(3-[trifluoromethylphenyl])piperazine
28	Som	e trade or other names: TFMPP.
29		4-Bromo-2,5-dimethoxyphenethylamine7392
30		2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its
31	optic	cal isomers, salts and salts of optical isomers7348
32		Alpha-methyltryptamine (other name: AMT)7432
33		5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its
34	isom	ers, salts and salts of isomers7439
35	(38) (37) 2	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)7509
36		2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)7508
37		2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)7519
38		2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)7518
39	(42) (41) 2	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)
40		7385
41		2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-
42	T-4)'	
43	(44) (43) 2	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)7517

- -

1	(45)(44) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)7521
2	(46)(45) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)
3	7524
4	(47)(46) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)7431
5	Some trade or other names: 5-methoxy-3-[2-(dimethylamino)
6	ethyl]indole.
7	(48)(47) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
8	methoxybenzyl)ethanamine7538
9	Some trade or other names: 25I–NBOMe; 2C–I–NBOMe; 25I;
10	Cimbi-5.
11	(49)(48) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
12	methoxybenzyl)ethanamine
13	Some trade or other names: 25C–NBOMe; 2C–C–NBOMe; 25C;
14	Cimbi-82.
15	(50)(49) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
16 17	methoxybenzyl)ethanamine7536 Some trade or other names: 25B–NBOMe; 2C–B–NBOMe; 25B;
17	Cimbi-36.
18 19	(51)(50) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
20	Some trade or other names: 25H-NBOMe.
20	(52)(51) 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-
22	methoxybenzyl)ethanamine
23	Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.
24	(53)(52) 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-
25	methoxybenzyl)ethanamine
26	Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.
27	(e) Any material, compound, mixture or preparation that
28	contains any quantity of the following substances having a depressant
29	effect on the central nervous system, including its salts, isomers, and
30	salts of isomers whenever the existence of such salts, isomers, and salts
31	of isomers is possible within the specific chemical designation:
32 33	(1) Etizolam Some two do on other normers (4 (2 obleven bound) 2 other 0
33 34	Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9- methyl-6H-thieno[3,2-f][1,2,4 triazolo[4,3-a][1,4]diazepine)
34 35	(2) Mecloqualone
35 36	(2) Methaqualone
37	(4) Gamma hydroxybutyric acid
38	(f) Unless specifically excepted or unless listed in another
39	schedule, any material, compound, mixture or preparation that
40	contains any quantity of the following substances having a stimulant
41	effect on the central nervous system, including its salts, isomers and
42	salts of isomers:
43	(1) Aminorex1585

1		Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline
2		or 4,5-dihydro-5-phenyl-2-oxazolamine
3	(2)	Fenethylline
4	(3)	N-ethylamphetamine
5	(4)	(+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-
6	(.)	2-oxazolamine)
7	(5)	N,N-dimethylamphetamine (also known as N,N-alpha-trimethyl-
8	(-)	benzeneethanamine; N,N-alpha-trimethylphenethylamine)1480
9	(6)	Cathinone (some other names: 2-amino-1-phenol-1-propanone,
10	(-)	alpha-amino propiophenone, 2-amino propiophenone and
11		norphedrone)
12	(7)	Substituted cathinones
13	()	Any compound, except bupropion or compounds listed under a
14		different schedule, structurally derived from 2-aminopropan-1-
15		one by substitution at the 1-position with either phenyl, naphthyl,
16		or thiophene ring systems, whether or not the compound is
17		further modified in any of the following ways:
18		(A) By substitution in the ring system to any extent with alkyl,
19		alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
20		substituents, whether or not further substituted in the ring
21		system by one or more other univalent substituents;
22		(B) by substitution at the 3-position with an acyclic alkyl
23		substituent;
24		(C) by substitution at the 2-amino nitrogen atom with alkyl,
25		dialkyl, benzyl, or methoxybenzyl groups; or
26		(D) by inclusion of the 2-amino nitrogen atom in a cyclic
27	,	structure.
28		g) Any material, compound, mixture or preparation that
29		tains any quantity of the following substances:
30	(1)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl),
31 32	(2)	its optical isomers, salts and salts of isomers
32 33	(2)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts and salts of isomers
33 34	((nenyifentanyi), its optical isomers, saits and saits of isomers h) Any of the following cannabinoids, their salts, isomers and
34 35	(s of isomers, unless specifically excepted, whenever the existence of
36		e salts, isomers and salts of isomers is possible within the specific
37		nical designation:
38	(1)	Tetrahydrocannabinols
39	(1)	Meaning tetrahydrocannabinols naturally contained in a plant of the
40		genus Cannabis (cannabis plant), as well as synthetic equivalents of
41		the substances contained in the plant, or in the resinous extractives of
42		Cannabis, sp. and/or synthetic substances, derivatives, and their
43		isomers with similar chemical structure and pharmacological activity
-		······································

1		such as the following: Delta 1 cis or trans tetrahydrocannabinol, and
2		their optical isomers Delta 6 eis or trans tetrahydrocannabinol, and
3		their optical isomers Delta 3,4 cis or trans tetrahydrocannabinol, and
4		its optical isomers (Since nomenclature of these substances is not
5		internationally standardized, compounds of these structures,
6		regardless of numerical designation of atomic positions covered.),
7		except tetrahydrocannabinols in any of the following:
8		(A) Industrial hemp, as defined in K.S.A. 2020 Supp. 2-3901, and
9		amendments thereto;
10		(B) solid waste, as defined in K.S.A. 65-3402, and amendments
11		thereto, and hazardous waste, as defined in K.S.A. 65-3430, and
12		amendments thereto, if such waste is the result of the-
13		cultivation, production or processing of industrial hemp, as-
14		defined in K.S.A. 2020 Supp. 2-3901, and amendments thereto,
15		and such waste contains a delta-9 tetrahydrocannabinol-
16		concentration of not more than 0.3%; or
17		(C) hemp products, as defined in K.S.A. 2020 Supp. 2-3901, and
18		amendments thereto, unless otherwise deemed unlawful-
19		pursuant to K.S.A. 2020 Supp. 2-3908, and amendments thereto.
20	(2)	Naphthoylindoles
21		Any compound containing a 3-(1-naphthoyl)indole structure
22		with substitution at the nitrogen atom of the indole ring by an
23		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
24		cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-
25		(4-morpholinyl) ethyl group, whether or not further substituted
26		in the indole ring to any extent and whether or not substituted in
27		the benzyl or naphthyl ring to any extent.
28	(3) (2	
29		Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane
30		structure with substitution at the nitrogen atom of the indole
31		ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
32		cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-
33		piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or
34		not further substituted in the indole ring to any extent and
35		whether or not substituted in the benzyl or naphthyl ring to any
36	(A)	extent.
37	(4) (3	
38		Any compound containing a 3-(1-naphthoyl)pyrrole structure
39		with substitution at the nitrogen atom of the pyrrole ring by an
40		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
41 42		cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2- (4 merholinyl)ethyl group whether or not further substituted in
42		(4-morpholinyl)ethyl group whether or not further substituted in the numela ring to any attent, whether or not substituted in the
43		the pyrrole ring to any extent, whether or not substituted in the

1	benzyl or naphthyl ring to any extent.
2	(5)(4) Naphthylmethylindenes
3	Any compound containing a naphthylideneindene structure with
4	substitution at the 3-position of the indene ring by an alkyl,
5	haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
6	benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
7	morpholinyl)ethyl group whether or not further substituted in
8	the indene ring to any extent, whether or not substituted in the
9	benzyl or naphthyl ring to any extent.
10	(6)(5) Phenylacetylindoles
11	Any compound containing a 3-phenylacetylindole structure with
12	substitution at the nitrogen atom of the indole ring by an alkyl,
13	haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14	benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
15	morpholinyl)ethyl group whether or not further substituted in
16	the indole ring to any extent, whether or not substituted in the
17	benzyl or phenyl ring to any extent.
18	(7)(6) Cyclohexylphenols
19	Any compound containing a 2-(3-hydroxycyclohexyl)phenol
20	structure with substitution at the 5-position of the phenolic ring
21	by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
22	cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
23	morpholinyl)ethyl group whether or not substituted in the
24	cyclohexyl ring to any extent.
25	(8)(7) Benzoylindoles
26	Any compound containing a 3-(benzoyl)indole structure with
27	substitution at the nitrogen atom of the indole ring by an alkyl,
28	haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
29	benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
30	morpholinyl)ethyl group whether or not further substituted in
31	the indole ring to any extent and whether or not substituted in
32	the benzyl or phenyl ring to any extent.
33	(9)(8) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-
34	de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone.
35	Some trade or other names: WIN 55,212-2.
36	(10)(9) 9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-
37	6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
38	Some trade or other names: HU-210, HU-211.
39	(11)(10) Tetramethylcyclopropanoylindoles
40	Any compound containing a 3-tetramethylcyclopropanoylindole
41	structure with substitution at the nitrogen atom of the indole
42	ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
43	cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-

1	piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
2	pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
3	tetrahydropyranylmethyl group, whether or not further
4	substituted in the indole ring to any extent and whether or not
5	substituted in the benzyl or tetramethylcyclopropyl rings to any
6	extent.
7	(12)(11) Indole-3-carboxylate esters
8	Any compound containing a 1H-indole-3-carboxylate ester
9	structure with the ester oxygen bearing a naphthyl, quinolinyl,
10	isoquinolinyl or adamantyl group and substitution at the 1
11	position of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
12	alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
13	piperidinylmethyl or 2-(4-morpholinyl)ethyl group, whether or
14	not further substituted on the indole ring to any extent and
15	whether or not substituted on the naphthyl, quinolinyl,
16	isoquinolinyl, adamantyl or benzyl groups to any extent.
17	(13)(12) Indazole-3-carboxamides
18	Any compound containing a 1H-indazole-3-carboxamide
19	structure with substitution at the nitrogen of the carboxamide by
20	a naphthyl, quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-
21	amino-1-oxoalkan-2-yl or 1-alkoxy-1-oxoalkan-2-yl group and
22	substitution at the 1 position of the indazole ring by an alkyl,
23	haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
24	benzyl, N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl
25	group, whether or not further substituted on the indazole ring to
26	any extent and whether or not substituted on the naphthyl,
27	quinolinyl, isoquinolinyl, adamantyl, 1-amino-1-oxoalkan-2-yl, 1-
28	alkoxy-1-oxoalkan-2-yl or benzyl groups to any extent.
29	(14)(13) Indole-3-carboxamides
30	Any compound containing a 1H-indole-3-carboxamide structure
31	with substitution at the nitrogen of the carboxamide by a
32 33	naphthyl, quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-
33 34	1-oxoalkan-2-yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1 position of the indole ring by an alkyl,
34 35	haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
33 36	benzyl, N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl
30 37	group, whether or not further substituted on the indole ring to
38	any extent and whether or not further substituted on the
39	naphthyl, quinolinyl, isoquinolinyl, adamantyl, 1-amino-1-
40	oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl groups to any
41	extent.
42	(15)(14) (1H-indazol-3-yl)methanones
43	Any compound containing a (1H-indazol-3-yl)methanone

43 Any compound containing a (1H-indazol-3-yl)methanone

1 structure with the carbonyl carbon bearing a naphthyl group

and substitution at the 1 position of the indazole ring by an alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, Nmethyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl group,
whether or not further substituted on the indazole ring to any
extent and whether or not substituted on the naphthyl or benzyl
groups to any extent.

8 Sec.<u>79.</u> {78.} On and after the effective date of this act, if the 9 secretary of state publishes notice of the certification required 10 pursuant to section<u>83</u> {82}, and amendments thereto, K.S.A. 65-4107 11 is hereby amended to read as follows: 65-4107. (a) The controlled 12 substances listed in this section are included in schedule II and the 13 number set forth opposite each drug or substance is the DEA 14 controlled substances code which has been assigned to it.

15 (b) Any of the following substances, except those narcotic drugs 16 listed in other schedules, whether produced directly or indirectly by 17 extraction from substances of vegetable origin or independently by 18 means of chemical synthesis or by combination of extraction and 19 chemical synthesis:

(1) Opium and opiate and any salt, compound, derivative or
 preparation of opium or opiate, excluding apomorphine, dextrorphan,
 nalbuphine, nalmefene, naloxone and naltrexone and their respective
 salts, but including the following:

-		· · · · · · · · · · · · · · · · · · ·
24	(A)	Raw opium9600
25	(B)	Opium extracts
26	(C)	Opium fluid9620
27	(D)	Powdered opium
28	(E)	Granulated opium9640
29	(F)	Tincture of opium
30	(G)	Codeine
31	(H)	Ethylmorphine9190
32	(I)	Etorphine hydrochloride9059
33	(J)	Hydrocodone
34	(K)	Hydromorphone
35	(L)	Metopon
36	(M)	Morphine
37	(N)	Oxycodone
38	(0)	Oxymorphone
39	(P)	Thebaine
40	(Q)	Dihydroetorphine9334
41	(R)	Oripavine
42	(2) Any salt, compound, isomer, derivative or preparation thereof
43	whi	ch is chemically equivalent or identical with any of the substances

1 referred to in paragraph (1), but not including the isoquinoline 2 alkaloids of opium.

3

(3) Opium poppy and poppy straw.

4 (4) Coca leaves (9040) and any salt, compound, derivative or 5 preparation of coca leaves, but not including decocainized coca leaves 6 or extractions which do not contain cocaine (9041) or ecgonine (9180).

7

(5) Cocaine, its salts, isomers and salts of isomers (9041).
(6) Ecgonine, its salts, isomers and salts of isomers (9180).

8 9

(6) Ecgonine, its saits, isomers and saits of isomers (9180).
 (7) Concentrate of poppy straw (the crude extract of poppy straw

in either liquid, solid or powder form which contains the
 phenanthrene alkaloids of the opium poppy) (9670).

12 (c) Any of the following opiates, including their isomers, esters, 13 ethers, salts and salts of isomers, esters and ethers, whenever the 14 existence of these isomers, esters, ethers and salts is possible within the 15 specific chemical designation dextrorphan and levopropoxyphene 16 excepted:

10	6 excepted.		
17	(1)	Alfentanil	
18	(2)	Alphaprodine9010	
19	(3)	Anileridine	
20	(4)	Bezitramide	
21	(5)	Bulk dextropropoxyphene (nondosage forms)9273	
22	(6)	Carfentanil	
23	(7)	Dihydrocodeine9120	
24	(8)	Diphenoxylate	
25	(9)	Fentanyl	
26	(10)	Isomethadone	
27	(11)	Levomethorphan	
28	(12)	Levorphanol	
29	(13)	Metazocine	
30	(14)	Methadone9250	
31	(15)	Methadone-intermediate,4-cyano-2-dimethyl amino-4,4-diphenyl	
32		butane	
33	(16)	Moramide-intermediate, 2-methyl-3-morpholino-1, 1-	
34		diphenylpropane-carboxylic acid9802	
35	(17)	Pethidine (meperidine)	
36	(18)	Pethidine-intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine	
37			
38	(19)	Pethidine-intermediate-B, ethyl-4-phenyl-piperidine-4-	
39		carboxylate	
40	(20)	Pethidine-intermediate-C, 1-methyl-4-phenyl-piperidine-4-	
41	. ,	carboxylic acid	
42	(21)	Phenazocine	
43		Piminodine	
	` '		

1	(23)	Racemethorphan9732
2	(24)	Racemorphan
3	(25)	Sufentanil
4	(26)	Levo-alphacetyl methadol9648
5		Some other names: levo-alpha-acetyl methadol, levomethadyl
6		acetate or LAAM.
7	(27)	Remifentanil
8	(28)	Tapentadol
9		Thiafentanil
10) (d) Any material, compound, mixture, or preparation which
11	cont	ains any quantity of the following substances having a potential
12		abuse associated with a stimulant effect on the central nervous
13	syste	
14	(1)	Amphetamine, its salts, optical isomers and salts of its optical
15	. /	isomers1100
16	(2)	Phenmetrazine and its salts1631
17	(3)	Methamphetamine, including its salts, isomers and salts of
18	()	isomers
19	(4)	Methylphenidate1724
20	(5)	Lisdexamfetamine, its salts, isomers, and salts of its isomers. 1205
21) (e) Unless specifically excepted or unless listed in another
22	sche	dule, any material, compound, mixture or preparation which
23		ains any quantity of the following substances having a depressant
24		et on the central nervous system, including its salts, isomers and
25	salts	of isomers whenever the existence of such salts, isomers and salts
26	of is	omers is possible within the specific chemical designation:
27	(1)	Amobarbital
28	(2)	Glutethimide2550
29	(3)	Secobarbital
30	(4)	Pentobarbital
31	(5)	Phencyclidine7471
32	(1	f) Any material, compound, mixture, or preparation which
33	cont	ains any quantity of the following substances:
34	(1)	Immediate precursor to amphetamine and methamphetamine:
35	(.	A) Phenylacetone8501
36		Some trade or other names: phenyl-2-propanone; P2P; benzyl
37		methyl ketone; methyl benzyl ketone.
38	(2)	Immediate precursors to phencyclidine (PCP):
39	(.	A) 1-phenylcyclohexylamine7460
40	(B) 1-piperidinocyclohexanecarbonitrile (PCC)
41		Immediate precursor to fentanyl:
42		A) 4-anilino-N-phenethyl-4-piperidine (ANPP)8333
43	(g) Any material, compound, mixture or preparation which

1	cont	ains any quantity of the following hallucinogenic substance, its
2		s, isomers and salts of isomers, unless specifically excepted,
3	whe	never the existence of these salts, isomers and salts of isomers is
4	poss	ible within the specific chemical designation:
5	(1)	Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] in an oral
6		solution in a drug product approved for marketing by the United
7		States food and drug administration7365
8	(2)	Marijuana7360
9	(3)	Nabilone7379
10		[Another name for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-
11		6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-
12		dibenzo[b,d]pyran-9-one]
13		h) Any material, compound, mixture or preparation containing
14		of the following narcotic drugs or any salts calculated as the free
15		ydrous base or alkaloid, in limited quantities as set forth below:
16	(1)	Not more than 300 milligrams of dihydrocodeinone
17		(hydrocodone) or any of its salts per 100 milliliters or not more
18		than 15 milligrams per dosage unit with a fourfold or greater
19		quantity of an isoquinoline alkaloid of opium
20 21	(2)	Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or any of its salts per 100 milliliters or not more
21 22		than 15 milligrams per dosage unit with one or more active,
23	6	nonnarcotic ingredients in recognized therapeutic amounts9806
23 24	(nonnarcotic ingredients in recognized therapeutic amounts9806i) Any tetrahydrocannabinols
23 24 25	À	nonnarcotic ingredients in recognized therapeutic amounts9806i) Any tetrahydrocannabinols
23 24 25 26	л g	nonnarcotic ingredients in recognized therapeutic amounts9806 i) Any tetrahydrocannabinols
23 24 25 26 27	N 8 ti	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26	N g ti C	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28	N g ti C is	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29	N g ti C is s	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29 30	N 8 ti C is s ti	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29 30 31	N 8 ti C is s ti ti ti	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29 30 31 32 33 34	N 8 ti c is s ti ti ti ti ti ti	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29 30 31 32 33 34 35	N g tř c is s tř tř tř tř tř tř tř	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29 30 31 32 33 34 35 36	N 8 ti c is s ti ti ti ii ii ii te	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	N 8 ti c is s ti ti ti ii ii ii te	nonnarcotic ingredients in recognized therapeutic amounts9806 <i>i)</i> Any tetrahydrocannabinols
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	N g th c is s t t t t t t t t t t t t t	 nonnarcotic ingredients in recognized therapeutic amounts9806 i) Any tetrahydrocannabinols
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	N g th c is s t t t t t t t t t t t t t	 nonnarcotic ingredients in recognized therapeutic amounts9806 <i>Any tetrahydrocannabinols</i>
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	N g th c is s t t t t t t t t t t t t t	 nonnarcotic ingredients in recognized therapeutic amounts9806 <i>Any tetrahydrocannabinols</i>
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	N g th c is s t t t t t t t t t t t t t	 nonnarcotic ingredients in recognized therapeutic amounts9806 <i>Any tetrahydrocannabinols</i>
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	N g th c is s t t t t t t t t t t t t t	 nonnarcotic ingredients in recognized therapeutic amounts9806 <i>Any tetrahydrocannabinols</i>

1	contains a delta-9 tetrahydrocannabinol concentration of not
2	more than 0.3%; or
3	(C) hemp products, as defined in K.S.A. 2020 Supp. 2-3901, and
4	amendments thereto, unless otherwise deemed unlawful pursuant
5	to K.S.A. 2020 Supp. 2-3908, and amendments thereto.}
6	Sec. 74. 80. {79.} K.S.A. 79-5201 is hereby amended to read as
7	follows: 79-5201. As used in this act article 52 of chapter 79 of the
8	Kansas Statutes Annotated, and amendments thereto:
9	(a) "Marijuana" means any marijuana, whether real or counterfeit, as
10	defined by K.S.A. 2020 Supp. 21-5701, and amendments thereto, which is
11	held, possessed, transported, transferred, sold or offered to be sold in
12	violation of the laws of Kansas;
13	(b)—"Controlled substance" means any drug or substance, whether real
14	or counterfeit, as defined by K.S.A. 2020 Supp. 21-5701, and amendments
15	thereto,-which that is held, possessed, transported, transferred, sold or
16	offered to be sold in violation of the laws of Kansas. Such term shall not
17	include marijuana;
18	(e)(b) "dealer" means any person who, in violation of Kansas law,
19	manufactures, produces, ships, transports or imports into Kansas or in any
20	manner acquires or possesses more than 28 grams of marijuana, or more
21	than one gram of any controlled substance, or 10 or more dosage units of
22	any controlled substance which that is not sold by weight;
23	(d)(c) "domestic marijuana plant" means any cannabis plant at any
24	level of growth-which that is harvested or tended, manicured, irrigated,
25	fertilized or where there is other evidence that it has been treated in any
26	other way in an effort to enhance growth;
27	(d) "marijuana" means any marijuana, whether real or counterfeit,
28	as defined in K.S.A. 2020 Supp. 21-5701, and amendments thereto, that is
29	held, possessed, transported, transferred, sold or offered for sale in
30	violation of the laws of Kansas; and
31	(e) "medical marijuana" means the same as defined in section 2, and
32	amendments thereto.
33	Sec. <u>-7581.</u> {80.} K.S.A. 79-5210 is hereby amended to read as
34	follows: 79-5210. Nothing in this act requires persons registered under
35	article 16 of chapter 65 of the Kansas Statutes Annotated, and amendments
36	thereto, or otherwise lawfully in possession of marijuana, medical
37	marijuana or a controlled substance to pay the tax required under this act.
38	Sec. <u>-76. 82.</u> {81.} K.S.A. <u>-44-1009, 44-1015</u> , 65-28b08, 79-5201 and
39	79-5210 and K.S.A. 2020 Supp. 19-101a, 21-5703, 21-5705, 21-5706, 21-
40	5707, 21-5709, 21-5710, 23-3201, 38-2269, 44-501, 44-706 and 65-1120
41	are hereby repealed.
42	New Sec. <u>83.</u> {82.} (a) If marijuana is rescheduled from schedule I
43	of the controlled substances act, 21 U.S.C. § 812, the secretary of

health and environment shall certify to the secretary of state that such
 rescheduling has occurred. Upon receipt of such certification, the
 secretary of state shall cause a notice of such certification to be
 published in the Kansas register.

5 (b) On and after the effective date of this act and the publication 6 of the notice by the secretary of state in the Kansas register as 7 provided by subsection (a), K.S.A. 65-4107, K.S.A. 2020 Supp. 21-5706 8 and 65-4105 and sections 2, 3, 4, 17, 18, <u>-30</u> {29} and <u>-39</u> {38} of this act 9 are hereby repealed.

10 Sec.<u>77.84.</u> {83.} This act shall take effect and be in force from and 11 after its publication in the statute book.